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Dermal fibroblasts positively contribute throughout the wounding response by 
secreting a profile of pro- and anti-inflammatory cytokines in the wound milieu. 
However, a chronically inflamed environment will, cause detrimental effects on 
the functional, secretory, and molecular properties of these cells. This study 
aims to understand how the effect of the pro-inflammatory cytokine TNF-α 
modulates both healthy and diabetic dermal fibroblast phenotype.  
To mimic a chronic inflammatory environment and assess whether fibroblasts 
respond similarly in different anatomical sites, donor-matched fibroblasts from 
face and scalp were pre-incubated for 3 days with different concentrations (2.5, 
25 or 250 ng/ml) of TNF-α. All concentrations significantly impaired proliferation 
by day 14 in cells from both sites and stimulated (papillary) metabolic activity at 
day 14.  
However, this did not correlate with an increase in papillary cell senescence 
since this did not appear until passage 17, and then only at a supra-
pathophysiological concentration.  
Migration of dermal fibroblasts, assessed by the scratch assay. TNF-α 
significantly inhibited the cells migration, particularly in diabetic fibroblasts, 
suggesting they are more sensitive to TNF-α. Since TNF-α may stimulate the 
secretion of soluble paracrine factors by dermal fibroblasts, conditioned medium 
was collected to assess its effect on other dermal fibroblasts, however, this had 
no significant effect on migration.  
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However, using gelatin zymography, it was found that TNF-α did stimulate the 
secretion of soluble paracrine factors that induce MMP activity in non-diabetic 
fibroblasts, mirroring previous observations that a pro-inflammatory environment 
can increase proteolytic activity, and indicating that diabetic fibroblasts were 
again more sensitive than healthy. No difference was observed with MMP-9 
activity and nor did the results with dermal fibroblasts reach statistical 
significance, perhaps because of a relatively low n-number. 
The ability of TNF-α to modulate the expression of genes associated with the 
ECM (MMP-1, -2, -9, TIMP-1, and -2) and senescence (Sirt1 and 6) was 
investigated. There was no change in Sirt1 and Sirt6 expression and no 
evidence of paracrine effects (conditioned medium) on any of the genes. TNF-α 
significantly induced mRNA expression of MMP-1 in healthy non-scratched and 
scratched diabetic fibroblasts, and TIMP-1 in healthy non-scratched cells. There 
was also considerable donor variability that prevented statistical significance 
being achieved under the other conditions.  
The secretion of various cytokines associated with inflammation was compared 
in healthy and diabetic fibroblasts in the presence and absence of TNF-α.          
Seven cytokines were secreted, by healthy and diabetic male and female 
fibroblasts, although diabetic female fibroblasts did not secrete two of them. 
TNF-α stimulated secretion of cytokines in healthy and diabetic, male and 
female cells but the profiles of those released were different between the 
different groups. There was no TNF-α induced paracrine effect on cytokine 
secretion by healthy dermal fibroblasts.  
In conclusion, changes in the microenvironment and the influx of pro- 
inflammatory cytokines may significantly alter the dermal fibroblast phenotype.             
Understanding these functional and molecular changes in response to 
inflammatory cytokines will give a better understanding of the differences 
between fibroblast activity in normal physiological wound healing and chronic or 
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TNFR1and 2: TNF-α receptors 1 and 2 
TNF-α: Tumour necrosis factor alpha 
TORC2/CRTC2: Transcriptional coactivator for the transcription factor CREB 
TRADD: TNFR associated death domain protein  
TRAF2: TNF-α receptor associated factor 
TREM-1: Triggering receptor expressed on myeloid cells-1 
UVR: Ultraviolet radiation 
VEGF: Vascular endothelial growth factor 




1-1: Skin function 
 
Human skin is considered to be the largest organ, because it covers the whole 
body and is continuous at entry and exits points of the body. It contains all four 
types of primary tissues epithelial, connective, muscle and nerve. Also, the 
blood vessels present in the dermis supply nutrients to the skin (Pullar et al., 
2017). Thus, skin functions are related to its structure (Mitchall and Peel, 2009; 
Chen et al., 2014; Young et al., 2014). One of the most important roles of skin is 
to act as a barrier; it provides protection against microbes, protection against 
chemical and physical damage, protects from damage by ultraviolet radiation 
(UVR) by increasing pigmentation, prevents excess water loss and regulates 
the body temperature via the sweat glands, while specialised Merkel cells are 
responsible for sensing the environment. In addition, the skin is the main site for 
the production of vitamin D (Mitchall and Peel, 2009; Chen et al., 2014; Young 
et al., 2014). 
 
1-2: Skin structure 
 
The skin consists of three major layers; the outer layer is called the epidermis 
(the epithelial tissue), and beneath that is the dermis that is mainly structured 
from connective tissue. The dermis is superficial to the hypodermis the deeper 
layer, which is also composed of connective tissue (Fig 1-1) and may be 
referred to, as the superficial fascia, or subcutaneous tissue (Mitchall and Peel, 
2009; Bettes et al.,  2013; Young et al., 2014).   
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1-2-1: The epidermis 
 
The epidermis is derived from the ectodermal layer during development and is 
composed of a stratified squamous keratinized epithelium. The most abundant 
cell is the keratinocyte, although other cells such as Merkel cells, Langerhans 
cells and melanocytes are also present (Richmond and Harris, 2014). An 
important function of the keratinocytes is to provide a waterproof barrier and 
protect the underlying tissues. The epidermis usually consists of four layers; 
although five layers are found only in thick skin (Fig 1-2), such as the soles of 
the feet and palms of the hands (reviewed by Rinnerthaler et al., 2015).  
The layers from the innermost are; the stratum germinativum or basale which is 
the deepest layer of the epidermis and contains highly proliferating epithelial 
cells as stem cells for the epidermis which maintains the homeostasis of the 
skin (Mitchall and Peel, 2009). The migration of cells from the bottom layer, the 
stratum germinativum to the stratum corneum in human skin takes 
approximately 4 weeks depending on the location and the thickness of the skin 
(Candi et al., 2005). The stratum spinosum is the thickest layer, which is 
comprised of the prickle cells, this layer is rich with desmosomes which are 
important in holding the cells together, resisting shearing forces and are 
responsible for layer’s spiny appearance (William, 2017). The stratum 
granulosum, is formed of keratinocytes, which are characterized by the 
presence of cytoplasmic granules of keratohyalin; some granules consist of 
lipids that increase the waterproofing of epidermal superficial layers when 
released, also cells of this layer form the outmost epidermal layer, the stratum 
corneum (Piotrowska et al., 2016). The stratum lucidum is a thin layer of 
keratinocytes only found in thick skin, it acts as a barrier to water, and 
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decreases the friction in thick skin (Betts et al., 2013). The stratum corneum is 
the outmost layer of the epidermis and consists of corneocytes, non-living cells 
that are constantly shed and sealed together with lipid-rich domains, forming a 
water-impermeable barrier (Pullar et al., 2017). This epidermis is separated 
from the underlying dermis by a basement membrane (Martini and Ober, 2006). 
 
 
1-2-2: The dermis 
 
The dermis is derived from the embryonic mesoderm and is classified as a 
connective tissue, made up of fibres including collagen, reticulin and elastin, 
and dermal fibroblasts. Dermal fibroblasts are responsible for the production of 
the extracellular matrix (ECM).  
The dermis also contains nerves, lymphatic and blood vessels, sweat glands, 
sebaceous glands, hair follicles and nail roots (Mitchall and Peel, 2009; Young 
et al., 2014). The dermis can be divided into two layers with no distinct 
boundary (Fig 1-3), the papillary and reticular layers (Martini and Ober, 2006). 
The papillary layer is the upper layer of the dermis and is composed of loose 
areolar connective tissue, with capillary loops that provide the skin with blood 
and sensory nerve fibres. Collagen fibres are produced as thin bundles 10µm    
in diameter. In general, the fibre bundles are thin and randomly arranged 
(Sanders et al., 1999). The principal type of collagen in this layer is type ӀӀӀ 
(Sorrell and Caplan, 2004; Bettes et al., 2013). Also, the human papillary dermis 
contains rete ridges, which project into the epidermis (stratum basale) to form 
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finger-like dermal papillae that help to increase the interactions between 
epidermis and dermis (reviewed by Sriram et al., 2015). 
The reticular layer sits under the papillary layer and connects the skin to the 
hypodermis. It is composed of dense irregular connective tissue, with 
predominant collagen and elastin fibres, but is less cellular than the papillary 
layer (Carroll, 2007). The collagen fibres in this layer are produced as parallel 
dense collagen bundles of more than 50µm in diameter (Sanders et al., 1999; 
Marcos-Garces et al., 2014). The principal type of collagen in this layer is type Ӏ 
(Sorrell and Caplan, 2004). In addition, the hair follicle bulb, the functional parts 
of the sebaceous glands and sweat glands are also located in the reticular 
dermis (Alberts et al., 2008). 
Molecular studies in cultured human primary dermal fibroblasts from different 
anatomical regions/sites and different aged donors (foetal and adult), have 
shown differences in location (topography), especially for the genes that are 
expressed for biological processes such as; growth, differentiation, ECM 
production, migration and metabolism (Chang et al., 2002; Rinn et al., 2006; 
Bryant and Nix, 2012).  
Korosec and her colleagues (2018), have found that fibroblasts can change the 
expression of a large number of their genes in vitro immediately, therefore it is 
difficult to use their subset-specific markers to isolate them from the cultures. 
Interestingly, they identified two cell surface markers, FAP and CD90 
(proliferation markers), which enable the isolation of the papillary from reticular 
fibroblasts in human skin via the fluorescence activated cell sorting (FACS) 
technique. Also, in humans, there were many differences between papillary and 
reticular dermis, in addition to their structure, both in vivo and in vitro include; 
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size and morphology, the collagen type III to type I ratio, differences in ECM 
protein composition, protein secretion/expression, and organization. All these 
differences have a significant effect on fibroblast behaviour, role, response in 
wound healing and scar formation, as well as at the cellular level of dermis 
(Sorrell and Caplan, 2004; reviewed by Sriram et al., 2015).  
In mice, it has been shown that different lineages of dermal fibroblasts have 
different gene expressions, the gene expression of different lineages of murine 
dermal fibroblasts are listed in (Table 1-1) (reviewed by Sriram et al., 2015). 
 
References Gene Expression (in mice) 
Driskell et al., 2013 PDGFRα, Lrig 1 and Blimp1 (Papillary DFs) 
PDGFRα, Dlk1 and Sca1 (Reticular & Hypodermal 
DFs) 
Rinkevich et al., 2015 En1 (Embryonic DFs); responsible for deposition of 
dermal connective tissue in future lineage. 
Table 1-1: Some genes that are expressed in different lineages of murine dermal 
fibroblasts (reviewed by Sriram et al., 2015). 
 
 
1-2-3: The hypodermis 
 
The hypodermis is composed of a thick layer of adipocytes encasing the bulbs 
of terminal anagen hair follicles. This layer has no distinct boundaries to the 
dermis and it connects the upper skin layers (dermis and epidermis) to 
underlying tissues such as bones and muscles (Betts et al., 2013). This layer of 
adipocytes can also referred to as subcutaneous adipose, hypodermis, and 
subcutis. It has multiple functions including; fat storing, maintaining the body 
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heat via insulation, and as a protectial cushion. In addition, the development of 
dermal adipocytes (hypodermis) is structurally independent from that of 
subcutaneous adipose tissue (reviewed by Gonzaga da Cunha et al., 2014). 
Some studies have identified a common developmental precursor for dermal 
fibroblasts and intradermal adipocytes (Joe et al., 2010; Uezumi et al., 2010; 
Schmidt and Horsley, 2013).  
Furthermore, the role of the adipocytes has been shown to be of significance for 
epidermal homeostasis during hair follicle regeneration and wound healing in 
mice (Schmidt and Horsley, 2013; Driskell et al., 2014). In human skin, 
adipocytes can secrete pro-inflammatory cytokines, because they can store the 





















Fig 1-1: Human skin structure.  
The human skin consists of three main layers; the epidermis, made of keratinocytes, 
the dermis, made of connective tissue, fibres and dermal fibroblasts. Beneath the 
dermis, the hypodermis, composed mainly of loose connective and fatty tissues. Also, 
























Fig 1-2: The different layers of human epidermis. 
The five layers of the epidermis in glabrous skin. The layers from top to bottom; the 
stratum corneum, the stratum lucidum, the stratum granulosum, the stratum 
spinosum and the stratum basale (germinativum). The stratum basale is separated 
from the underlying papillary dermis by a basement membrane (Yagi and Yonei, 






















Fig 1-3: The papillary and reticular dermis. 
The two major layers of human dermis; the papillary dermis and reticular dermis are 
separated by the rete subpapillare. The papillary dermis project into the epidermis by 
rete bridges or dermal papillae (Sorrell and Caplan, 2004).  
 
 
1-3: Skin appendages 
 
The skin appendages include, sweat and sebaceous glands, hair follicles and 
the nail. Sweat glands are present as two secretory types; the eccrine and 
apocrine sweat glands. Sweat glands are characterized by their existence all 
over the human body, the secretory cells are located deep in the dermis and 
even in the hypodermis, and the duct opens on the surface of the skin. In 
contrast, the apocrine sweat gland is present only in certain anatomical regions, 
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such as the axilla, and around the nipples, and forms part of the pilosebaceous 
unit. Unlike the eccrine glands, they secrete directly into the hair follicle (Mitchall 
and Peel, 2009), in a similar way to the sebaceous glands. In contrast, the 
sebaceous glands secrete sebum, a lipid substance produced by holocrine 
secretion, which helps to lubricate the hair fibre, acts as anti-microbial and 
waterproofs the skin and hair. Sebaceous glands are larger on the face and 
scalp, but absent on the palms and soles of the hands and feet, that have no 
pilosebaceous units (Young et al., 2014).  
Human hair follicles exist as three types, which can be described as terminal or 
vellus in adult human skin, and the third type called lanugo is found in the skin 
of the foetus (Buffoli et al., 2013). There is also sometimes said to be a type of 
terminal hair called intermediate hair. These are smaller, and less pigmented 
than terminal hairs, and they do not penetrate as deep into the dermis as 
terminal hair follicles (Miranda et al., 2010). 
Lanugo hair is very soft and unpigmented and is shed before birth, when it is 
replaced by terminal or vellus hair follicles depending on the site in the human 
body. Vellus hair follicles are small, fine and unpigmented, whereas terminal 
hair follicles produce a large amount of pigment, such as those found on the 
scalp, eyebrows and eye lashes (Lai-Cheong and McGrath, 2013).  
Interestingly, these appendices such as the hair follicles and sweat glands 
contain epithelial cells and a reservoir of stem cells, which are important in the 
regeneration of the epidermis (re-epithelialisation) in wound healing and thus, 
wounds heal faster in haired skin (Millar, 2002; Martin and Nunan, 2015). 
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The hair follicle structure is divided into two parts, the upper permanent part, 
which does not take part in the hair cycle, and the lower transient part, which is 
remodelled with each hair cycle. The hair follicle is composed of eight epithelial 
layers; these are the cuticle, cortex and medulla (hair shaft), the inner root 
sheath composed of Henle's, Huxley's and the inner root sheath cuticle, the 
companion layer and outer root sheath (Fig1-4) (Buffoli et al., 2013). The bulge 
contains the stem cells and is part of the outer root sheath, and is located at the 
level of the insertion of the arrector pili muscle (Fig1-5). The bulb consists of the 
mesenchyme-derived dermal papilla, which is continuous with the dermal 
sheath; a connective tissue which surround the whole hair follicle (reviewed by 
Westgate, 1997; Ross and Pawlina, 2011). Finally, the dendritic melanocytes 
derived from the neural crest are also located in the bulb and produce the hair 
pigment (Cotsarelis, 2006 b; Rittie and Fisher, 2015).  
Importantly, hair growth is cyclical, which means new hairs are produced 
throughout life.  The hair cycle involves four main phases which are anagen, a 
phase with active growth; catagen, a regressing phase; telogen when the hair 
follicle enters a resting stage; and exogen, when the hair is shed (reviewed by 
























Fig 1- 4: The structure of the human hair follicle.  
A histological section displays the hair bulb layers (a) mesenchymal dermal papilla 
(b) epithelial matrix (c) melanocytes (d) medulla (e) hair cortex (f) hair cuticle (g) 
Huxley’s layer (h) Henle’s layer (i) the inner root sheath (j) the outer root sheath, 
and (k) connective tissue sheath (Alsaad et al., 2007). 
 




















Fig 1-5: The hair follicle cycle. 
The human hair follicle stages; anagen, forming a new hair. Upon cessation of 
anagen, the follicle regresses in catagen, returning to telogen. The old hair is shed 
in exogen when the new hair grows (Cotsarelis, 2006 a). 
 
 
1-4: The dermal fibroblast 
 
Dermal fibroblasts are the predominant mesenchymal cell type in the skin 
dermis, with the central role of synthesizing the extracellular matrix (ECM) 
(Alberts, 2008). The ECM consists of proteins such as proteoglycans and 
glycosaminoglycans with crucial functions, such as regulation of tissue 
structure, and maintenance of the cellular microenvironment by the secretion of 
growth factors and cytokines, and the production of matrix metalloproteinases 
(MMPs). Fibroblasts are responsible for the composition of fibres especially 
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collagen fibres in addition to elastic and reticular fibres (Mine et al., 2008).         
Because dermal fibroblasts are changing with age, the fibres will change with 
age too. Therefore, these cells became the researchers’ main focus for their 
crucial role in aging (Tigges et al., 2014; Korosec et al., 2018).  
One important property of dermal fibroblasts is their heterogeneity, Harper and 
Grove (1979) reported differences in function and structural features between 
the papillary and reticular dermis, and they suggested that, the dermal layers 
contain two different fibroblast lineages with distinct morphology and functions, 
in humans. Subsequently, in mice it has been confirmed that dermal fibroblasts 
arise from two distinct lineages (Driskell et al., 2013; reviewed by 
Thangapazhum et al., 2014; Rinkevich et al., 2015). First from the upper 
“papillary dermis” and the second from the deeper “reticular dermis”, called 
papillary fibroblasts and reticular fibroblasts respectively (Driskell et al., 2013; 
Mastrogiannaki et al., 2016). More reports have recognized that fibroblasts from 
different micro-anatomic regions have specific properties depending on their 
particular niche, and they can be further divided into fibroblasts that are 
associated with the hair follicle, including the dermal sheath, which acts as a 
reservoir for new dermal papilla cells (Jahoda, 2003) and dermal papilla cells, 
which have a role in hair follicle regeneration (Rompolas et al., 2012) (reviewed 
by Thangapazhum et al., 2014).    
Representation of the heterogeneous populations of dermal fibroblasts with a 
variety of features should be considered in any study (Mine et al., 2008; Driskell 
et al., 2013; reviewed by Thangapazhum et al., 2014; Rinkevich et al., 2015). In 
human mammary skin, it has been observed that papillary dermal fibroblasts 
and reticular dermal fibroblasts have different functional and genetic markers 
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demonstrating the regional importance of fibroblast sub populations (Pageon et 
al., 2012; Rinkevich et al., 2015) (Table 1-2). Papillary dermal fibroblasts were 
characterized by a higher proportion of smaller sized cells with low granularity 
and a higher growth/clonogenic potential than reticular dermal fibroblast 
populations (Mine et al., 2008).  
 
Papillary markers Reticular markers 
Podoplanin (PDPN)  Calponin1 (CNN1) 
Netrin 1 (NTN1) Transglutaminase 2 (TGM2) 
C-C Chemokine receptor type 11(CCRL1) Cadherin 2 (CDH2) 
Table 1-2: Markers of the papillary and reticular dermal fibroblasts  
Some markers that distinguish human papillary fibroblasts from reticular dermal 
fibroblasts (Janson et al., 2013).  
 
 
The other difference is that papillary dermal fibroblasts divide faster than 
reticular dermal fibroblasts in culture (Sorrell and Caplan, 2004). During aging, a 
reduction in the growth capacity of papillary dermal fibroblasts may result from a 
decline in their response to growth/mitogenic factors, leading to a decrease in 
their number (Reenstra et al., 1993; Pageon et al., 2012). Interestingly, after 
long series of passages (P16- P22) in monolayer culture, papillary dermal 
fibroblasts transform into reticular fibroblasts (Janson et al., 2013).   
Generally, dermal fibroblasts play a key role the regulation of epidermal 
morphogenesis, especially cells which have been shown to affect the formation 
of the basement membrane and can directly communicate with keratinocytes 
(Sorrell and Caplan, 2004; Lee and Cho, 2005; Mine et al., 2008). Also, the 
modification of papillary dermal fibroblast secretions, such as the secretion of 
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cytokines, growth factors and MMPs; these proteinases degrade the ECM and 
are regulated by the tissue inhibitors of metalloproteinases (TIMPs), and 
together can have a significant impact on the production and remodelling of the 
ECM components (Werner et al., 1994 ; Odorisio et al., 2002).  
 
 
1-5: Wound Healing 
 
A wound can be defined as a break in the barrier of the skin extending to the 
dermis, muscle and even bone. It may be delineated in many ways; by its 
aetiology, anatomical location, by the method of closure, by symptoms or by the 
appearance of the tissue types in the wound bed, and whether it is an acute or 
chronic wound (Enoch and Price, 2004). 
 
 
1-5-1: Phases of wound healing 
 
Wounds are classified into two types, acute and chronic wounds, depending on 
the healing process. In general, normal wound healing is a complex process 
involving a series of overlapping events, which leads to the repair of the injured 
skin/tissue. The phases of normal wound healing consist of several interacting 
overlapping events, which are in the sequence of haemostasis, inflammation, 
proliferation and remodelling (Singer and Clark, 1999; Greaves et al., 2013; 


















Fig 1-6: Mechanism of normal human wound healing. 
Tissue injury starts with haemostasis (clot formation), and inflammation, which involves 
the recruitment of macrophages and neutrophils that secrete cytokines and growth 
factors to promote cellular migration and proliferation of keratinocytes, fibroblasts and 
endothelial cells. Proteases (MMPs) also are secreted by skin cells that aid in the 
remodelling phase (McCarty and Percival, 2013).  









Haemostasis or coagulation occurs immediately after injury, when platelets 
begin to adhere and clump at sites of exposed collagen in the wound. The 
activated platelets, following activation by thrombin, will undergo a change in 
their morphology (platelet aggregation), which is more suitable for clotting in 
order to stop the bleeding. The clot consists of fibrin, fibronectin and vitronectin 
(Darby et al., 2014; Olczyk et al., 2014). Then platelets release multiple growth 
factors (Weyrich and Zimmerman, 2004), including platelet derived growth 
factor (PDGF), insulin-like growth factor-1 (IGF-1), epidermal growth factor 
(EGF), and transforming growth factor beta (TGF-β) (Singer and Clark, 1999). 
All these growth factors initiate the wound healing cascade which attract and 
activate fibroblasts, endothelial cells, neutrophils and macrophages (Demidova-
Rice et al., 2013; Darby et al., 2014). 
 
2. Inflammation 
During this phase the release of growth factors and pro-inflammatory cytokines 
from endothelial cells, keratinocytes and fibroblasts induce the chemotaxis, 
attraction and proliferation of neutrophils and macrophages, the inflammatory 
cells (Singer and Clark, 1999). They cooperate to remove dead cells, 
bacteria/pathogens and debris from the wounds by phagocytosis (Wilgus, 2008; 
Martin and Nunan, 2015), and release reactive oxygen species (ROS) that can 
act as an antimicrobial agent (Demidova-Rice et al., 2013). In addition to         
the release of inflammation stimulating molecules, the damage-associated 
molecular patterns (DAMPs) that are secreted by wound scratched or dead 
cells, and pathogen‐associated molecular patterns (PAMPs) that are secreted 
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by pathogens of infection, will initiate the inflammatory responses (Qian et al., 
2016; Roh and Sohn, 2018). Macrophages are key regulators of wound healing 
as they release further cytokines and growth factors into the wound, to recruit 
fibroblasts, keratinocytes and endothelial cells, to repair the wound (Darby et 
al., 2014). The removal of inflammatory cells by apoptosis, a programmed cell 
death, indicates the resolution of this phase (Eming et al., 2007). 
 
3. Proliferation 
Proliferation or growth of new tissue is characterized by the replacement of the 
provisional fibrin/fibronectin matrix with new granulation tissue. In this phase, 
fibroblasts proliferate, migrate, synthesise new collagen, and form new 
granulation tissue to allow re-epithelialisation to occur (Robson, 2003; Darby et 
al., 2014; Olczyk et al., 2014). Fibroblasts differentiate into myofibroblasts in 
response to TGF-β1 signalling via Smad2/3 phosphorylation (Li and Wang, 
2011) and together migrate into the wound site and produce the matrix proteins 
including fibronectin, hyaluronic acid (HA), collagens and proteoglycans, to form 
a new provisional ECM that gives more support for further ingrowth of cells 
(Singer and Clark, 1999; Midwood et al., 2004; Demidova-Rice et al., 2013). 
Collagen synthesis is essential since collagens provide strength and integrity. 
These collagens are essential components of all phases of wound healing, 
because they will become the foundation of the ECM; fibroblasts synthesise and 
secrete type III collagen to form a new matrix during wound healing (Zhu et al., 
2016). Vascular endothelial cells form new blood vessels (angiogenesis), to 
replace damaged capillaries (Montesinos et al., 2002; Chin et al., 2005; Mohd et 
al, 2012).  Granulation tissue formation is made up of capillaries and tissue 
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macrophages in a matrix of collagen (Nowak and Olejek, 2004), and 
glycosaminoglycans (GAGs) including HA (Kozma et al., 1998; Tomasek et al., 
2002). 
Finally re-epithelialisation occurs where a single layer of epithelial cells migrate 
from the wound edges, and skin appendices (Martin and Nunan, 2015), such as 
the hair follicles and sweat glands. Further proliferation is stimulated by EGF- is 
released from injured epidermis and KGF- is released from mesenchymal cells, 
which are potent stimulators of epithelial mitogenesis and chemotaxis to provide 
cover for the new tissue (Demidova-Rice et al., 2013; Darby et al., 2014). 
 
4. Remodelling 
The remodelling or contraction phase, is where matrix synthesis, remodelling 
and wound contraction occur simultaneously. In this phase, the granulation 
tissue matures to form a scar. Fibronectin and HA are broken down, and 
collagen bundles increase in diameter. Type Ӏ collagen is replaced by collagen 
type ӀӀӀ (Kuwaba et al., 2001; Reinke and Sorg, 2012; Olczyk et al., 2014). A 
balance between MMPs and their inhibitors TIMPs is important in remodelling 
wounds. As TIMP activity increases, it thereby down regulates levels of pro-
inflammatory cytokines that stimulate MMP production. Thus, MMP activity is 
decreased (Trengove et al., 1999; Zhao et al., 2013). 
Wound remodelling occurs when the underlying contractile connective tissue 
brings the wound margins closer together by increasing tissue tension. 
Contraction is an interaction between myofibroblasts (dermal fibroblasts which 
differentiate into myofibroblasts) and the ECM, which is influenced by factors 
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such as TGF-β, PDGF and fibroblast growth factor (FGF) (Hinz, 2007; 
Demidova-Rice et al., 2013). 
These myofibroblasts express alpha smooth muscle actin (α-SMA), 
microfilaments that exhibit contractile properties and can be used as a 
myofibroblast defining marker (Hinz et al., 2007; Desmouliere et al., 2005; 
Olczyk et al., 2014). Cells that are no longer needed such as macrophages and 
myofibroblasts are removed by apoptosis, and are replaced by dermal 
fibroblasts, which produce the collagen type Ӏ, and maintain the homeostasis of 














1-5-2: The acute wound 
 


















      Fig 1-7: Acute human wound healing stages. 
(A) The haemostasis phase (the platelets aggregate and release growth factors); 
(B) the inflammation phase (neutrophils migrate and accumulate); (C) the 
proliferation phase (keratinocyte migration and proliferation, recruitment of 
fibroblasts and synthesis of collagen, neoangiogenesis); (D) the remodelling phase 




1-5-3: Dermal fibroblasts in wound healing 
 
Fibroblasts are pivotal during the wound healing process, after wounding they 
are attracted from the wound edges, or from the mesenchymal stem cells and 
start to proliferate and migrate into the wound bed to produce ECM proteins 
(reviewed by Thangapazhum et al., 2014; Shi et al., 2015). ECM proteins act as 
a scaffold for inflammatory cell migration and granulation tissue generation 
(Kendall and Feghali-Bostwick, 2014), and during the inflammatory phase 
dermal fibroblasts produce a spectrum of cytokines (Werner et al., 2007)    
(Table 1-3). The main roles of the dermal fibroblasts in the wound healing 
process has been described in section 1-5-1.    
In addition to the production of ECM, fibroblasts secrete a variety of growth 
factors and MMPs that promote or regulate wound healing (Greaves et al., 
2013) (Table 1-3). Basic fibroblast growth factor (bFGF) is a potent mitogen that 
stimulates the migration, proliferation and differentiation of cells including 
fibroblasts, keratinocytes, endothelial cells and melanocytes (Shi et al., 2015), 
and regulates ECM production (Shi et al., 2013).Vascular endothelial growth 
factor (VEGF) promotes angiogenesis through its receptors on endothelial cells 
(Kendall and Feghali-Bostwick, 2014), and hepatocyte growth factor (HGF) all 
promote wound healing. (Ko et al., 2011; Loyd et al., 2012). HGF has a 
spectrum of effects on wound healing including stimulation of angiogenesis, 
regulation of matrix deposition and degradation, and promoting re-
epithelialisation of keratinocytes by stimulating keratinocyte migration and 
proliferation (Conway et al., 2006). There are many proteins expressed by 
fibroblast specific proteases MMPs such as, MMP-2, which are required during 
the remodelling phase (Trengove et al., 1999; Gill and Parks, 2008; Olaso et al., 
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2011). In mice, the expression of MMP-9 and MMP-13 during the late 
remodelling phase is believed to promote scar-free healing (Gawronska-kozak, 
2011; reviewed by Thangapazhum et al., 2014).  
Interestingly, Driskell et al, (2013) explained that wound repair in mice is 
mediated by reticular dermal fibroblasts, which are responsible for producing 
the ECM that initiates the wound healing process. These fibroblasts synthesis a 
matrix rich tissue that lacks hair follicles, while the papillary dermal fibroblasts 

















Abbreviation  Class  Produced by Function 
Interleukin 1,6 ,8 IL1, IL6, IL8 Cytokine  Macrophages, 
Keratinocytes 
Pro-inflammatory; recruit 
fibroblasts and keratinocytes 
Interleukin 2 IL2  Cytokine T-lymphocytes Recruits fibroblasts 




TNF-α Cytokine Macrophages Pro-inflammatory: promotes  








Promotes keratinocyte and 
fibroblast proliferation, 
Keratinocyte migration, and 
granulation tissue formation 
Fibroblast growth 
factor acidic and 
basic 






Cause angiogenesis, fibroblast 
chemotaxis and proliferation 
Keratinocyte 












(PDGF exists in 
several forms: AA, 







Cause neutrophil and fibroblast 
chemotaxis, fibroblast 
proliferation, and synthesis of 




(alpha and beta) 







Cause fibroblast and 
keratinocyte chemotaxis, 
angiogenesis, upregulates 
TIMP, inhibits production of 
MMPs and keratinocyte 













Cause angiogenesis (mitogenic 
for endothelial cells). Expression 
increased in the presence of 
hypoxia 
Tissue inhibitor of 
metalloproteinase 










Degrades the extracellular 
matrix 
Table 1-3: The main cytokines, growth factors and proteases that participate in 





1-6: The role of the dermal fibroblast in inflammation 
 
 Dermal fibroblasts have a significant role in switching from acute inflammation 
to chronic persistent inflammation, and they can modulate the quality, quantity 
and duration of inflammation by a number of pathways (Flavell et al., 2008; 
Kumar et al., 2013). 
The interaction between circulating leukocytes from the blood stream and 
endothelial cells helps the emigration of the leukocytes through the vascular 
endothelial barrier, to reach the underlying tissue (Zittermann and Issekutz, 
2006; Kumar et al., 2013). After activation of endothelial cells, leukocytes 
extravasate and induce an inflammatory response in the microenvironment, via 
the release of pro-inflammatory stimuli, such as tumour necrosis factor (TNF-α) 
and interferon gamma (INF-γ). Chemotactic factors, including interleukin 8 (IL-8) 
and monocyte chemoattractant protein (MCP-1), act to recruit monocytes, 
neutrophils, and lymphocytes, as well as regulating migration and infiltration of 
monocytes, and are involved in attracting the leukocytes to the site of 
inflammation (Johnston and Butcher, 2002; Kumar et al., 2013; Linthout et al., 
2014). 
Interestingly, fibroblasts accelerate the homing of the leukocytes and promote 
activation of endothelial cells at the same time (Nash et al., 2004), since they 
produce chemokines including MCP-1, at high levels compared with 
macrophage inflammatory protein (MIP-1) and express chemokine receptors 
(Hogaboam et al., 1998). MCP-1 also stimulates collagen expression and 
endogenous up-regulation of TGF-β expression in fibroblasts, leading to 
stimulation of collagen synthesis (Gharaee-Kermani et al., 1996). The induction 
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of chemokines following activation of fibroblasts with inflammatory stimuli such 
as TNF-α is regulated by the pro-inflammatory nuclear transcription factor NF-
кB (Enzerink, and Vaheri, 2011; Linthout et al., 2014).  
In mice, the lack of RelB expression (a member of the NF-кB family of 
transcription factors, which activates and regulates the KB-regulated genes 
expressed in lymphoid tissue) in fibroblasts leads to an increase in pro-
inflammatory chemokine production via fibroblasts and increased inflammatory 
cell accumulation (Smith et al., 1997), indicating that NF-кB activity may cause 
persisting inflammation (Newton et al., 1997; Linthout et al., 2014). Also 
fibroblasts can promote or inhibit the recruitment of leukocytes on endothelial 
cells via the induction, or inhibition, of cytokine-induced expression of adhesion 
molecules on endothelial cells (McGettrick et al., 2009). Another important 
function of fibroblasts in inflammation is that they regulate the behaviour of the 
immune cells and their retention and survival in damaged tissue, via crosstalk 
between the fibroblasts and immune cells (Smith et al., 1997). 
 
1-7: Chronic wounds 
 
A chronic wound fails to heal in the standard time frame, resulting in a non-
healing wound (Fig1-8). It is associated with an impairment of the normal 
healing process, which is interrupted at one or more phases, usually this results 
in a halting of the process in the inflammatory or proliferative phases (Singer 
and Clark, 1999; Al-Mulla et al., 2011). Chronic wounds are characterized by an 
increased incidence of bacterial biofilms, leading to persistent inflammation, and 
an excessive proteolytic activity that destroys the ECM (Chin et al., 2005), due 
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to high levels of MMPs with lower expression of TIMPs. Also non-healing wound 
fluid does not have growth factors, while the pro-inflammatory cytokines such as 
IL-1, IL-6 and TNF-α are elevated (Trengove et al., 2000). Fibroblasts within 
these wounds are unable to proliferate and/or migrate, which means their 
responses are poor (Agren et al., 2000; Mohd et al., 2012), since they have lost 
their functional receptors that respond to cytokines and growth factors (Mohd et 
al., 2012;  Demidova-Rice et al., 2013). 
Furthermore, there are many causes and types of chronic wounds, for instance 
chronic venous leg ulcers (CVLUs), pressure ulcers, also arterial ulcers and 
diabetic disease (Enoch and Price, 2004; Demidova-Rice et al., 2013). There 
are similarities among these pathophysiologic phenomena and/or diseases, 
which include a prolonged inflammatory phase, persistent infection, formation of 
drug- resistance microbial biofilms, and the inability of dermal and/or epidermal 
cells to respond to reparative stimuli, which collectively results in a failure of 
these wounds to heal (Edwards and Harding, 2004; Demidova-Rice et al., 
2013). A complication of aging and diabetes can lead to, and exacerbate 
vascular pathologies, including both arterial and venous insufficiencies, and 
worsen pressure ulcers. Another complication that leads to the development of 
chronic wounds in diabetic patients is neuropathy, often linked to vascular 
impairment, deficiencies in muscle metabolism, and a number of microvascular 
pathologies. The wounds are recognized by cellular phenotypic abnormalities, 
including low mitogenic potential and the inability to respond to environmental 









Fig 1-8:  Chronic wound biology. 
The diagram illustrates the chronic wound which can be infected with biofilm 
microorganisms, and exhibit lengthened and excessive inflammation. Re-
epithelialisation stalls while hyperproliferation of keratinocytes occurs. High expression 
of MMPs, leads to defective granulation tissue, and poor fibroblast infiltration. This is 
accompanied by impaired angiogenesis, elevated levels of oxygen free radicals, 
abundance of collagen type ӀӀӀ and an increase in inflammatory cell numbers (Martin 






1-8: The inflammatory phase in chronic wounds 
 
Inflammation is an important stage in wound healing that is disrupted and 
deregulated in chronic wounds (Satish, 2015). The inflammatory phase takes 
place early in the sequence lasting only a few days, followed by progression to 
tissue regeneration including re-epithelialization, granulation tissue formation, 
angiogenesis and tissue remodelling (Zhao et al, 2013).  
Non-healing wounds are characterized by a prolonged inflammatory phase, 
which alters the progression of wound healing and can be accompanied with 
microbial infection that contributes to the prolongation of this inflammation 
(Zhao et al, 2013). Moreover, this prolongation may lead to chronic 
inflammation by altered production of pro- and anti-inflammatory cytokines, 
causing an impaired angiogenesis process, and decreasing granulation tissue 
formation by reducing migration and proliferation of keratinocytes and 
fibroblasts (Goova et al., 2001; Blakytny and Jude, 2008). The extended 
inflammatory phase may relate to an imbalance between pro and anti- 
inflammatory cytokines in chronic wounds, particularly the high levels of 
interleukins IL-1, IL-6 and Il-8 and TNF-α (Fivenson et al., 1997; Satish, 2015). 
The continuous exposure to pro-inflammatory cytokines may stimulate the 
production of MMPs, while inhibiting the synthesis of TIMPs (Trengove et al., 
1999; McCarty and Percival, 2013), whereas IL-1 and TNF-α enhance 
collagenase secretion (Barchowsky et al., 2000). Another explanation is that the 
inflammatory phase disrupts the normal balance between deposition and 
degradation of ECM components. The degradation and remodelling of the ECM 
by MMPs, which is a major factor in wound repair, and the failure in the control 
of its expression results in excessive ECM degradation with a delay in healing. 
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Also it is important in the recruitment of leukocytes, regulation of angiogenesis 
and re-epithelialisation (Diegelmann and Evans 2004; Schultz and Wysocki, 
2009; McCarty and Percival, 2013).    
 
1-9: Tumour necrosis factor-alpha 
        
Tumour necrosis factor- alpha (TNF-α) or cachexin is a pleiotropic and pro-
inflammatory cytokine, which is considered the most important inflammation 
marker for it is present in both acute and chronic inflammation processes (Wang 
and Lin, 2008; Agren et al., 2015). TNF-α expression levels are responsible for 
controlling the inflammation process switching from acute to chronic, which 
exhibit the key role of TNF-α. Furthermore, the excessive expression of TNF-α 
can lead to chronic, inflamed, non-healing wounds and/or inflammatory 
diseases (Han et al., 2001a; Intiso et al., 2003; Arican et al., 2005; Gohel et al., 
2008; Montgomery and Bowers, 2012). 
Although the inflammatory cells such as the macrophages are the main 
producer of this cytokine, it can be secreted by other immune cells that are 
involved in inflammation responses, and even by cells such as fibroblasts and 
neurons (Han et al., 2001a; Intiso et al., 2003; reviewed by Xu et al., 2013).  
TNF-α exists in two forms; the trans- membrane (membrane-bound) and the 
secreted form, and both are biologically functional and active (Varfolomeev and 
Vucic, 2018). The central function of TNF-α is to regulate the immune response 
by regulating and controlling the immune cells and it aids in maintaining 
homeostasis of the immune system (reviewed by Xu et al., 2013; Varfolomeev 
and Vucic, 2018). In addition, TNF-α can participate in many biological functions 
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such as cell activation, proliferation and apoptosis, depending on its 
concentration and the target cell type (Ruckert et al., 2000; Petrache et al., 
2000) (Fig 1-9). The TNF-α cytokine has two main receptors, which are TNFR1 
(receptor type one; p55) and TNFR2 (receptor type two; p75) (Theiss et al., 
2005; reviewed by Xu et al., 2013). Receptor TNFR1 is 55kDa and receptor 
TNFR2 is 75kDa, TNFR1 can be found in most cell types and can be activated 
by both forms of TNF-α (membrane- bound and soluble). Also it is believed that 
most TNF-α signalling pathways are performed by binding to this receptor, 
whereas TNFR2 can be found in immune cells and endothelial cells, and binds 
with high affinity to the membrane- bound form (Montgomery and Bowers 2012; 













Fig 1-9: Effects of TNF-α on target cells. 
The various effects of TNF-α at the cellular level lead to inflammation, cell survival 




1-9-1: TNF- α signalling pathways 
 
TNF-α effects are mediated by binding to the two types of cell membrane 
receptors TNFR1 and TNFR2 (Poggi et al., 2013; Moelants et al., 2013), or 
binding to receptor type one (TNFR1) (Bose, 2015). One of three main TNF-α 
pathways, the inflammation or NF-kB activation pathway (Fig 1-10); starts by the 
binding of TNF-α to the extracellular domain of its receptor TNFR1, causing 
conformational changes in the receptor itself, which leads to dissociation of the 
inhibitory protein Silencer of death domains (SODD) from the death domain 
(DD). This allows the adapter protein molecule interacts with TNF-R1-
associates death domain protein and form (TRADD), which attaches to the 
intracellular side of the receptor and provide a scaffold for the sequenced 
binding events (reviewed by Turner et al., 2014). TRADD recruits two 
molecules, (TNF-α receptor associated factor 2) TRAF2 and RIP1 (receptor 
interacting protein), then TRAF2 recruits Ik-B kinase, or IKK complex- an 
enzyme transfer phosphate group from high energy compound. The IKK 
complex phosphorylates Ik-Bα resulting in subsequent events through ubiquitin-
mediated proteasomal degradation. Targeted degradation of Ik-Bα leads to 
release of NF-kB (free NF-kB dimers are mainly p50/p65 or p50/c-Rel), which is 
a transcription factor that translocates to the nucleus. NF-kB mediates the 
transcription of vast numbers of pro-inflammatory cytokines and inflammatory 



























Fig 1-10: Triggering of the NF-kB pro-inflammatory signalling pathway by TNF-α. 
 
NF-kB signalling pathway starts by binding the trimeric cytokine to it is receptor TNFR1, 
which attracts TRADD, followed by TRAF2. RIP1binding to TRADD, leads to 
phosphorylation of IKK enzyme, phosphorylation of Ik-Bα by IKK, resulting in Ik-Bα 
promotes its polyubiquitination and degradation, and thus releasing of NF-kB dimers to 








1-9-2: TNF-α and wound healing 
 
The pro-inflammatory cytokine TNF-α has a significant role in the inflammatory 
phase in the process of wound healing, but excessive levels of this cytokine 
may cause chronic, inflamed non-healing wounds by lengthening this phase 
and increasing the inflammatory cell numbers such as neutrophils and 
leukocytes (Tellechea et al., 2010; reviewed by Xu et al., 2013). Some 
researchers reported that elevated TNF-α levels lead to a significant increase in 
chronic wounds, such as chronic venous leg ulcers, compared to acute or 
healing wounds (Gohel et al., 2008; Tellechea et al., 2010; Khanna et al., 2010).  
TNF-α has various effects on the dermal fibroblast. The cytokine inhibits both 
the differentiation of dermal fibroblasts to myofibroblasts, which is important to 
contract the wound. TGF-β1 via the Smad signalling pathway both in vitro and 
in vivo induces the expression of the α-SMA gene (Goldberg et al., 2007), and 
the production of ECM proteins such as fibronectin and type I collagen. In 
addition, TNF-α stimulates MMP (MMP-1,-2,-3,-9 and -13) expression, all these 
effects may lead to non-healed and chronic wounds (Arancibia et al., 2013; Zhu 
et al., 2016). The in vitro effects of TNF-α are time, and dose-dependent;        
low concentrations of TNF-α promote remodelling/healing of injured and 
senescent tissue indirectly by stimulating inflammation and increasing the 
number of macrophages, which release growth factors that stimulate fibroblast 
proliferation (Tracey and Cerami, 1990; Barrientos et al., 2008). However, high 
concentrations of TNF-α (for a long time) can induce apoptosis of dermal 
fibroblasts and have a deleterious effect on healing (Petrache et al., 2000; 




1-10: Cytokines  
 
Cytokines are small molecular weight proteins of 5-20 kDa, which are also 
called soluble factors (Gulati et al., 2016). Cytokines have a crucial regulatory 
role in mediating the inflammatory and immunity responses (Cameron and 
Kelvin, 2003; Dinarello, 2007; Holdsworth and Gan, 2015), as well as mediating 
the reactions of a number of biological processes such as: immune cell 
proliferation and differentiation, haematopoiesis, inflammation, angiogenesis, 
tumorigenesis, infections, and induction of wound healing, through specific 
receptors (Behm et al., 2011; Gulati et al., 2016; Mclnnes, 2017). Thus, they 
can be used as diagnostic markers for health or disease, and as therapeutic 
agents (Dinarello, 2007; Holdsworth and Gan, 2015). Cytokines are secreted 
from a range of different cells, in particular immune cells, but also other cells 
such as fibroblasts, endothelial cells and stromal cells (Chung, 2009, Turner et 
al., 2014). They include many families; the chemokine family, the interferons, 
the interleukins, the lymphokins, lymphocyte growth factors, the tumour 
necrosis factor family and adipokines (Zhang and An, 2007; Bishara, 2012; 
Feng et al., 2016). Cytokines can act in a number of ways; on the cells that 
secreted them (autocrine), or modulate the neighbouring cells (paracrine), and 
also action on long distance cells (endocrine) (Mirza and Koh, 2015; Feng et al., 
2016). They can be classified depending on their function, or the secreted cells, 
or the target of action and/or biological chemical structure (Anaya et al., 2013; 
Gulati et al., 2016). 
As mentioned before, wound healing is a complex process, which involves the 
coordination of different types of immune and skin cells. Their migration, 
infiltration, recruitment, proliferation and differentiation at the site of the wound 
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are controlled and regulated by a complex signalling/interaction network, which 
involves a large number of intracellular messengers including several cytokines, 
chemokines and growth factors, in overlapping wound healing process phases, 
as described in section 1-5-2. Dysregulation in the expression or function of 
these molecules will alter or delay the normal healing process (Behm et al., 
2011).   
The inflammatory phase is mediated by multiple growth factors and cytokines 
and/or chemokines. The role of the chemokines are to recruit leukocytes, 
macrophages and inflammatory cells via migration and proliferation to the 
wound site as sources for growth factors, and to remove the debris, as well as 
to provide host defence, for example CX3CL1, which induces macrophages 
recruitment (Ishida et al., 2006; Ishida et al., 2008; Behm et al., 2011). Also, in 
this stage, there is an increase in the expression of pro-inflammatory genes 
such as IL-1α, IL-1β, IL-6, and TNF-α, which induce inflammation (Mohd et al., 
2012; Satish, 2015; Ligi et al., 2016a). High levels of IL-1 or IL-6 were detected 
in chronic wounds, which are considered as markers for these wounds, and 
their prolonged inflammatory phase (Chin et al., 2005; Satish, 2015). In the 
proliferative phase, there is a switch to collagen synthesis and granulation 
tissue formation, via releasing IL-4, which acts as anti-inflammatory cytokine 
and triggers the production of precursor collagen proteins. IL-4 also induces the 
expression of IL-27, which inhibits the production of pro-inflammatory cytokines. 
In addition, the IL-6 mediates the infiltration of immune cells indirectly, collagen 
deposition, angiogenesis, and keratinocyte proliferation via inducing growth 
factors. In the remodelling phase. Some interleukins are considered to act as 
regulators of MMPs, e.g. MMP-3 induction via IL-22 would have a positive 
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impact on epidermal skin cell division (Yates et al., 2007; McCarty and Percival, 
2013), similarly, IL-1 inhibits TIMP-1 and induces MMP-1,-3 and -9 in 
fibroblasts. And for chemokines, both CXCL10 and CXCL11 mediate pathways 
that initiate the remodelling phase after mediating the end of the proliferative 
phase, via CXCR3 receptor (Satish, 2015).    
  
1-11: Matrix Metalloproteinases MMPs 
 
 
Matrix metalloproteinases MMPs are a family of zinc (Zn2+) -dependent 
endopeptidases, 23 genes have been identified for the members of this family   
in humans, these members can be found as soluble or membrane-type (Itoh, 
2015). MMPs have a specific degrading ability for extracellular matrix ECM 
proteins, the major component of the dermis. They are involved in many 
biological functions such as; development, morphogenesis, regeneration and 
wound healing, facilitate cell migration or invasion, and skin aging (Gohel et al., 
2008; Gawronska-kozak, 2011; Frankowski et al., 2013; Chen et al., 2013). 
These proteolytic enzymes are also considered as inflammation markers in 
inflammatory diseases and inflamed chronic non-healing wounds (Weckroth et 
al., 1996, Han et al., 2001a, b). Due to their proteinase actions they are 
presented in all wound healing phases; i.e. influx of immune cells, keratinocyte 
and dermal fibroblast migration, angiogenesis and ECM remodelling (Gill and 
Park, 2008; Gawronska-kozak, 2011). Importantly, the expression of MMPs in 
the remodelling phase without balancing by their inhibitors (TIMPs) that 




Thus, an imbalance between MMPs and TIMPs leads to impaired wound 
healing and chronicity (Diegelmann and Evans, 2004; Gawronska-kozak, 2011; 
reviewed by Xu et al., 2013).  
The MMP family include the collagenases (MMP-1, -8, -13), which cleave 
unique sites of collagen types I, II, III and V; the gelatinases (MMP-2, -9) which 
degrade gelatin; the stromelysins (MMP-3, -10 and -11) that degrade a range of 
ECM molecules, macrophage metalloelastases (MMP-12), and membrane-type 
MT-MMPs e.g. (MMP-14) (Gawronska-kozak, 2011; Frankowski et al., 2013). In 
addition, MMPs mediate the release of growth factors and pro-inflammatory 
molecules such as FGFs, IGF, TGF-β and TNF-α. MMPs are structured from a 
single peptide, a pro-peptide, a catalytic domain (has a zinc binding site), and 









 Fig 1-11: MMPs simple structure. 
(A) MMPs (collagenases and stromelysins) contain SP, Pro, catalytic and hemopexin 
domains, (B) Gelatinases have a similar structure with additional FN domains (SP: 
single peptide, Pro: propeptide, catalytic domain has zinc binding site hemopexin-like 
c-terminal domain (made up 4 repeated units binding by s-s bridge and inserted FN: 3 
fibronectin type II repeats. The hinge region H links hemopexin-like C-terminal domain 






The gelatinolytic enzymes (MMP-2, -9) or gelatinase A and gelatinase B are two 
important members which are comprised of fibronectin-like domains for collagen 
binding, and both can cleave type IV and/or types I, V, VII, XI collagen and 
laminin as well as gelatin (Han et al., 2001a; Frankowski et al., 2013 ). Both 
have a functional role in the wound healing process because of their ability in 
remodelling the basement membrane, and this feature controls cell migration 
and proliferation during both metastasis in cancer and in wound healing (Han et 
al., 2001a; Gohel et al., 2008). MMP-2 and MMP-9 are secreted into the tissues 
in the form of pro-MMP-2 and pro-MMP-9 (inactivated forms) and their 
conversion to the active form is controlled by removing the N-terminal 
prodomain by autocatalytic cleavage (Han et al., 2001a; Frankowski et al., 
2013). Elevated levels of MMP-3, MMP-1 and MMP-7 activate pro-MMP-9, 
while elevated levels of MMP-14 and MMP-16 activate pro-MMP-2 (Murphy et 
al., 1999; Morrison et al., 2001). 
 
 
1-12: TIMPs- tissue inhibitors of matrix metalloproteinase   
 
MMP activity can be regulated/inhibited by four inhibitors, named tissue 
inhibitors of metalloproteinases (TIMPs), 21–34 kDa proteins in size, which are 
endogenously expressed (Lambert et al., 2004; Brew and Nagase, 2010; Moore 
and Crocker, 2012). They are secreted by variety of cells including fibroblasts, 
epithelial and endothelial cells, smooth muscle cells and many tumour cells 
(Shapiro, 2009; Ulrich et al., 2010), and in human skin by dermal fibroblasts and 
keratinocytes (Lopez-Lopez et al., 2014). TIMPs can inhibit MMPs via tight, 
non-covalent binding with 1:1 stoichiometry (Ulrich et al., 2010; Giannandrea 
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and Parks, 2014). TIMP-1, TIMP-2, and TIMP-4 are secreted proteins (non-
bound), whereas TIMP-3 is bound to the extracellular matrix to promote MMP 
inhibition (Arpino et al., 2015). Interestingly, TIMP-1 can strongly inhibit a range 
of MMPs, but has a low affinity for the membrane-type MMPs (MT) - MMPs, 
which is different to others (Brew and Nagase, 2010; Löffek et al., 2011).  
TIMPs are considered to play a key role in ECM homeostasis, and in the 
progression of wound healing. The imbalance between MMP and TIMP activity 
would cause a chronic wound, and excessive MMP activity leads to enhanced 
degradation of ECM, essential growth factors and cytokines causing persistent 
inflammation in chronic wounds (Moore and Crocker, 2012; Lopez- Lopez et al., 
2014; Arpino et al., 2015). Furthermore, in fibroblasts, TIMP-2 has to form a 
complex relationship with MMP-2 to be secreted. As TIMP-2 can inhibit MMP-2, 
it also can dock proMMP-2 to the cell membrane, where the enzyme is 
activated by (MT) - MMPs (Shapiro, 2009). In diabetic wound studies, a 
decrease in TIMP-2 expression, while an increase in MMPs expression resulted 
in the failure of diabetic wounds to heal (Lobmann et al., 2002; Lopez- Lopez et 
al., 2014).  
TIMP-3 controls the ECM remodelling during wound healing. In rodent skin 
studies, Timp-3 knockout mice displayed abnormal collagen and fibronectin 
remodelling (Caley et al., 2015). TIMP-4 has an important role in inflammatory 
diseases such as psoriasis. Psoriatic studies in human, showed that TIMP-4 is 
the most important inhibitor of psoriatic skin degeneration, which is increased by 




1-13: Skin ageing 
 
Skin ageing is a chronological process that leads to structural and functional 
changes, and can be induced by both intrinsic (chronological) and extrinsic 
(environmental) factors. Aging skin is characterized by a reduction in thickness, 
alterations in biochemical properties and reduced collagen production, with 
increased fragmentation of dermal collagen fibrils that is a result of elevated 
MMP-1 activity, all of which slows wound healing (Percival, 2009; Fisher et al., 
2009; Quan. et al., 2012). This reduction is also associated with disorganization 
of type Ӏ collagen, a decline in collagen Ӏ production resulting in impaired 
function, an increase in type ӀӀӀ collagen, an increase in skin laxity, a decrease 
in HA content, and reduction in elastin, which leads to prominent wrinkles 
(Montagna and Carlisle, 1979; Percival, 2009; Baumann et al., 2009; Reviewed 
by Kammeyer and Luiten, 2015). These aging signs arise from the changes in 
ECM properties that leads to a defective remodelling phase, impairing or 
delaying wound closure (Coppe et al., 2010). In addition, the proliferative ability 
of keratinocytes and fibroblasts become decreased. A decline in the rate of 
keratinocyte proliferation leads to epidermal atrophy (Gilchrest, 1983), while 
fibroblasts appear senescent and the proportion of senescent fibroblasts 
increases with age (Frants et al., 2010). Senescent fibroblasts have a reduced 
migratory capacity and are unresponsive to stimulatory growth factor signals, so 
they are unable to replicate. They also have increased MMP expression, while 
TIMP expression is reduced (reviewed by Kammeyer and Luiten, 2015). In 
addition, senescent fibroblasts result in high levels of fibronectin in the ECM due 
to an increase in the rate of synthesis (Kondo and Yonezawa, 1992; Coppe et 
al., 2010), and an alteration in the physical nature of the fibronectin causes a 
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decrease in cell adhesive properties, so generally the ability of fibroblasts to 
produce ECM proteins is impaired in older people (Ashcroft et al., 1995).  
Studies on aging associated with murine wound healing have shown that after 
wounding there is a delay in the formation of granulation tissue in older mice 
due to the decrease in fibroblast numbers and collagen density (Kligman and 
Lavker, 1998). There is also an association between skin aging and the delay in 
macrophage infiltration, angiogenesis and re-epithelialisation.  
In humans, TGF-β1 plays a key role in wound healing in vivo (Al-Mulla et al., 
2011). TGF-β1 expression is decreased in the wounds of elderly females 
compared with younger females (Ashcroft et al., 1997). Interestingly, TGF-β is a 
major growth factor involved in collagen synthesis by activation of fibroblasts to 
produce collagen (Quan et al., 2012).  
 
1-13-1: Senescent cells 
 
The first description for cellular senescence was in 1965 by Hayflick, as a 
genetic program that limits the proliferation of normal human cells (Campisi and 
d’Adda di, 2007; Daniel et al., 2015). Cellular senescence is now linked to 
tumour suppression and aging (cellular senescence refers to irreversible growth 
arrest which means the loss of proliferative ability) (Hayflick and Moorhead, 
1961; Campisi and d’Adda di, 2007; Rodier and Campisi, 2011). Cellular 
senescence contributes to aging since senescence associated phenotypes can 
participate in both tumour progression and inhibit normal tissue repair (Rodier 
and Campisi, 2011). In vitro, cultured dermal fibroblasts can be induced into 
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senescent cells by replicative senescence (long-term passaging), or stress 
induced premature senescence, or by causing nuclear DNA damage using 
ionizing radiation (Coppe et al., 2008; Coppe et al., 2011; Daniel et al., 2015). 
Senescent cells can be recognized by their enlargement and flattened shape 
and expression of senescence- associated β-galactosidase (SA-β-Gal) activity 
(Dimri et al., 1995; Quan et al., 2012; Rock et al., 2015). Other properties          
of senescent cells include irreversible growth arrest; enhanced 
heterochromatinization (Kreiling et al., 2011); they have an altered secretory 
phenotype, with robust secretion of numerous growth factors such as insulin- 
like growth factor binding protein-6 (IGFBP6), interleukins (IL- 4, IL-8 and IL-1β), 
cytokines (TNF-α), and proteases (MMP-1, MMP-3 and MMP-10). In addition to 
other senescence–associated secretory phenotype (SASP). Furthermore, 
SASP proteins such as these described above in some studies may facilitate 
wound healing, participate in biological processes and contribute to aging 
(Rodier and Campisi, 2011; Daniel et al., 2015; Ohgo et al., 2015). Interestingly, 
senescent cells remain viable and metabolically active, along with an increased 
resistance for apoptotic death (Dimri et al., 1995). 
A study by Röck et al (2015) found some microRNAs (miRNAs) which are 
noncoding RNAs, have a functional role in regulating skin cell senescence in 
vitro and dermal aging via binding to HAS2 (membrane enzyme hyaluronic acid 
synthase 2, which mediates HA synthesis). This results in reduced HAS2, which 
leads to induction of senescence markers and inhibition of proliferation (Mancini 




1-14: Skin alterations with aging 
 
Scientific studies of skin aging have focused on the dermis as the most affected 
part of the skin by aging alterations (Quan et al., 2015). The dermis becomes 
damaged, thin and the collagen fibrils are thinning, reduced in their organization 
and increased fragmentation (Quan et al., 2012). Moreover, alterations in 
collagen fibrils will impair the structural integrity of the skin and its functional 
properties, resulting in increased skin fragility (Quan et al., 2012). Furthermore, 
age- dependent alterations in the dermal ECM create a microenvironment that 
facilitates the formation and growth of epithelial cancer (Kudravi and Reed, 
2000; Bissell et al., 2005).  
Both impaired function and migration of dermal fibroblasts can have a 
significant influence on skin aging (Quan et al., 2010; Quan et al., 2015).        
Fibroblasts exhibit reduced spreading and contact with collagen fibrils, causing 
the loss of their typical morphology and have a collapsed appearance (Varani et 
al., 2004; Fisher et al., 2008; Qin et al., 2014). The reduction of fibroblast 
spreading has two effects; it up-regulates MMP-1 expression through the 
activation of the transcription factor (AP-1) which controls MMP-1 expression 
and causes collagen fragmentation, and secondly causes a down-regulation of 
collagen production through TGF-β inhibition, which is the major factor in 
collagen synthesis and other ECM protein production (Varga et al., 1987; Quan 
et al., 2010). Furthermore, these alterations expand to the aged epidermis at 
the intersection of the epidermis and dermis, which is named the dermal-
epidermal junction (DEJ), which becomes more flattened with age (Percival, 




1-15: Sirtuins  
  
Silent regulation information 2 (SIR 2) was the first sirtuin discovered to be 
responsible for lifespan extension in yeast (reviewed by Li and Kazgan, 2011; 
Hubbard and Sinclair, 2013; Ma et al., 2014). Sirtuin enzymes function            
by oxidizing their NAD+ (reviewed by Kelly, 2010a), they can regulate chromatin 
or genes; respond to epigenetic changes, which are heritable changes in gene 
expression without any modulations in the DNA sequence, and these changes 
have pivotal roles in skin growth and homeostasis, including wound healing 
(Perdigoto et al., 2012; Plikus et al., 2015; Zhang and Duan, 2015; reviewed by 
Saldanha et al., 2016).  
Also, sirtuins are effective in an organism’s response to stress and toxicity. 
Therefore, they contribute in lifespan/longevity, obesity/cellular metabolism, 
inflammation, heart disease, cancer, neurological activity and aging (reviewed 
by Kelly, 2010b; Hubbard and Sinclair, 2013). Sirtuin substrates and functions 
are summarized in Table 1-4.  
Histone acetylation can be explained as adding the acetyl group from acetyl Co 
A onto the lysine residues in the histone tail. Two basic enzymes that control 
the acetylation are histone acetyltransferase (HAT) and histone deacetylases 
(HDACs), (Kiefer, 2007; Ruthenburg et al., 2007; Arrowsmith et al., 2012). 
Moreover, acetylation is considered as a dynamic balance between the two 
enzymes (Kiefer, 2007). In mammals, HATs can be found in 5 families, while 
HDACs can be divided into 4 basic classes, the class III HDACs include the 
nicotinamide adenine dinucleotide+-dependent (NAD+-dependent) sirtuins (Ma 
et al., 2014). In mammals, there are seven sirtuin genes which express the 
Sirt1-7 enzymes. Sirt 1, 2, 6 and 7 are expressed primarily in the nucleus, Sirt 2 
47 
 
is localised in the cytoplasm, while the last group Sirt 3, 4 and 5 are located in 
the mitochondria (reviewed by Kelly, 2010a; reviewed by Li and Kazgan, 2011).   
In humans, there is a strong relationship between sirtuins and wound healing. 
The pro-inflammatory cytokine IL-22 modulates human keratinocyte proliferation 
and differentiation, its effect can be controlled by Sirt1 through acetylation of the 
STAT3-dependent pathway, which inhibits the IL-22 inflammatory effects and 
regulates keratinocyte proliferation (Dal Farra and Domloge, 2006; Blander et 
al., 2009; Sestito et al., 2011). In mice, the lack of Sirt 6 in diabetic wounds is 
characterized by activation of the NF-kB pathway activation, resulting in 
inflammation and impaired angiogenesis, caused by the decrease in VEGF 
















Table 1-4: Sirtuins of mammals  
The mammalian sirtuins 1-7, activity, their substrates and sirtuin functions 
(reviewed by Li and Kazgan, 2011). p53: tumour suppressor protein 53; Foxo: 
forkhead box O; Bax: Bcl2 associated X protein; Hif: hypoxia-inducible factor; 
HSF1: heat shock factor 1; STAT3: signal transducer and activator of transcription 
3; PGC-1α: peroxisome proliferator-activated receptor gamma coactivator 1α: 
TORC2/CRTC2: a transcriptional coactivator for the transcription factor CREB; 
LXR: liver X receptor; FXR: farnesoid X receptor; SREBP: sterol regulatory 
element binding protein; PER2: period circadian protein homolog 2; H4: histone 4; 
AceCS2: acetyl-CoA synthetase 2; LCAD: long-chain acyl CoA dehydrogenase; 
HMG-CoA synthase 2: 3-hydroxy-3-methylglutaryl CoA synthase 2; IDH2: 
isocitrate dehydrogenase 2; MnSOD: Mn-superoxide dismutase; SOD2: 
superoxide dismutase 2; GDH: glutamate dehydrogenase; CPS1: carbamoyl 
phosphate synthetase 1; CtIP: C-terminal binding protein interacting protein; H3K9: 
histone 3 acetyl-lysine 9; H3K56: histone 3 acetyl-lysine 56; CtIP, C-terminal 
















Sirtuin Activity Substrates  Functions 
SIRT1 
 









Tubulin,H4,Foxo3a Cell cycle, tumour 
suppressor 
















H3K9, H3K56, CtIP, SIRT6 DNA repair, metabolism, 
inflammation 
SIRT7 Deacetylase              
       
P53 rDNA transcription 
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1-16: Type 2 diabetes mellitus (T2DM) 
 
Type 2 diabetes is a metabolic disorder, which is characterized by elevated 
glucose levels in the blood, and it is the most common type of diabetes (Leon 
and Maddox, 2015; reviewed by Tadic and Cuspidi, 2015). Type 2 diabetes can 
cause serious long-term health problems which include; eyes (vision loss and 
blindness), heart (cardiovascular diseases and stroke), chronic wounds, which 
fail to close, along with aging, (reviewed by Baltzis et al., 2014; Mirza and Koh, 
2015), and kidney failure (Amutha and Mohan, 2016). Moreover, neuropathy, 
microvascular disorders and angiopathy are all complications of diabetes and 
contribute to a 12-25% lifetime risk of developing diabetic ulcers, which are the 
main cause of limb amputations (Das et al., 2016). Type 2 diabetes can be 
caused by a defect in insulin hormone secretion, which is normally produced by 
the beta cells in the pancreas, and is responsible for controlling and regulating 
the amount of glucose in the blood. It can be associated with obesity, or due to 
having a family history (can be inherited) of type 2 diabetes (Kaku, 2010; 
reviewed by Wu et al., 2014).  
The main difference between diabetes type 1 and 2 is that, type one is insulin-
dependent diabetes mellitus, while type 2 is influenced by the environment, or 
due to insulin deficiency (low production levels), or insulin resistance (Kaku, 
2010; De Lade et al., 2016), e.g. the target tissue of multiple organs is resistant 
to the action of insulin (Alves et al., 2008). Insulin resistance is accompanied by 
persistent hyperglycemia- very high levels of circulating glucose, with pancreatic 
β-cell dysfunction. The glucose is not used as fuel for energy and remains         
in the circulation, causing an attenuation in protein, lipid and carbohydrate 
metabolism, which is a classical feature of type 2 diabetes (Kaku, 2010; Saini, 
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2010). The molecular explanation for insulin resistance phenomena is that an 
attenuation in the normal insulin activation signalling pathway IRS-1/PI3K/Akt, 
which is responsible for the regulation of glucose transport in response to 
insulin, leads to insulin resistance (Choi and Kim, 2010). 
Patients with type 2 diabetes suffer from impaired wound healing and persistent 
inflammation, micro- and macro-circulatory dysfunction, hypoxia, and impaired 
neuropeptide signalling. Diabetic chronic wounds manifested with impaired 
angiogenesis, increased MMP levels, increased levels of pro-inflammatory 
cytokines, hyperglycemia, which leads to glycation of collagen, plasma, and 
other proteins. Protein glycation forms the advanced glycation end products 
(AGEs). All of which reduce the solubility of the ECM and most inflammatory 
alterations, resulting in impaired wound closure (Argyropoulos et al., 2016; Feng 
et al., 2016). Interestingly, in human, AGEs participate in the pathogenesis of 
diabetic complications and other diseases such as; rheumatoid arthritis, 
osteoporosis and even aging (Singh et al., 2014). Some studies have shown 
that, collagen glycation can increase the formation and migration of 
myofibroblasts, resulting in the development of fibrosis in diabetes (Yuen et al., 













While the role of dermal fibroblasts in the production of the ECM has long been 
recognised, additional roles of the dermal fibroblasts in inflammation, 
particularly during cutaneous wound healing, are only now starting to emerge.  
The hypothesis of this study is that the dermal fibroblast acts as a gatekeeper of 
the inflammatory response in human skin during wound healing with a central 
role in regulating acute and chronic inflammation, fibrosis, and the resolution of 
inflammation. 
Since chronic inflammation leads to phenotypic changes detrimental to wound 
repair, primary human dermal fibroblasts will be cultured in the presence of the 
pro-inflammatory cytokine TNF-α to mimic a pro-inflammatory chronic wound 
environment.  
 
The first aim of this study is to determine functional changes in dermal 
fibroblasts, e.g. proliferation, metabolic activity and migration in the presence of 
different concentrations of TNF-α, and for different lengths of exposure. 
Human dermal fibroblasts are an extremely heterogeneous population arising 
from two different lineages with different phenotypes depending upon 
anatomical location, their position in the dermis, whether they are from hair-
bearing skin, and the age and sex of the donor. Therefore, primary dermal 
fibroblasts will be cultured from the skin of women of a similar age, from a 




The next aim of this study is to identify the secretory phenotype of dermal 
fibroblasts in response to inflammatory cytokines, such as TNF-α. The 
senescent phenotype induces an irreversible arrest of proliferation, but the 
fibroblast is still metabolically active, with an altered senescent associated 
secretory phenotype (SASP). An increase in the percentage of senescent 
fibroblasts in response to TNF-α will be measured by the expression of β-
galactosidase, and the culture media will be collected for further analysis. 
 
In order to analyse changes in the secretory phenotype of the dermal 
fibroblasts, this study will measure the changes in the secretion of the 
gelatinases, MMP-2 and MMP-9 by zymography for healthy donors and diabetic 
patients, to determine whether they are induced by the pro-inflammatory 
cytokine TNF-α.  
 
In order to gain a better understanding of the molecular differences that may 
discriminate fibroblasts in chronically, inflamed wounds from these in acute 
wounds, dermal fibroblasts from healthy donors and diabetic patients will be 
cultured in presence of different concentrations of TNF-α and changes in the 
expression of extracellular matrix and senescence genes, such as (MMP-1, 






The final aim of this study is to establish whether dermal fibroblasts exposed to 
a chronic inflammatory environment will demonstrate changes in their secretion 
profile of cytokines that may help to identify markers for new therapeutic targets 




















2 Materials and Methods 
2-1: Cell culture 
 
Primary human dermal fibroblasts were obtained from previously established 
cells frozen in liquid nitrogen. The original skin samples were obtained from 
Ethical Tissue Bank from female cosmetic surgery (facelift) skin, which were 
established as described in (Kamala, 2014). Cells used in all experiments are 
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77 F P6  ✓ 
 
Comparison of 2% and 10% 
growth media 
Table 2-1: Healthy dermal fibroblasts donor details. Age, gender, passage, skin 
source and assays used for all healthy dermal fibroblast donors. Note that phenotype 
varies with passage number so different techniques are used for their characterisation. 
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2-2: Diabetic cell culture 
 
Diabetic primary human dermal fibroblasts were obtained from diabetic patient’s 
leg skin following amputation. The consent from diabetic patients and ethical 
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✓ Migration assay, Gelatin 
zymography, RT-PCR, 
Human cytokine array, 
10539 
 
65 F P3 
 
✓ Migration assay, Gelatin 
zymography, RT-PCR, 
Human cytokine array, 
10206 66 M P3 ✓ Migration assay, Gelatin  
zymography, RT-PCR 
Table 2-2: Type 2 diabetic mellitus (T2DM) dermal fibroblasts patient details. Age, 
gender, passage, skin source and assays used for all diabetic dermal fibroblast 
















2-2-1: Isolation of primary diabetic dermal fibroblasts  
 
After obtaining the skin samples from diabetic patients (type 2 diabetes 
mellitus), the fat layer was removed and discarded using a small forceps and 
scissor till reaching the dermis layer which appeared white. Then the skin 
sample was cut to small pieces, 1cm2 for each using forceps and scalpel. After 
that, the pieces were washed and sterilised twice in phosphate buffer saline 
(PBS) containing 1% penicillin/streptomycin (100U/ml and 100μg/ml) (Gibco) 
and 1% of amphotericin B (250μl/ml) (Gibco) in Falcon tubes (50ml). These 
pieces were transferred into 50ml Falcon tubes or Petri dishes which contain 
dispase II (protease) solution (Sigma-Aldrich, UK) (100mg of dispase II in 100ml 
PBS) in fridge for one overnight at 4˚C- to facilitate separating the epidermis 
from dermis. Next day, by using two forceps and 100 mm Petri dishes, the 
epidermis were pulled out from the dermis and the pieces were washed in tubes 
containing normal growth media for 2-3 times to remove dispase II traces. 
Quickly, the pieces were moved to T75 culture flasks contain 12ml of growth 
media and incubated at 37˚C in 5% CO2, for 4 weeks with changing the media 
each 1-2 days till the dermal fibroblasts started emerging from the dermis, 
attaching to the flask and proliferating. After, the attached dermal fibroblasts 





















Fig 2-1: Growing stages of primary 
dermal fibroblasts. (A) DFs were 
derived from small human skin piece, 
(B) DFs spreading and (C) Field full 
with confluent DFs, (skin piece as a 






2-3: Tumour necrosis factor 2.5, 25 and 250 (ng/ml) 
concentrations 
 
The physiological levels of TNF-α in the human differ with the different tissues 
that in which TNF-α presents, such as blood serum or plasma, human tissue 
samples such as skin, wounds and wound fluids, and also differ with different 
health conditions, such as chronic inflammation, sepsis, and diabetes.            
The normal circulating levels of TNF-α is (11.2 ± 7.3 pq/ml) (Arican et al., 2005), 
while in human normal skin, TNF-α levels are (1470.86 ± 3186.6 pg/g) (Grellner 
et al., 2000). Endo (1993) has shown, that TNF-α plasma levels range           
from 109 - 358 pq/ml in burns patients, which results from bacterial 
infection/septicaemia. Interestingly, the experimental concentration of TNF-α 
that induces the maximal response is (10 ng/ml) greatly exceeding levels in 
normal human plasma and acute-sepsis patient’s serum, indeed a serum 
concentration of (5 ng/ml) was not found in patients with acute sepsis (Turner et 
al., 2010). In heart inflammation, the concentration of (15-30 ng/ml) induced 
maximal inflammatory response (Lin et al., 2015). In diabetes, the serum TNF-α 
level was (94.28 ± 5.01 pg/mL), and urinary TNF-α level was (7.12 ± 
8.09 pg/mg) (Lampropoulou et al., 2014), with a correlation between TNF-α 
serum levels and diabetes duration (Danielson et al., 2016). 
Present study concentrations, 2.5 and/or 25 ng/ml are higher than the normal 
conditions of TNF-α and supra-physiological concentrations were chosen to 
simulate the inflammatory environment and to investigate any effects on dermal 
fibroblasts function and secretory phenotype, while 250 ng/ml is a supra-
pathophysiology concentration and was used to investigate whether TNF-α has 
a concentration-dependent effects, and as a maximal stimulus.  
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2-4: Normal growth media  
 
Dermal fibroblasts were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) (Sigma-Aldrich, UK) supplemented with 10% foetal bovine serum FBS, 
L-glutamine (10mM), penicillin/streptomycin (100U/ml and 100μg/ml) and 
amphotericin B (250μl/ml), cells were incubated at 37˚C in 5% CO2 incubator 
(Thermo Scientific Heracell, UK) in T75 culture flasks (Sarstedt, UK), and the 
media was changed every 2-3 days. 
 
2-5: Serum free assay media (serum free DMEM media) 
 
In some experiments, cells were incubated in serum-free growth medium 
DMEM that contains all the necessary supplements as described in 2-4, but 
lacking the serum, at 37˚C in 5% CO2 overnight. This medium was used to 
remove any traces of serum from previous treatment media.       
 
2-6: Passaging of cells 
 
Once cells had reached 80-90% confluence, they were passaged and 
transferred to a new T75 cm2 culture flask or seeded into 6-well plates (Clear 
Sterile, UK). First, the growth medium was discarded and the cell monolayers 
were washed 2-3 times with 10ml PBS. After the PBS was discarded, the cells 
were trypsinized using 0.05% trypsin/EDTA (Gibco) in amounts of 3ml for T75 
and 1.5 ml for T25 flasks, and incubated for 5-10 minutes at 37˚C in 5% CO2. 
The cells were examined under the phase contrast microscope (x4 and x10) to 
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determine whether they were detaching. Then the trypsin was neutralized by 
adding growth medium (3.5-7ml) dependent on flask size, containing 10% FBS 
to inhibit the trypsin effects. The cells were centrifuged for 5 minutes at 1000 
rpm, the supernatant was discarded and the cell pellet was re-suspended in 5-
10 ml growth medium dependent on flask size containing 10% FBS. The cells 
were re-seeded into new culture flasks (Corning, UK), with a split ratio of 1:3. 
The cell suspension was transferred into a T75 flask and topped up with 10 ml 
growth medium; for T25 flasks the cell suspension was topped up with 5ml 
growth medium. 
 
2-7: Freezing and thawing  
 
Cells that were not required for immediate use were stored in liquid nitrogen. 
Cells were trypsinized, neutralized with 7ml 10% FBS growth medium and 
transferred into a 15ml Falcon tube, and centrifuged to form a pellet. The 
supernatant was discarded and the cell pellet re-suspended in 1ml freezing 
medium Cryo-SFM (PromoCell) and transferred into Cryo Pure tubes (Sarstedt, 
UK). The tubes were placed in liquid nitrogen vapour for 24 hours before 
transferring into liquid nitrogen until required. 
When needed, the cells were thawed quickly after moving from liquid nitrogen 
by immersion in warm water, transferred immediately into a T75 flask to which 
10 ml 10% FBS growth medium had been added. Cells were incubated at 37˚C 
in 5% CO2 and after 24 hours, they were checked to confirm they had attached 
to the flask and the medium was changed. 
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2-8: Cell counting 
 
The cells were trypsinized and neutralized with 10% FBS growth medium. The 
suspended cells were counted using a Neubauer haemocytometer (Hawksley, 
UK) slide. An aliquot (100µl) was mixed with 100µl trypan blue exclusion dye 
(Sigma-Aldrich, UK). Then, 10µl of this was added to each chamber of the 
haemocytometer-slide. The total number of cells in 1ml was calculated by 
counting the number of the cells in each of the four corner squares of the grid 
and calculating the mean. The final value was calculated by multiplying by 104 
and the dilution factor (the cell suspension was mixed in 1:1 ratio with trypan 
blue dye, therefore the dilution factor was 2) to give cell/ml.    
 
2-9: A comparison of dermal fibroblast proliferation in medium 
supplemented with 2% and 10% FBS 
 
Dermal fibroblasts were seeded into 6-well plates, at a cell density of 20,000 
cells per well. Triplicate wells were incubated in either 2ml of medium containing 
2% FBS, or with 2ml of medium supplemented with 10% FBS (i.e. normal 
growth medium). The cells were incubated at 37˚C in 5% CO2, and the media 
was replaced every two days. The number of cells per well was counted in 
duplicate for each well, as described in section 2-8, triplicate wells were counted 





2-10: The effect of TNF-α on dermal fibroblast proliferation 
 
2-10-1: Manual cell counting- trypan blue 
 
Matched dermal fibroblasts derived from scalp and facial skin of the same donor 
were seeded at a density of 10,000 cells per well into 12-well plates (Corning 
Incorporated Costar, 3512, UK). Triplicate wells were incubated with either 1ml 
10% FBS growth medium, or 1ml 10% FBS growth media containing either 2.5, 
25 or 250 ng/ml of TNF-α (Sigma-Aldrich, UK) at 37˚C in 5% CO2 for 72h. After 
3 days, the media was replaced without TNF-α. The number of the cells in 
triplicate wells were counted every on days 3, 5, 7, 10, 12 and 14, and each well 
was counted in duplicate using the trypan blue exclusion dye, as described in 




2-10-2: CyQUANT assay (direct cell proliferation) 
 
CyQUANT is a fluorescence-based proliferation microplate assay for 
determining the number of proliferating cells (Invitrogen, 35011, USA). The 
principle of the assay is a cell-permeant DNA-binding dye (component A) in 
combination with a background suppression reagent (component B). The 
nucleic acid stain is a masking dye that blocks the staining of dead cells, and 
also cells with compromised cell membranes, resulting only in the staining of 
healthy cells, by which the assay can measure cell proliferation accurately.   
Component A is a green fluorescent nucleic acid stain with a feature of a live 
cell-permeable reagent that mainly concentrates in the nucleus of mammalian 
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cells, while component B is a background suppression dye and is impermeable 
in living cells and will suppress the green fluorescence, so both dyes together 
provide an assay based on both DNA content and membrane integrity. 
To generate a standard curve (standard wells), fully confluent cells were 
trypsinized, neutralized with 10% FBS growth medium, and re-suspended in a 
medium. Using a Neubauer haemocytometer, one millilitre of cell suspension 
should contain 105-106 cells per ml (as recommended). Five serial dilutions 
were generated in the wells of microtiter plate from the one millilitre of cell 
suspension and growth media with cell number ranging from 1000-5000 in 
100µl volume. A standard curve is in Appendix 8-2. 
In the sample wells, cells were seeded in 96 well microtiter plates (Corning 
Incorporated Costar, UK) at cell density of 2,000 cells per well. Four replicate 
wells were used for standards, samples, and controls. Three microtiter plates 
were set up at the same time for analysis after day 3, 7 and 14. Prior to the 
assay, cells were incubated in 100µl of 10%FBS growth media with or without 
TNF-α at three different concentrations (2.5, 25 and 250 ng/ml) and incubated 
at 37˚C in 5% CO2 for 72h. At day 3 the media was replaced with 100µl of 10% 
FBS growth media, and replenished with 10%FBS every three days.  
According to the manufacturer’s instructions 2X detection reagent was prepared 
by mixing 11.7ml of growth media, 48µl of component A and 240 µl of 
component B, then 100µl of 2X detection reagent was added into cell culture 
media for each well, and the cells were incubated for 60 minutes at 37˚C in 5% 
CO2. Changes in fluorescence were measured using Infinite 200 PRO 
microplate reader (Tecan, Switzerland), with excitation at 508 nm and emission 
at 527 nm. A standard curve was performed and ranged from (1000-5000) cells, 
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to calculate the cells numbers (for converting fluorescence values into cell 
numbers) for days 3, 7 and 14. 
 
2-11: TNF-α induces the metabolic activity of dermal fibroblasts 
at day 14 
 
Cell metabolism was measured using the Alamar blue assay (colorimetric 
assay) (Invitrogen, USA), a reagent used to quantify cellular metabolic activity. 
This reagent contains the non-fluorescent blue coloured molecule resazurin 
(oxidised form), and its reduction by metabolically active cells will convert 
resazurin into resorufin (reduced form), which is a highly fluorescent pink 
coloured molecule. 
 
               Resazurin weakly fluorescent                    Resorufin highly fluorescent 
 
Fig 2-2: Chemical structures of resazurin and resorufin. Resazurin is reduced to 
fluorescent resorufin by metabolically active cells. 
 
Cells were seeded in 96-well microtiter plates at a cell density of 2000 cells per 
well. Under all conditions, the samples, controls and blanks were performed in 
four replicate wells. Three microtiter plates were set up at same time for 
measuring metabolic activity after day 3, 7 and 14.  Prior to performing the 
Alamar blue assay, cells were incubated in 200µl of 10% FBS growth medium 
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with, or without, TNF-α at three different concentrations (2.5, 25 and 250 ng/ml) 
at 37˚C in 5% CO2 for 72h. After 3 days the media was replaced with 100µl of 
10% FBS growth media, which was replenished every 3 days. Ten microliters of 
the Alamar blue reagent was added to all the wells (100µl capacity) directly into 
the cell growth media, then the plates were wrapped in foil and cells were 
incubated at 37˚C in 5% CO2 for 4 hours when the colour changed into pink. 
Directly, the absorbance was measured at 570nm using Infinite 200 PRO 
microplate reader (Tecan, Switzerland), and plots were drawn, the absorbance 
versus treatment concentrations. 
 
2-12: Induction of senescence in cultured dermal fibroblasts  
 
The senescence-associated β-galactosidase assay is a cytochemical assay that 
detects the expression of senescence-β-Galactosidase (β-Gal) at pH 6, as a 
marker of senescent cells; in vitro (Dimri et al., 1995). 
Dermal fibroblasts were seeded at a low density of 7000-7500 cells per well in 
6-well plates and cultured in 10% FBS growth medium for 1-2 days. Cells were 
washed twice with 1ml PBS and incubated with 2.5, 25 or 250 ng/ml of TNF-α in 
10% FBS growth medium, or 10% FBS growth medium, or serum free assay 
medium for 48h. Cells were washed once with 2ml PBS before fixing with 1x 
fixative solution (Cell Signaling Technology, USA). 
According to the manufacturer’s instructions, the 1x fixative solution was 
prepared by diluting 10x fixative solution with distilled water, and then 1ml was 
added to each well and left for 10-15 minutes at room temperature. The cells 
were washed twice with 2ml PBS to remove the fixative solution and incubated 
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with 1ml of the 1x β-galactosidase staining solution at pH 6 (Cell Signaling 
Technology, USA). The 1x β-galactosidase staining solution was prepared by 
diluting the 10x staining solution with distilled water and, one millilitre of 1x β-
galactosidase staining solution contained; 930µl 1x staining solution, 50µl 
20mg/ml X-gal stock solution in dimethylformamide (DMF) (Sigma-Aldrich, UK), 
10µl solution A and 10µl  solution B. The pH was adjusted to 6 with HCl. 
Immediately, the plate was sealed with parafilm to prevent the solution from 
evaporating and placed in CO2-free incubator at 37 ˚C (Genlab, UK) for 24h. 
The cells were photographed under the light microscope for the development of 
a blue colour indicating senescent cells. For long- term storage, the staining 
solution was removed from each well and replaced with 1 ml 70% glycerol in 
H2O (Sigma-Aldrich, UK), before the cells were stored at 4˚C. At least five 
images were taken radially for each well using an Olympus Nikon TS100 digital 
camera connected to the phase contrast microscope (Ernst Leitz Wetzlar 
GMBH, Germany), at x40 (eyepiece x10 and objective x4) magnification. The 
level of cellular senescence after 24h was quantitated by counting the number 
of blue cells and dividing by the total number of the cells and then multiplying by 
100%.  
 
2-13: Preparation of conditioned media to determine changes in 
MMP-2 and -9 secretion  
 
Dermal fibroblasts were seeded into either 6-well plates, or 12.5 cm2 flasks at a 
cell density of 50,000 cells per well. Cells were incubated with 1ml 10% FBS 
growth medium at 37˚C in 5% CO2 and grown to confluence (90-100%). The 
cells were washed 2-3 times with 2ml PBS and were growth arrested by 
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incubating in 2ml serum free media for 24h. Cells were washed twice with 2ml 
PBS and incubated with either 1ml 10% FBS growth medium containing 2.5 or 
25 or 250 ng/ml of TNF-α, or with 1ml 100 nM phorbol 12-myristate 13-acetate 
(PMA) (Sigma-Aldrich, UK) in 1% FBS medium, or with 1ml 10% FBS growth 
medium, or 1ml 1% FBS medium for 48h. The cell media was collected and 
centrifuged at 900 rpm for 6 minutes to remove the cell debris, then frozen at -
80 ˚C until used in the zymography assays.  
 
2-14: Conditioned media CM 
 
Cells were cultured in 6-well plate at cell density of 50,000 cells per well, and 
incubated with 2ml 10% FBS growth medium at 37˚C in 5% CO2 for 72h, till they 
were confluent (90-100%). The cells were washed twice with PBS, and 
incubated with serum free DMEM media for 24h. After that, cells were washed 
two times with PBS and treated/incubated with 1ml of TNF-α in two different 
concentrations 2.5 or 25 (ng/ml), or without TNF-α as control, the conditioned 
media was collected after 24h (Fig 2-3 A). The conditioned media CM was 











- Cytokine profile array. 
In some experiment conditions the conditioned media was added to another 
dermal fibroblasts (Fig 2-3 B).  
 
                               













Fig 2-3: Preparation of conditioned media. (A) Confluent cultured DFs were washed 
with PBS and incubated with serum-free DMEM media for 24h, then cells were washed 
again, and incubated with or without TNF-α 2.5 or 25 ng/ml for 24h. After, DFs 
conditioned media were collected, and frozen (B) The collected CM was tested in the 
zymography, and human cytokine profile assays to measure the TNF-α effect and/or 
added to another recipient cells (scratched or non-scratched), collected again after 








2-15: Scratched wound migration assay 
 
Cells were seeded into 6-well plates, at cell density of 50,000 cells per well, and 
incubated in 2ml of 10% FBS growth medium for 72h till cells were fully 
confluent. At the same time parallel 6-well plates were set up that were treated 
identically, but not scratched. Prior to making the scratch, both scratched and 
non-scratched cells were serum-starved for 24h using serum free DMEM 
medium. For scratched cells, a linear scratch was made across the diameter of 
each well using the scratch wound device designed by Dr. Kamala (Kamala, 
2014), which removes a fixed width (0.8 mm) of cells. 
Both scratched and non-scratched monolayers were washed with 2ml PBS 
twice to remove cell debris. The effect of TNF-α was tested by adding two 
millilitre of 10% FBS of growth medium (control), or 2ml of 2.5 or 25 (ng/ml) of 
TNF-α prepared in 10% FBS growth medium, to triplicate wells. This effect was 
assessed for healthy and diabetic scratched and non-scratched dermal 
fibroblasts. For scratched (migrated) cells, the migration of the cells between 
the wound edges was determined at after 24h. The measurement of the cell 
migration (distance) between the wound edges was made from the images of 
the scratch wound taken using a digital camera (Olympus Nikon TS100, Japan) 
connected to the phase contrast microscope (Ernst Leitz Wetzlar GMBH, 
Germany) at the same six points in triplicate wells and the average was taken. 
All images were taken at x40 total magnification (eyepiece x10 and objective 
x4). The migration of the cells between the wound edges was measured at the 




The average migratory distances at different time points were calculated, and 
the data statistically analysed using GraphPad Prism7. For non-scratched (non-
migrated cells), they were incubated without imaging for 24h. After, the 
conditioned media (direct TNF-α conditioned media) were collected from both 
scratched and non-scratched cells and kept at -80˚C until requiring for 
zymography assay and the remaining cells were used for performing RT-PCR 
assay.   
 
2-16: Soluble factors and indirect effect of TNF-α on the 
migration of dermal fibroblasts 
 
The soluble factors and the indirect effect of TNF-α (conditioned TNF-α) were 
performed by adding 2ml of 10% FBS conditioned growth medium (control 
conditioned), or 2ml 10% FBS conditioned media prepared in the presence of 
2.5 or 25 (ng/ml) TNF-α, or 2ml of conditioned growth medium with 2.5 or 25 
(ng/ml) of TNF-α in 10% FBS growth medium (direct/fresh TNF-α), to triplicate 
wells for scratched and non-scratched healthy dermal fibroblasts. The doubled-
conditioned media were collected from both scratched and non-scratched cells 
and kept at -80˚C until requiring for zymography assay and the remaining cells 










2-17: Gelatin zymography 
 
Gelatin zymography was used to quantitate the gelatinolytic MMP-2 (Gelatinase 
A) and MMP-9 (Gelatinase B) activity of the conditioned media from dermal 
fibroblasts, as described in section 2-13 and 2-14.  
The conditioned media was diluted as appropriate (1:40) with 2x non-reducing 
sample buffer (Appendix 8-1). The electrophoresis gels were prepared with 
acrylamide gels containing a final concentration of 1.5 mg/ml gelatin (Sigma-
Aldrich, UK). The separating gel contained 3.75ml of separating gel buffer 
(composed of 1.5M Tris base pH 8.8), 150µl 10% Sodium dodecyl sulphate 
(SDS), 3.7ml 30% acrylamide /0.8% bis-acrylamide mix, 75µl 10% ammonium 
persulfate (APS) (Sigma-Aldrich, UK) and 1.325ml distilled water, while the 
stacking gel contained 1.875ml stacking gel buffer (0.5M Tris base pH 6.8), 75µl 
10% SDS, 0.975µl 30% acrylamide /0.8% bis-acrylamide mix, 37.5µl 10% APS 
and 4.58ml distilled water (see Appendix 8-1 for  all buffer compositions). 
Tetramethylethylene diamine (TEMED) (Sigma- Aldrich, UK) was added to 
polymerize the gels; 30µl for the separating gel and 15µl for the stacking gel.  
Twenty microliters of diluted conditioned medium was loaded into the gels and 
the electrophoresis was performed for 110 minutes at 120V in 350ml running 
buffer (Appendix 8-1). Then the gels were washed three times (each time 20 
minutes in 80ml 5x washing buffer for two gels) with gentle agitation, using a 
shaker (Grant-Bio, UK) at room temperature. The gels were incubated with 1x 
incubation buffer (Appendix 8-1) to reactivate the gelatinases activity (100ml for 
each gel), for 24h in incubator at 37 ˚C -without CO2 supplier (Genlab, UK). 
Finally, to visualize the enzymes as clear bands of lysis on a blue background, 
the gels were stained in Coomassie brilliant blue staining solution (Appendix 8-
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1) (100ml to stain two gels) for 20 minutes with shaking at room temperature 
until the bands appeared. Images were taken using a UV/white light conversion 
screen-visualization system (Bio-Rad, UK) and analysed using Image J to 
calculate the percentage of MMP-2 and MMP-9 compared to controls.  
 
2-17-1: Analysis of gelatin zymography 
 
Stained gels images were taken using a UV/white light conversion screen-
visualization system (Bio-Rad, UK). The images were analysed using the Image 
J programme. This programme converts the images to densitometry values 
(data) which were then converted to percentages. Bands were quantified using 
densitometry, which was representative of MMP activity and expressed relative 









Fig 2-4: ImageJ analysis of zymograms. (A) Images of zymograms were opened in 
Image J, and identical lanes identified. (B) Densitometric analysis of identified bands. 
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2-18: Quantitative real time PCR (RT-qPCR)   
 
RT-qPCR involves; total RNA extraction, cDNA synthesis and finally the real 
time PCR which amplifies and measures the amount of cDNA containing the 
gene of interest.  
 
2-18-1: Total RNA extraction 
 
Cells were seeded into 6-well plates at cell density of 50,000 cells per well and 
incubated in 10%FBS growth media at 37˚C of 5% CO2 until fully confluent. 
Then cells were serum-starved for 24h using serum free DMEM medium. Some 
seeded cells were scratched linearly and some seeded cells were not (both 
cells were taken from migration assay section 2-15). Both scratched and non-
scratched cells were washed with 2ml PBS twice to remove debris or scratched 
cells.  
The total RNA was extracted from these treated Scratch and non-scratched 
cells using RNeasy mini kit (Qiagen, 74104, UK) silica column method. Cells 
were washed with PBS twice to remove treatment traces. According to 
manufacturer’s instructions, cells were lysed by adding 250μl/well lysis buffer 
RLT and collected in micro-centrifuge tubes (on ice), then the tubes were 
vortexed for homogenization. A volume of 350μl of 70% ethanol was added for 
binding conditions (precipitates nucleic acids), and the solution was mixed by 
pipetting. The entire 700μl volume of the homogenised solution was transferred 
to spin RNeasy columns and centrifuged for 15 seconds at 12,000 rpm (this 
allow the RNA to bind to the column), the flow-through was discarded, and the 
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column was washed with 350μl RW1 washing buffer for 15 seconds at 12,000 
rpm to remove any salts and proteins and the flow-through was discarded. A 
mixture of 10µl of DNase I in 70µl of RDD was added to the column and 
incubated at room temperature for 15 minutes to allow the degradation of any 
DNA that may have bound to the column. Again, the column was washed with 
350μl RW1 washing buffer and centrifuged for 15 seconds at 12,000 rpm, and 
the flow-through was discarded.   
 Two washing steps were made, Buffer RPE of 500μl volume was added to the 
centre of the column and was centrifuged for 15 seconds at 12,000 rpm, the 
flow-through was discarded, and this step was repeated with extending the 
centrifuging time for two minutes, the flow-through was discarded. The RNeasy 
columns were transferred to a new collection tubes 2ml and were centrifuged to 
full speed of 12,000 rpm for one minute, then the RNeasy column was placed in 
a new collection tubes 1.5ml  and 45μl RNase free water was added directly to 
the column. These tubes were centrifuged for 1minute at 12,000 rpm to elute 
the RNA. To get a high concentration of RNA, the last step was repeated (by re-
using the eluted water back on the same column), then the RNA was stored at -
80 ˚C in the same collection tube. 
 
 
2-18-1-1: Quantification of total RNA extraction  
 
The concentration of total RNA was quantified using NanoPhotometer P-330 
(IMPLEN) in ng/µl. The Nanophotometer can measure the concentration and 
quality of RNA by reading the absorbance at 230, 260 and 280nm, so 
photometer was blanked by using RNase DNase free water (solvent) and the 
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RNA purity/quality was measured. Optical density ratios O.D. 260/ O. D. 280 > 
1.8 and O. D. 260/O.D. 230 > 2 were considered as pure. If the ratio is lower 
than 1.8 or 2, it gives an indication of contamination existence such as proteins 
or phenol red that can be absorbed at 280nm. 
 
2-18-2: cDNA synthesis through reverse transcription 
 
Reverse transcription of total RNA was performed to synthesis the cDNA from 
extracted RNA using the High-Capacity cDNA reverse transcription kit (AB 
Applied Biosystems, UK) according to the manufacturer’s instructions (manual 
protocol). The 2x master mix components was prepared before preparing cDNA 
reaction tubes (Table 2-3). Fifteen microliters of master mix (RT) was added to 
5µl of purified RNA sample per tube, giving a final volume of 20µl.  
 
                   Component Volume 
10X Reverse Transcription Buffer   2 µl 
25X dNTPs Mix (100mM)  0.8 µl 
10X RT Random primers 2 µl 
MultiScribe™ Reverse Transcriptase (RT), 
50 U/μL 
1 µl 
RNase Inhibitor  1 µl 
Nuclease-free H2O 8.2 µl 
Total amount 15 µl 
                Table 2-3: The 2X RT master mix components. 
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The thermocycler (Techne, USA) was programmed to heat the RNA to 25˚C for 
10 minutes for annealing conditions; then to increase in temperature to 37 ˚C for 
120 minutes to allow the reverse transcriptase enzyme to catalyse second 
strand synthesis, after the reaction temperature increased to 85˚C for 5 minutes 
for inactivate the reaction and then dropped to 4˚C to final hold. The yield cDNA 
was stored at (-20 to - 25˚C) until use.  
 
 
2-18-3: Real time PCR 
 
RT-qPCR is a method to amplify the target gene from cDNA strand. Taqman 
gene expression assay is based on 5' nuclease chemistry, which uses a 
fluorogenic probe to enable the detection of a specific PCR product as it 
accumulates during PCR. RT-qPCR reaction was performed in duplicate in 96-
well plate (Bio-Rad, USA), and each reaction contains as shown in table 2-4. 
               
Component Volume 
Primer (pair of specific unlabelled 
primers) 
1.25 µl 
Taqman Universal PCR Master Mix- 
FAM™ 
12.5 µl 
cDNA 2.5 µl 
Nuclease-free H2O 8.75 µl 
Final volume 25µl 
        Table 2-4: The RT-PCR reaction mixture. 
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RT-qPCR was carried out on Bio-Rad CFX Connect™ Real-Time PCR 
Detection System, USA, and CFX Manager Software, (USA).   
The PCR plate was ran according to the protocol of the TaqMan® gene 
expression assay. The plate was heated to 95˚C for 10 minutes to activate the 
DNA polymerase/Taq activation, after a standard PCR reaction was undertaken 
(denaturation of the DNA template at 95˚C for 15 s, annealing of the primer and 
probe to their specific target sequences and complementary second strand 
synthesis at 60˚C for 1 minutes/Extension), 50 cycles.  
During the Taqman gene expression assay, cDNA is denatured, primers and 
probe annealed, and during polymerization the gene-specific probe is cleaved 
and fluorescence emitted. With each cycle the intensity of the fluorescence is 
proportional to the amount of synthesized products (which is proportional to 







Fig 2-5: Taqman assay principles. The figure adapted from the web site of 














2-18-3-1: Analysis of RT-PCR data 
 
The CFX Manager Software was used for analysing the data, which generates 
the CT values for all target genes (MMP-1, MMP-2, MMP-9, TIMP1, TIMP2, 
Sirt1, and Sirt6) and endogenous control (housekeeping gene) GAPDH (Table 
2-5). ΔCT was calculated from CT for the target gene (sample) and the reference 
GAPDH gene, using the equation:   
ΔCT = CT (target gene) - CT (reference gene) 
This normalizes to the reference gene (GAPDH). A further calculations, 2-ΔCT 
was generated to convert the negative number into positive (in considering the 
relationship between CT and expression are inverse). Then the 2-ΔCT value for 
the target gene was multiplied with 100 to find out the % GAPDH, which was 
plotted and analysed by GraphPad Prism7. 
 
Catalogue N. Primer 
4331182 - Hs02786624_g1 for human GAPDH 
- Hs00899658_m1 for human MMP1 
- Hs01548727_m1 for human MMP2 
- Hs00957562_m1 for human MMP9 
- Hs01092512_g1 for human TIMP1 
- Hs00234278_m1 for human TIMP2 
- Hs01009006_m1 for human SIRT1 
Hs00966002_m1 for human SIRT6 







2-19: Human cytokine array assay (antibody array) 
 
Relative levels of human cytokines and chemokines were identified by the 
antibody array method, which acts as a tool to simultaneously detect 36 
cytokines differences between samples. The principle of the assay is, that 
capture antibodies have been spotted in duplicate on nitrocellulose membranes, 
and the cell conditioned media (samples) contain the proteins (antigens), then 
immune complexes were formed on the correspondence spots on the 
membrane with different intensity that can be visualized by streptavidin-HRP 
(streptavidin conjugated to horseradish-peroxidase) and chemiluminescent 
detection reagents- Chemi reagents (1 and 2). 
The spots are arranged in each membrane as; positive controls 3 pairs of spots, 
negative controls 1 pair of spot and 36 pairs of spots for determining cytokines 
difference levels in different samples, (Appendix 8-4).  
One millilitre from each conditioned medium, that collected from the migration 
assay (sections 2-15 and  2-16, the direct and paracrine effect of TNF-α) from 
healthy and diabetic donor cells of; 10%FBS growth conditioned media (direct 
control), or 10%FBS double growth conditioned media (paracrine control), or 
2.5 (ng/ml) of TNF-α conditioned media (direct TNF-α), and 2.5 (ng/ml) of TNF-
α double conditioned media (paracrine TNF-α) were assayed to determine the 
relative expression levels of 36 human cytokines. 
The assay was carried out according to the manufacturer’s instructions (R & D 
systems bio-techne, ARY005B, USA). The nitrocellulose membranes were 
blocked by adding 2ml of array buffer 4 (block buffer) into each well of the         
4-Well Multi-dish, on a shaker for one hour with array number should be facing 
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upward. In meanwhile the samples (centrifuged conditioned media) were 
prepared in separated tubes, by mixing 1ml from each conditioned media with 
500µl of array buffer 4 with a final volume of 1.5ml, then 15 µl of human 
cytokine array detection antibody cocktail (prepared according to the 
manufacturer’s instructions) was added for each sample, these mixtures of 
sample/antibody were mixed and incubated at room temperature for one hour. 
After, the array buffer 4 was removed from the wells of the 4-Well Multi-dish and 
replaced with the sample/antibody mixtures for each sample, covered with the 
lid and incubated for overnight at 2-8 ˚C on a shaker. 
Next, the membranes were washed in individual square Petri dishes with 20ml 
of 1x washing buffer (was prepared by diluting 40ml of 25x of washing buffer in 
960ml of distilled water) for three times in total (each time for 10 minutes on a 
shaker at room temperature). The streptavidin-HRP was diluted in array buffer 5 
using the dilution factor (1µl HRP: 2000µl array buffer 5) and 2ml of diluted 
streptavidin-HRP was taken into each well of the 4-Well Multi-dish. After the 
membranes were transferred into the 4-Well Multi-dish containing the diluted 
streptavidin-HRP, the plate was covered with the lid and incubated for 
30minutes at room temperature on a shaker. The membranes were washed 
again for three times as described above. The membranes were dried and 
placed on the bottom of the plastic sheet protector (kit supplier), and the chemi 
reagent 1 and 2 mixture (chemiluminescent detection reagents) was prepared 
instantly. Finally, to visualize the intensity of spots, 1ml of chemi reagent 1 and 
2 mixture was added onto each membrane, then covered with the top plastic 
sheet protector and were incubated for 1 minute at room temperature (wrapped 
in foil). Images were taken using a UV/white light conversion screen-
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visualization system (Bio-Rad, UK) and Image J software was used to analyse 
the images.  
 
 2-19-1:  Analysis of human cytokine array 
 
The images were analysed using Image J programme, which measures the 
densitometry of the spots and converts pixels into values, the average signal 
(pixel density) was calculated for each pair of duplicated spots (each pair 
representing a cytokine depending on transparency- coordinate reference) (kit 
supplier), a background subtractions were carried out for all spots. The negative 
values were dismissed, while the positive values were considered and these 
values compared to identify any differences between signals on control or TNF-
α treated samples. 
 
2-20: Statistical analysis 
 
Data is displayed in as mean ± SEM. The tests that used were ANOVA (one-
way and two-way ANOVA). An ANOVA test is used to find out the differences 
between three or more groups (to determine significance of mean group 
differences). One-way ANOVA is used to compare one categorical variable or 
single factor with three or more groups, while two-way ANOVA is used to 
compare two or more categorical variable or two factors with multiple groups. 






3-1: Comparison of the rate proliferation of dermal fibroblasts 
in media supplemented with 2% or 10% FBS 
 
It is well established that FBS stimulates proliferation of human dermal 
fibroblasts. However, the presence of serum may mask the effects of growth 
factors and hormones added to the culture media. Therefore to determine the 
effect of reducing the concentration of FBS on the growth of papillary dermal 
fibroblasts in culture, two different concentrations of FBS were compared in the 
same cell type.  
To determine the differences in dermal fibroblast proliferation in response to 
growth factors, hormones and attachment factors in serum that stimulate cell 
growth as well as the role of serum as a spreading factor, cells were incubated 
in either 2% or 10% FBS supplemented media for up to 12 days. (Figure 3-1). 
There was a significant difference in the proliferation rate of dermal fibroblasts 
incubated in two different concentrations of 2% and 10% FBS over a 12 day 
period. From day 6 the rate of proliferation of fibroblasts incubated in 10% FBS 
was significantly faster (p<0.001) than corresponding cells cultured in 2% FBS 
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Figure 3-1: Proliferation of dermal fibroblasts cultured in different FBS 
concentrations of 2% and 10%. DFs were cultured in either 2% or 10% FBS and 
counted every 2 days for 12 days. Each point represents the mean of triplicate wells +/- 
SEM from one donor. (Female, facial skin, age 77, P6); *** denoted p< 0.001 using 






















3-2:  TNF-α inhibits dermal fibroblast proliferation 
 
3-2-1: Manual cell counting 
 
A comparison in growth rate between two different populations of dermal 
fibroblasts was undertaken. This was comparable to the design of previous 
experiments for papillary dermal fibroblasts (Kamala, 2014).   
To determine whether dermal fibroblasts derived from scalp (haired skin) and 
facial skin (non-haired) showed differences in proliferation, three donor-matched 
cultures were grown in 10% FBS supplemented media for up to 14 days. There 
was no significant difference in the basal rate of proliferation over this time 
period (Fig 3-2). 
When dermal fibroblasts were pre-incubated with TNF-α (2.5, 25 and 250 ng/ml) 
for 3 days, cell proliferation was significantly reduced by day 14 at all 
concentrations of TNF-α in dermal fibroblasts derived from female scalp (Fig 3-3 
A). This was mirrored in donor-matched dermal fibroblasts derived from facial 
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Figure 3-2: Comparison of the rate proliferation of donor-matched cultures of 
dermal fibroblasts derived from facial and scalp skin. Primary cultures of DFs from 
three matched females donors scalp (n=3) and facial (n=3) skin, (P4-6), were cultured 
for up to 14 days and counted every 2-3 days. Each point represents the mean of 3 
donors +/- SEM, and proliferation was assessed in three triplicate wells for each donor. 




















        
Figure 3-3: Pre-incubation with TNF-α inhibits the proliferation of donor-matched 
cultures of dermal fibroblasts derived from facial and scalp skin. Primary cultures 
of DFs were incubated with different concentrations of TNF-α for 3 days and then 
replenished with 10% FBS growth medium for a further 11 days. Triplicate wells were 
counted in duplicate every 2-3 days. Cells were established from two different sites of 
the same donors (A) DFs derived from female (haired) scalp and (B) corresponding 
facial (non-haired) skin (n= 3 donors). Each point represents the mean of 3 donors +/- 
SEM. Female donors, (P4-6), age range (52-64 years); * p<0.05, ** p<0.01 and *** p< 
0.001, two-way ANOVA. 
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3-2-2: Direct cell proliferation- CyQUANT 
 
To confirm the effect of TNF-α on dermal fibroblast proliferation quantitated by 
manual cell counting, another direct cell proliferation CyQUANT assay was 
used. Dermal fibroblasts from four healthy donors were pre-incubated with three 
different concentrations of TNF-α (2.5, 25 and 250 ng/ml) for 3 days as in the 
previous experiment (section 3-2-1) and then for 11 days in growth medium 
containing 10% FBS without TNF-α (Fig 3-4). Significant differences were 
observed at day 7 and 14 in the rate of cell proliferation. At day 7, the 
proliferation rate was reduced significantly following pre-incubation with 2.5 
ng/ml of TNF-α, and a significant decrease in cell proliferation was observed at 
day 14 following pre-incubation with the lowest concentrations of TNF-α (2.5 







































































Figure 3-4: CyQUANT direct proliferation assay. DFs derived from female facial skin 
were pre-treated with three different concentrations of TNF-α (2.5, 25 and 250 ng/ml) 
for 3 days. Media was replenished with 10% FBS growth media every 3 days for 14 
days (A) The proliferation rate at day 3, (B) at day 7 and (C) at day 14. Each point 
represents the mean of four replicates wells +/- SEM of four donors (n=4), (P7-8), age 
range (45-67y). The data are presented twice: Scatter Plots A-C show the means for 
each individual by group; Histograms A-C show the means per group. Proliferation was 
significantly reduced by the lowest concentrations (2.5 and 25 ng/ml) of TNF-α at day 
14;* P<0.05 and ** p<0.01, one-way ANOVA. The fluorescent measurements were 




3-3: Pre-incubation with TNF-α for 3 days leads to an increase 
in the metabolic activity of dermal fibroblasts at day 14  
 
Because TNF-α inhibits the proliferation of dermal fibroblasts by day 14, there is 
the possibility that TNF-α is reducing metabolic activity, so the metabolic activity 
of the cells was assayed till day 14. 
Dermal fibroblasts from facial skin of four healthy donors were assayed for 
changes in their metabolic activity after pre-treatment with TNF-α at three 
different concentrations of (2.5, 25 and 250 ng/ml) for 3 days followed by 
incubation in growth media containing 10% FBS without TNF-α for a further 11 
days. There was no significant change in metabolic activity until day 14 (Fig 3-
5), when the metabolic activity was increased significantly by pre-treatment with 
the lower concentration of 2.5 ng/ml TNF-α when compared to the control (Fig 



















































Figure 3-5: Pre-incubation with TNF-α stimulates metabolic activity. Alamar blue 
metabolic activity assay. DFs derived from female facial skin were incubated with 
increasing concentrations of TNF-α (2.5, 25 and 250 ng/ml) for 3 days. Then the 
medium was replenished without TNF-α every 3 days for up to 14 days. Each point 
represents the mean of four replicates wells +/- SEM of four donors (n=4), (P4-5) age 
range (45-67y). The data are presented twice: Scatter Plots A-C show the means for 
each individual by group; Histograms A-C show the means per group. Changes in 
metabolic activity are shown at day 3 (A) day 7 (B) and day 14 (C). Metabolic activity 
was significantly higher following pre-incubation with 2.5 ng/ml TNF-α at day 14;* 
P<0.05, one-way ANOVA. Absorbance was measured using plate reader at 570nm. 
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3-4:  Induction of senescence in cultured dermal fibroblasts by 
TNF-α 
 
As TNF-α reduced the proliferation of dermal fibroblasts and seemed to 
increase metabolic activity, which suggests the cells may become senescent 
cells (cells are not dividing, but are metabolically active). Its ability to modulate 
senescence was therefore measured using beta-galactosidase assay. When 
cultured dermal fibroblasts were incubated with a concentration of 250 ng/ml of 
TNF-α for 48h, representative images shown in (Fig 3-6), there was a significant 
increase in the percentage of dermal fibroblasts expressing beta-galactosidase 
compared to the controls (p=0.001), (Fig 3-7), while the lower concentrations 
(2.5 and 25 ng/ml) of TNF-α had no effect. This was only observable in cells 
which had proliferated in culture up to passage 17, and was not detected in 

















































































































































































































































































































































































































Figure 3-7: TNF-α induces senescence. DFs were incubated with three 
concentrations of TNF-α (2.5 or 25 or 250 ng/ml) for 48h in 10% FBS before staining 
for beta-galactosidase at pH 6.0 for 24h. DFs were derived from female, facial skin, 
age 55y, Passage 17. Each point represents the mean of five technical replicates (five 

















3-5: TNF-α inhibits migration of dermal fibroblasts derived from 
healthy donors and diabetic patients  
 
From the previous experiment (senescence assay), it seemed the cells are not 
senescent because if the wound healing environment was inflamed or chronic 
(cells incubated in an inflammatory environment) the migration response of the 
cells would be reduced/decreased, but as senescent cells, they could not 
migrate. 
In order to measure the impact of TNF-α on dermal fibroblast migration, TNF-α 
was added in two different concentrations 2.5 or 25 ng/ml to scratched cells. In 
healthy dermal fibroblasts, TNF-α significantly impaired migration after 24h in 
the concentration of 25 ng/ml (Fig 3-8) and (Fig 3-10 A). However, TNF-α 
significantly inhibited diabetic dermal fibroblast migration after 24h at both 























































































































































































































































































































































































































































































































































































































































Figure 3-10: TNF-α inhibits migration of dermal fibroblasts from healthy donors 
and diabetic patients after 24h. (A) Scratched DFs from female donors (n=6), facial 
skin, P3, age range (36-67y) were incubated in the presence or absence of TNF-α (2.5 
or 25 ng/ml). Each point represents the mean of triplicate wells +/- SEM of 6 donors.    
** p<0.01, one-way ANOVA. (B) Diabetic DFs from (2males/2females) (n=4), lower leg, 
P3, age range (52-66y). Migrated diabetic DFs were incubated in the same conditions 
(2.5 or 25 ng/ml) of TNF-α. * P<0.05, one-way ANOVA.    
 
 





3-6: Effect of paracrine factors from TNF-α conditioned media 
on healthy dermal fibroblast migration  
 
As TNF-α can cause the up-regulation of secreted factors by treated cells, 
conditioned media was collected and added to healthy dermal fibroblasts to 
determine whether any paracrine effects modulated migration of other 
fibroblasts, while there was an inhibitory trend for the TNF-α paracrine effect to 
inhibit healthy dermal fibroblast migration after 24h, this did not reach statistical 
significance (Fig 3-11) and (Fig 3-13), although it appeared to mirror the direct 
effect of TNF-α (Fig 3-10). This appeared to be a direct effect of TNF-α rather 
than a result of any soluble factors increased, since the combination of 
conditioned control media with fresh TNF-α (2.5 or 25 ng/ml) added to it , had a 
similar effect on healthy dermal fibroblast migration after 24h (Fig 3-12) and (Fig 
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Figure 3-13: Paracrine effect of TNF-α on healthy dermal fibroblasts migration 
after 24h. Conditioned media was collected from two healthy female donors (n=2), 
facial skin, P7-8, age range (52-60y), which had been incubated in the presence or 
absence of TNF-α, 2.5 or 25 ng/ml and was added to healthy recipient DFs. The 
addition of TNF-α, 2.5 or 25 ng/ml TNF-α CM to the healthy recipient dermal fibroblasts 
from five female donors (n=5), facial skin, P3, age range (36-67y); non-significant, one-
way ANOVA. The application of TNF-α (2.5 or 25 ng/ml) combined with conditioned 
control media (CMCon-without TNF-α) was added to same recipient DFs; no significant 











3-7: Optimisation of the zymography technique for quantifying 
MMP-2 and MMP-9 
 
Levels of the inflammatory markers MMP-2 and MMP-9 were determined to 
confirm whether the wounded and non-wounded cells reflected those in an 
inflammatory environment and whether diabetic wounded and non-wounded 
cells are more sensitive to an inflammatory environment as shown by increased 
MMPs secretion. High MMPs secretion would cause a breakdown of wound 
healing and induced the production of pro-inflammatory cytokines.   
Gelatin zymography evaluates the degradation of gelatin by MMP-2 and -9 in 
conditioned media. If the conditioned medium is too concentrated, degradation 
can be over saturated, which makes quantitation inaccurate. Therefore, it is 
important to perform a series of dilutions to achieve a defined tight band of lysis 
(Fig 3-14). All conditioned media for optimisation of the assay were collected 
from dermal fibroblasts established from female facial skin (donor age 55y) and 
assayed at passage 10. The phorbol ester (PMA) was included as a positive 
control as it a known inducer of MMP-2 and -9 activity, in vitro (Agren et al., 

































Figure 3-14: Optimisation of zymography loading. DFs were derived from female, 
facial skin, age 55y, Passage 10. DFs were cultured with TNF-α (2.5 or 25 or 250 
ng/ml) in 10% FBS, or 100 nM PMA (Phorbol 12-myristate 13-acetate) for 48h and 
conditioned media were collected. This conditioned media was diluted (A) 1:1, (B) 1:20, 
(C) 1:40 or (D) 1:80 with loading buffer and the resulting digested bands imaged. The 
MMP-2 and MMP-9 bands appear as a clear band of lysis on a dark background of 




3-8: MMP-2 and MMP-9 activity in conditioned media of 




3-8-1: Secretion of MMP-2 in conditioned media from scratched 
dermal fibroblasts 
 
Conditioned media was collected from dermal fibroblasts that had been 
scratched and cultured in the presence of 2.5 or 25 ng/ml TNF-α for 24h 
(migration assay 2-15) and MMP-2 activity assayed by zymography. Data was 
normalized to growth medium (10% FBS) taken from the bottle. For healthy 
dermal fibroblasts, TNF-α had no effect on MMP-2 secretion (Fig 3-15 A). 
However, in diabetic dermal fibroblasts, 25 ng/ml TNF-α increased MMP-2 
expression by 261%, although this was highly variable and not statistically 





































Figure 3-15: Effect of TNF-α on MMP-2 secretion in healthy and diabetic 
scratched dermal fibroblasts. Conditioned media was collected from scratched cells 
cultured with TNF-α after 24h from (section 3-5). (A) Healthy DFs from female donors 
(n=6), facial skin, P3 and age range (36-67y). (B) Diabetic DFs from 2males/2females 





3-8-2: Secretion of MMP-9 in conditioned media from scratched 
dermal fibroblasts 
 
TNF-α had a variable effect on MMP-9 secretion which was consistently lower 
than MMP-2 secretion. In healthy dermal fibroblasts, both concentrations 
tended to increase MMP-9 secretion, but this was not statistically significant or 
dose-dependent (Fig 3-16 A). In diabetic dermal fibroblasts, TNF-α appeared to 
dose-dependently increase MMP-9 secretion, but again this was not significant 







































Figure 3-16: Effect of TNF-α on MMP-9 secretion in healthy and diabetic 
scratched dermal fibroblasts. Conditioned media was collected from scratched cells 
cultured with TNF-α after 24h from (section 3-5). (A) Healthy DFs from female donors 
(n=6), facial skin, P3 and age range (36-67y). (B) Diabetic DFs from 2males/2females 





3-8-3: Secretion of MMP-2 in conditioned media from non-
scratched dermal fibroblasts 
 
MMP-2 secretion was also measured in parallel dermal fibroblasts that had 
been treated with TNF-α, but had not been scratched. In both healthy and 
diabetic dermal fibroblasts, there was no significant, or dose-dependent (Fig 3-
















































Figure 3-17: Effect of TNF-α on MMP-2 secretion in healthy and diabetic non-
scratched dermal fibroblasts. Conditioned media was collected from cells cultured 
with TNF-α after 24h from (section 3-5). (A) Healthy DFs from female donors (n=6), 
facial skin, P3 and age range (36-67y). (B) Diabetic DFs from 2males/2females (n=4), 





3-8-4: Secretion of MMP-9 in conditioned media from non-
scratched dermal fibroblasts 
 
In non-scratched dermal fibroblasts, MMP-9 secretion was again lower than 
MMP-2. Levels of MMP-9 secretion in both healthy and diabetic dermal 
fibroblasts under TNF-α stimulation were higher than the controls in a dose-











































Figure 3-18: Effect of TNF-α on MMP-9 secretion in healthy and diabetic non-
scratched dermal fibroblasts. Conditioned media was collected from cells cultured 
with TNF-α after 24h from (section 3-5). (A) Healthy DFs from female donors (n=6), 
facial skin, P3 and age range (36-67y). (B) Diabetic DFs from 2males/2females (n=4), 




3-9: Effect of TNF-α conditioned media from healthy dermal 
fibroblasts on MMP-2 and -9 secretion 
 
To determine the influence of paracrine factors and to investigate whether TNF-
α has an indirect paracrine effect on MMP-2 and -9 secretion, conditioned 
media was collected from cells that had been cultured in the presence and 
absence of the TNF-α in the scratch assays of section 2-16, and from parallel 
non-scratched cells that were cultured under the same conditions. 
The stimulation of paracrine factors by TNF-α conditioned medium significantly 
increased MMP-2 secretion by healthy scratched dermal fibroblasts at both 
concentrations of 2.5 and 25 ng/ml TNF-α in the conditioned media, but adding 
TNF-α directly to previously conditioned media control had no effect (Fig 3-19 
A). MMP-2 induction in non-scratched dermal fibroblasts was also higher than 
the controls at 2.5 and 25 ng/ml TNF-α, but this was highly variable and not 
significant (Fig 3-19 B). 
The paracrine effect on MMP-9 secretion by healthy scratched dermal 
fibroblasts was variable, but not significant and this effect was similar to direct 
application of TNF-α combined with the conditioned control, which had no 
significant effect (Fig 3-20 A). In non-scratched dermal fibroblasts, there was 
also no statistically significant difference, and for the conditioned media control 






























Figure 3-19: Paracrine effect of TNF-α on MMP-2 secretion in healthy scratched 
and non-scratched dermal fibroblasts. Conditioned media was collected from 
scratched and non-scratched cells that had been cultured in the presence or absence 
of 2.5 or 25 ng/ml TNF-α for 24h. DFs, from female donors (n=6), facial skin, P3 and 
age range (36-67y). (A) Scratched DFs, both 2.5 and 25 ng/ml CM induced MMP-2 
significantly; *p<0.05 and **p<0.01, one-way ANOVA, and (B) Non-scratched DFs no 











































Figure 3-20: paracrine effect of TNF-α on MMP-9 secretion in healthy scratched 
and non-scratched dermal fibroblasts. Conditioned media was collected from 
scratched and non-scratched cells that had been cultured in the presence or absence 
of 2.5 or 25 ng/ml TNF-α for 24h. DFs, from female donors (n=6), facial skin, P3 and 
age range (36-67y). (A) Scratched DFs, TNF-α paracrine had no significant differences, 
one-way ANOVA, and (B) Non-scratched DFs, TNF-α paracrine had no significant 




3-10: Changes in gene expression in response to TNF-α 
 
3-10-1: The effect of TNF-α on MMP-1 mRNA expression in 
healthy and diabetic dermal fibroblasts 
 
As TNF-α had functional effects on dermal fibroblasts (section 3-5 and 3-6) and 
induced the secretion of MMP (section 3-7 to 3-9), its ability to modulate the 
expression of a range of extracellular matrix and senescence genes was 
investigated. All RNA samples were of high concentration (12-34 ng/µl) and 
purity (260/280 ≥ 1.8, 260/230 ≥ 2). 
In healthy non-scratched dermal fibroblasts, TNF-α significantly increased 
MMP-1 gene expression at both concentrations of TNF-α (2.5 and 25 ng/ml) 
compared to control. This increase in MMP-1 mRNA expression was also 
mirrored in scratched cells, but was not significant (Fig 3-21 A). 
The effect of TNF-α on MMP-1 expression in diabetic dermal fibroblasts 
cultured under the same conditions was also investigated. Interestingly, diabetic 
control (basal) gene expression of MMP-1 was considerably higher than that 
seen in healthy cells; 1637% vs 235% (scratched cells) and 1669% vs 478 % 
(non-scratched cells) (Fig 3-21 A and B). 
In diabetic dermal fibroblasts, under both conditions, MMP-1 expression with 
TNF-α stimulation was higher in a dose-dependent manner but this was only 
significant at the highest concentration of TNF-α in diabetic scratched cells (Fig 





In order to determine whether gender plays a role in MMP-1 gene expression in 
response to TNF-α in diabetic patients, the effect of TNF-α on dermal fibroblasts 
derived from female and male patients was compared (Fig 3-21 C and D). In 
diabetic male dermal fibroblasts (n=2) MMP-1 gene expression was higher than 
the controls at the highest concentration of TNF-α for both non-scratched and 
scratched cells but not significantly so. In diabetic female dermal fibroblasts 
(n=2), the effect of TNF-α on MMP-1 expression under both culture conditions 

















Figure 3-21: Effect of scratching and TNF-α incubation on MMP-1 mRNA 
expression. DFs were incubated in the presence and absence of TNF-α for 24h at two 
different concentrations 2.5 or 25 ng/ml. DFs were either scratched or parallel DFs 
were left unscratched (intact) for healthy donors and diabetic patients before RNA was 
extracted. (A) Expression levels of MMP-1 in healthy cells comparing scratched and 
non-scratched, in the presence of TNF-α (2.5 or 25 ng/ml), n=5 female donors, facial 
skin, P3, (36-67y). (B) Diabetic DFs from 2males/2females (n=4), P3, lower leg, (52-
66y), and (C) The effect of TNF-α on MMP-1 gene expression in DFs from male 
diabetic patients (n=2), and (D) in DFs from female diabetic patients (n=2). *p<0.05 and 
**p<0.01, one-way ANOVA.  
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3-10-2: The effect of TNF-α on MMP-2 mRNA expression in 
healthy and diabetic dermal fibroblasts 
 
MMP-2 gene expression was analysed as TNF-α had previously been shown to 
modulate protein expression by zymography (section 3-8). In healthy dermal 
fibroblasts, TNF-α had no significant effect on MMP-2 expression under both 
cell conditions at either concentration of TNF-α (Fig 3-22 A). 
In diabetic dermal fibroblasts, TNF-α caused no statistically significant 
difference in MMP-2 expression in both non-scratched and scratched cells     
(Fig 3-22 B). In non-scratched cells, (basal) MMP-2 gene expression was higher 
in diabetic cells compared to healthy cells (1936% vs. 650%, respectively). 
Noticeably, MMP-2 expression in both healthy basal was (2103% control 
scratched vs. Less than 1000%, control non-scratched) (Fig 3-22 A and B).   
No significant differences have observed on MMP-2 mRNA expression in both 
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Figure 3-22: Effect of scratching and TNF-α incubation on MMP-2 mRNA 
expression. DFs were incubated in the presence and absence of TNF-α for                 
24h at two different concentrations 2.5 or 25 ng/ml. DFs were either scratched or 
parallel DFs were left unscratched (intact) for healthy donors and diabetic patients.                      
(A) Expression levels of MMP-2 in healthy cells comparing scratched and non-
scratched, in the presence of TNF-α (2.5 or 25 ng/ml), n=5 female donors, facial skin, 
P3, (36-67y). (B) Diabetic DFs from 2males/2females (n=4), P3, lower leg, (52-66y), 
and (C) The effect of TNF-α on MMP-2 gene expression in DFs from male diabetic 





3-10-3: The effect of TNF-α on MMP-9 mRNA expression in 
healthy and diabetic dermal fibroblasts 
 
In healthy dermal fibroblasts, there was no statistically significant upregulation 
in MMP-9 mRNA expression TNF-α in non-scratched and scratched cells (Fig 3-
23 A).  
In diabetic dermal fibroblasts, MMP-9 mRNA expression was higher than in the 
controls, in both scratched and non-scratched cells, but did not reach statistical 
significance (Fig 3-23 B). There was no difference in basal MMP-9 mRNA 
expression between diabetic and healthy controls under either condition (Fig 3-
23 A and B).  
TNF-α had no effect on MMP-9 expression in male and female diabetic cells, 












Figure 3-23: Effect of scratching and TNF-α incubation on MMP-9 mRNA 
expression. DFs were incubated in the presence and absence of TNF-α for               
24h at two different concentrations 2.5 or 25 ng/ml. DFs were either scratched or 
parallel DFs were left unscratched (intact) for healthy donors and diabetic patients.        
(A) Expression levels of MMP-9 in healthy cells comparing scratched and non-
scratched, in the presence of TNF-α (2.5 or 25 ng/ml), n=5 female donors, facial skin, 
P3, (36-67y). (B) Diabetic DFs from 2males/2females (n=4), P3, lower leg, (52-66y), 
and (C) The effect of TNF-α on MMP-9 gene expression in DFs from male diabetic 
patients (n=2), and (D) in DFs from female diabetic patients (n=2). All non-significant, 
one-way ANOVA. 
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3-10-4: The effect of TNF-α on TIMP-1 mRNA expression in 
healthy and diabetic dermal fibroblasts 
 
In healthy dermal fibroblasts, TNF-α significantly increased TIMP-1 mRNA 
expression by (234%) at a concentration of 25 ng/ml in non-scratched cells. 
Although a similar effect of TNF-α (225%) was observed at a 2.5 ng/ml 
concentration in scratched cells, it was not significant (Fig 3-24 A).  
In diabetic dermal fibroblasts, TNF-α did not significantly alter TIMP-1 
expression in non-scratched cells (Fig 3-24 B). Control (basal) expression was 
higher in diabetic fibroblasts compared to healthy control fibroblasts under non-
scratched conditions (1028% vs. 307%). Nevertheless, this difference was not 
apparent in scratched fibroblasts since TIMP-1 mRNA expression in diabetic 
fibroblasts was similar to that in non-diabetic cells (Fig 3-24 A and B).  
When the diabetic fibroblasts were split by gender, no significant differences 





Figure 3-24: Effect of scratching and TNF-α incubation on TIMP-1 mRNA 
expression. DFs were incubated in the presence and absence of TNF-α for              
24h at two different concentrations 2.5 or 25 ng/ml. DFs were either scratched or 
parallel DFs were left unscratched (intact) for healthy donors and diabetic patients. (A) 
Expression levels of TIMP-1 in healthy cells comparing scratched and non-scratched, 
in the presence of TNF-α (2.5 or 25 ng/ml), n=5 female donors, facial skin, P3, (36-
67y). (B) Diabetic DFs from 2males/2females (n=4), P3, lower leg, (52-66y), and (C) 
The effect of TNF-α on TIMP-1 gene expression in DFs from male diabetic patients 
(n=2), and (D) in DFs from female diabetic patients (n=2). **p<0.01. All rest non-
significant, one-way ANOVA. 
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3-10-5: The effect of TNF-α on TIMP-2 mRNA expression in 
healthy and diabetic dermal fibroblasts 
 
In healthy dermal fibroblasts, whether scratched or non-scratched conditions, 
TNF-α had no statistically significant effect on TIMP-2 expression (Fig 3-25 A).  
Similarly, in diabetic dermal fibroblasts, under non-scratched and scratched 
conditions (Fig 3-25 B), there was no significant effect of TNF-α. The expression 
of TIMP-2 in the diabetic control dermal fibroblasts was higher than the healthy 
dermal fibroblasts under both conditions (686% vs. 509%) in non-scratched, 
and in scratched cells (641% vs. 340%) (Fig 3-25 A and B).  
As with TIMP-1 expression, no gender differences could be demonstrated but 
the sample size was only n = 2 (Fig 3-25 C and D).  







Figure 3-25: Effect of scratching and TNF-α incubation on TIMP-2 mRNA 
expression. DFs were incubated in the presence and absence of TNF-α for              
24h at two different concentrations 2.5 or 25 ng/ml. DFs were either scratched or 
parallel DFs were left unscratched (intact) for healthy donors and diabetic patients. (A) 
Expression levels of TIMP-2 in healthy cells comparing scratched and non-scratched, 
in the presence of TNF-α (2.5 or 25 ng/ml), n=5 female donors, facial skin, P3, (36-
67y). (B) Diabetic DFs from 2males/2females (n=4), P3, lower leg, (52-66y), and (C) 
The effect of TNF-α on TIMP-2 gene expression in DFs from male diabetic patients 
(n=2), and (D) in DFs from female diabetic patients (n=2). All non-significant, one-way 
ANOVA. 
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3-10-6: The effect of TNF-α on Sirt1 mRNA expression in 
healthy and diabetic dermal fibroblasts 
 
In healthy dermal fibroblasts, TNF-α had no effect on Sirt1 mRNA expression in 
either scratched or non-scratched dermal fibroblasts (Fig 3-26 A). 
In diabetic dermal fibroblasts, TNF-α also had no significant effect on Sirt1 
expression under both conditions (Fig 3-26 B). The diabetic control cells 
expressed at least double the levels of Sirt1 mRNA compared to healthy control 
dermal fibroblasts under both conditions (7% vs. 3.6%) in non-scratched cells, 
and (6% vs. 2%) in scratched cells (Fig 3-26 A and B).  
No significant observations in diabetic male and female dermal fibroblasts in 
Sirt1 expression were made. The pattern of Sirt1 mRNA in response to TNF-α 














Figure 3-26: Effect of scratching and TNF-α incubation on Sirt1 mRNA 
expression. DFs were incubated in the presence and absence of TNF-α for               
24h at two different concentrations 2.5 or 25 ng/ml. DFs were either scratched or 
parallel DFs were left unscratched (intact) for healthy donors and diabetic patients.        
(A) Expression levels of Sirt1 in healthy cells comparing scratched and non-scratched, 
in the presence of TNF-α (2.5 or 25 ng/ml), n=5 female donors, facial skin, P3, (36-
67y). (B) Diabetic DFs from 2males/2females (n=4), P3, lower leg, (52-66y), and (C) 
The effect of TNF-α on Sirt1 gene expression in DFs from male diabetic patients (n=2), 
and (D) in DFs from female diabetic patients (n=2). All non-significant, one-way 
ANOVA. 


























T N F -  d irc t  a p p lic a t io n


























T N F -  d irc t  a p p lic a t io n

























T N F -  d i re c t  a p p lic a t io n


























T N F -  d i re c t  a p p lic a t io n



























T N F -  d i re c t  a p p lic a t io n



























































T N F -  d irc t  a p p lic a t io n































3-10-7: The effect of TNF-α on Sirt6 mRNA expression in 
healthy and diabetic dermal fibroblasts 
 
In healthy dermal fibroblasts, TNF-α had no effect on Sirt6 mRNA expression 
under non-scratched and scratched conditions (Fig 3-27 A). 
Similarly, in diabetic dermal fibroblasts, TNF-α had no effect on Sirt6 mRNA 
expression under both conditions (Fig 3-27 B). As for Sirt1 expression, the 
control (basal) expression in diabetic cells was higher than in healthy dermal 
fibroblast under both conditions (5% vs 2%) in non-scratched cells, and (4% vs 
1.3%) in scratched cells (Fig 3-27 A and B).  
In both gender cells no significant effect was observed on Sirt6 expression by 
TNF-α under both conditions (Fig 3-27 C and D). 
     



































Figure 3-27: Effect of scratching and TNF-α incubation on Sirt6 mRNA 
expression. DFs were incubated in the presence and absence of TNF-α for              
24h at two different concentrations 2.5 or 25 ng/ml.  DFs were either scratched or 
parallel DFs were left unscratched (intact) for healthy donors and diabetic patients.       
(A) Expression levels of Sirt6 in healthy cells comparing scratched and non-scratched, 
in the presence of TNF-α (2.5 or 25 ng/ml), n=5 female donors, facial skin, P3, (36-
67y). (B) Diabetic DFs from 2males/2females (n=4), P3, lower leg, (52-66y), and (C) 
The effect of TNF-α on Sirt6 gene expression in DFs from male diabetic patients (n=2), 
and (D) in DFs from female diabetic patients (n=2). All rest non-significant, one-way 
ANOVA. 
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3-11: Paracrine effect of TNF-α on MMP-1, MMP-2 and MMP-9 
mRNA expression by healthy dermal fibroblasts 
 
To determine whether TNF-α had an indirect effect on MMPs expression by 
stimulating soluble paracrine factors, the effect of media conditioned by dermal 
fibroblasts in the presence of TNF-α was investigated, in healthy dermal 
fibroblasts under both conditions; either with scratching and without scratching. 
In non-scratched dermal fibroblasts, the expression of MMP-1 mRNA was 
several-fold higher with TNF-α conditioned media (25ng/ml) (Fig 3-28 A) but this 
was not statistically significant. Similar results were obtained when dermal 
fibroblasts were incubated directly with TNF-α (Fig 3-21 A). Adding TNF-α 
directly to the conditioned media induced a similar upregulating of MMP-1, 
indicating that TNF-α in the medium rather than secreted paracrine factors 
stimulated this response. A similar response observed in scratched dermal 
fibroblasts, but was significant (Fig 3-28 B).  
There was no difference in MMP-2 mRNA expression in response to TNF-α 
conditioned media under either cell condition (Fig 3-29 A and B), which was 
similar to what was observed when dermal fibroblasts were incubated directly 
with TNF-α (Fig 3-22 A).  
TNF-α conditioned media had no effect on MMP-9 mRNA expression, in either 
non-scratched or scratched dermal fibroblasts (Fig 3-30 A and B). Interestingly, 
there appeared to be an additive effect of TNF-α supplemented conditioned 
medium in a dose-dependent manner, but this was highly variable and did not 

























Figure 3-28: Effect of scratching and TNF-α paracrine incubation on MMP-1 
mRNA expression. DFs were incubated in the presence or absence of TNF-α for 24h 
at two different concentrations 2.5 or 25 ng/ml. DFs were scratched and a parallel DFs 
were left unscratched (intact), (n=5) female donors, facial skin, P3, age range (36-67y). 
(A) Expression levels of MMP-1 in healthy non-scratched cells, and (B) in healthy 
scratched cells. *p<0.05 and **p<0.01, one-way ANOVA.  




























Figure 3-29: Effect of scratching and TNF-α paracrine incubation on MMP-2 
mRNA expression. DFs were incubated in the presence or absence of TNF-α for 24h 
at two different concentrations 2.5 or 25 ng/ml. DFs were scratched and a parallel DFs 
were left unscratched (intact), (n=5) female donors, facial skin, P3, age range (36-67y). 
(A) Expression levels of MMP-2 in healthy non-scratched cells, and (B) in healthy 
scratched cells. All non-significant, one-way ANOVA.  



























Figure 3-30: Effect of scratching and TNF-α paracrine incubation on MMP-9 
mRNA expression. DFs were incubated in the presence or absence of TNF-α for 24h 
at two different concentrations 2.5 or 25 ng/ml. DFs were scratched and a parallel DFs 
were left unscratched (intact), (n=5) female donors, facial skin, P3, age range (36-67y). 
(A) Expression levels of MMP-9 in healthy non-scratched cells, and (B) in healthy 









3-12: Paracrine effect of TNF-α on TIMP-1 and TIMP-2 mRNA 
expression by healthy dermal fibroblasts 
 
The pattern of expression of TIMP-1 mRNA in response to TNF-α conditioned 
media (Fig 3-31 A) was similar to that seen when TNF-α was added directly (Fig 
3-24 A). Supplementation of control conditioned media with TNF-α similarly had 
no effect. In scratched cells, TNF-α conditioned media also showed no 
significant effect on TIMP-1 mRNA expression (Fig 3-31 B).  
TNF-α conditioned media did not significantly affect TIMP-2 expression at both 
concentrations in non-scratched cells. Supplementation of control conditioned 
media with fresh TNF-α had a similar effect on TIMP-2 expression (Fig 3-32 A). 
This pattern was similar to that observed when TNF-α was added directly to 
dermal fibroblasts (Fig 3-25 A). There was no change in TIMP-2 expression in 
response to TNF-α in scratched cells (Fig 3-32 B), which again was similar to 
the response of scratched dermal fibroblasts when TNF-α was added directly 


























Figure 3-31: Effect of scratching and TNF-α paracrine incubation on TIMP-1 
mRNA expression. DFs were incubated in the presence or absence of TNF-α for 24h 
at two different concentrations 2.5 or 25 ng/ml. DFs were scratched and a parallel DFs 
were left unscratched (intact), (n=5) female donors, facial skin, P3, age range (36-67y). 
(A) Expression levels of TIMP-1 in healthy non-scratched cells, and (B) in healthy 
























Figure 3-32: Effect of scratching and TNF-α paracrine incubation on TIMP-2 
mRNA expression. DFs were incubated in the presence or absence of TNF-α for 24h 
at two different concentrations 2.5 or 25 ng/ml. DFs were scratched and a parallel DFs 
were left unscratched (intact), (n=5) female donors, facial skin, P3, age range (36-67y). 
(A) Expression levels of TIMP-2 in healthy non-scratched cells, and (B) in healthy 








3-13: Paracrine effect of TNF-α on Sirt1 and Sirt6 mRNA 
expression by healthy dermal fibroblasts 
 
TNF-α conditioned media had no significant effect on Sirt1 gene expression at 
both concentrations, in non-scratched cells. The non-significance is due to high 
donor variability so either increasing sample size or repeating expression assay 
may confirm any biological effect of TNF-α conditioned media on Sirt1 
expression). Supplementation of control conditioned media with TNF-α also had 
no statistically significant effect (Fig 3-33 A). In scratched cells, there was no 
change in Sirt1 expression under any conditions (Fig 3-33 B), which was similar 
to the results seen when TNF-α was added directly (Fig 3-26 A). 
There was no paracrine effect of TNF-α on Sirt6 expression either in non-
scratched cells or scratched cells (Fig 3-34 A and B). This was similar to the 




























Figure 3-33: Effect of scratching and TNF-α paracrine incubation on Sirt1 mRNA 
expression. DFs were incubated in the presence or absence of TNF-α for 24h at two 
different concentrations 2.5 or 25 ng/ml. DFs were scratched and a parallel DFs were 
left unscratched (intact), (n=5) female donors, facial skin, P3, age range (36-67y). (A) 
Expression levels of Sirt1 in healthy non-scratched cells, and (B) in healthy scratched 

























Figure 3-34: Effect of scratching and TNF-α paracrine incubation on Sirt6 mRNA 
expression. DFs were incubated in the presence or absence of TNF-α for 24h at two 
different concentrations 2.5 or 25 ng/ml. DFs were scratched and a parallel DFs were 
left unscratched (intact), (n=5) female donors, facial skin, P3, age range (36-67y). (A) 
Expression levels of Sirt6 in healthy non-scratched cells, and (B) in healthy scratched 









3-14: The effect of TNF-α, or TNF-α induced paracrine factors 
on cytokine release by healthy and diabetic dermal fibroblasts  
 
The release of cytokines, growth factors, and chemokines by cultured dermal 
fibroblasts in response to TNF-α was quantitated 24h after scratching. The 
Proteome Profiler Array measures 36 different cytokines as described in Table 
3-1. The description of these cytokines and representative images of their 
expression are in (Appendix 8-4). In healthy dermal fibroblasts, under normal 
conditions, the secretion of 7/36 cytokines (CCL2/MCP-1, CXCL1/GROα, 
CXCL12/SDF-1, IL-6, IL-8, MIF and Serpin E1/PAI-1) were detected. The same 
seven cytokines were detected in diabetic male dermal fibroblasts under basal 
conditions, while in diabetic female dermal fibroblasts, the cytokines 
(CCL2/MCP-1 and IL-6) were not detected (see section 4-13). 
In healthy dermal fibroblasts, the presence of 2.5 ng/ml TNF-α stimulated the 
secretion of an additional five cytokines (MIP-1α/ MIP-1β, G-CSF, GM-CSF, IL-
32α and TNF-α), which were not detected under basal conditions, Table 3-1 
and (Fig 3-35 A). In addition, TNF-α appeared to stimulate an increase in the 
secretion of CXCL1 (87.45%) and IL-6 (207.13%), in contrast, it seemed to 
decrease MIF secretion by 68.51% (Fig 3-35 A) (see section 4-13). 
In female diabetic dermal fibroblasts, TNF-α induced the secretion of a further 6 
cytokines that were not detected under its basal condition. These were 
(CCL2/MCP-1, CCL5/RANTES, ICAM-1/CD54, GM-CSF, IL-6, and TNF-α), 
Table 3-1 and (Fig 3-35 B). In addition, TNF-α further increased secretion of 
CXCL1/GROα by 52.01%, but decreased secretion of MIF and Serpin E1/PAI-1 




In male diabetic dermal fibroblasts, TNF-α also induced the secretion of ICAM-
1/CD54 and TNF-α, which were not detected under basal conditions (Table 3-
1). However, in contrast to female diabetic dermal fibroblasts, TNF-α did not 
induce secretion of GM-CSF or CCL5/RANTES, (Table 3-1) and (Fig 3-35 C).    
In a similar manner to female diabetic dermal fibroblasts, TNF-α further 
increased the secretion of CXCL1/GROα by 90.34%, and decreased secretion 
of MIF and Serpin E1/PAI-1 by 76.93% and 52.3% respectively in male diabetic 
dermal fibroblasts (Fig 3-35 C). However in contrast to female diabetic dermal 
fibroblasts, in male diabetic dermal fibroblasts, TNF-α induced CXCL12/SDF-1 
secretion by 98.29% and stimulated secretion of IL-6 by 13.23% (Fig 3-35 C). 
To investigate whether dermal fibroblasts paracrine factors modulate cytokine 
secretion, healthy dermal fibroblasts were incubated with dermal fibroblast 
media that had been conditioned in the presence or absence of TNF-α. There 
was no difference in cytokine secretion between control conditioned (CMCon) or 
TNF-α 2.5 ng/ml conditioned media. The recipient dermal fibroblasts secreted 
the same 7 cytokines (CCL2/MCP-1, CXCL1/GROα, CXCL12/SDF-1, IL-6, IL-8, 
MIF and Serpin E1/PAI-1) in the presence and absence of TNF-α, and there 
was no change in the level of secretion in the presence of TNF-α CM (Fig 3-36).  
In contrast to the direct effect of TNF-α on dermal fibroblasts, the TNF-α 
conditioned media did not stimulate the secretion of MIP-1α/ MIP-1β, G-CSF, 
GM-CSF, IL-32α or TNF-α (Table 3-1).      
 








Healthy donor  
♀ 
♀ 
Diabetic patient  
♀ 






















_ _ _ _ _ _ _ _ 
CCL2/MCP-1 
 
✔ ✔ ✔ ✔ _ ✔ ✔ ✔ 
MIP-1α/MIP-1β 
 
_ ✔ _ _ _ _ _ _ 
CCL5/RANTES _ _ _ _ _ ✔ _ _ 
CD40Ligand/TNFSF5 _ _ _ _ _ _ _ _ 
Complement 
component C5/C5a 
_ _ _ _ _ _ _ _ 
CXCL1/GROα ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
CXCL10/IP-10 _ _ _ _ _ _ _ _ 
CXCL11/I-TAC _ _ _ _ _ _ _ _ 
CXCL12/SDF-1 ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
G-CSF _ ✔ _ _ _ _ _ _ 
GM-CSF _ ✔ _ _ _ ✔ _ _ 
ICAM-1/CD54 _ _ _ _ _ ✔ _ ✔ 
IFN-γ _ _ _ _ _ _ _ _ 
IL-1α/IL-1F1 _ _ _ _ _ _ _ _ 
IL-1β/IL-1F2 _ _ _ _ _ _ _ _ 
IL-1ra/IL1-F3 _ _ _ _ _ _ _ _ 
IL-2 _ _ _ _ _ _ _ _ 
IL-4 _ _ _ _ _ _ _ _ 
IL-5 _ _ _ _ _ _ _ _ 
IL-6 ✔ ✔ ✔ ✔ _ ✔ ✔ ✔ 
IL-8 ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 




Table 3-1: Cytokine, Chemokine, and growth factors were up-regulated and/or 
downregulated by control or 2.5 ng/ml or CMCon or 2.5 ng/ml CM by the healthy 
donor and diabetic patients DFs conditioned media 
 
Human 36 Cytokine, Chemokine and growth factors, detected and non-detected. 
CCL1/I-309: Chemokine, (C-C motif) ligand1/ Human Cytokine I-309; CCL2/MCP-1: 
Chemokine, (C-C motif) ligand 2/ monocyte chemoattractant protein 1; MIP-1α/MIP-1β: 
Macrophage Inflammatory Proteins (α and β); CCL5/RANTES: Chemokine, C-C motif 
ligand 5/ RANTES; CD40Ligand/TNFSF5: Member of TNF-α superfamily/ CD154; 
Complement component C5/C5a: Complement component 5 (complement system); 
CXCL1/GROα: Chemokine, C-X-C motif ligand 1/GROα; CXCL10/IP-10: Chemokine, 
C-X-C motif ligand 10/ Interferon gamma-induced protein 10 (IP-10); CXCL11/I-TAC: 
Chemokine, C-X-C motif ligand 11/ Interferon-inducible T-cell alpha chemoattractant; 
CXCL12/SDF-1: Chemokine, C-X-C motif ligand 12/ stromal cell-derived factor 1 (SDF-
1); G-CSF: Granulocyte-colony stimulating factor; GM-CSF: Granulocyte-macrophage 
colony-stimulating factor; ICAM-1/CD54: Intercellular Adhesion Molecule/CD54; IFN-γ: 
Interferon gamma; IL-1α/IL-1F1: Interleukin-1 alpha/ IL-1F1 Protein; IL-1β/IL-1F2: 
Interleukin-1 beta/ IL-1F2 Protein; IL-1ra/IL1-F3: Interleukin-1 receptor antagonist (IL-
1RA); IL-2: Interleukin-2; IL-4: Interleukin-4;  IL-5: Interleukin-5; IL-6: Interleukin-6; IL-8: 
Interleukin-8; IL-10: Interleukin-10; IL-12 p70: Interleukin-12/ heterodimer p70); IL-13: 
Interleukin-13; IL-16: Interleukin-16; IL-17A: Interleukin-17A; IL-17E: Interleukin-17E; 
IL-18/IL-1F4: Interleukin-18/ IL-1F4 Protein; IL-21: Interleukin-21; IL-27: Interleukin-27; 
IL-32α: Interleukin-32α; MIF: Macrophage migration inhibitory factor; Serpin E1/PAI-1: 
Serpin E1/Plasminogen activator inhibitor-1; TNF-α: Tumour necrosis factor-α; TREM-
1: Triggering receptor expressed on myeloid cells 1. The symbols ✔: detected,   - : 
not detected.    
IL-12 p70 _ _ _ _ _ _ _ _ 
IL-13 _ _ _ _ _ _ _ _ 
IL-16 _ _ _ _ _ _ _ _ 
IL-17A _ _ _ _ _ _ _ _ 
IL-17E _ _ _ _ _ _ _ _ 
IL-18/IL-1F4 _ _ _ _ _ _ _ _ 
IL-21 _ _ _ _ _ _ _ _ 
IL-27 _ _ _ _ _ _ _ _ 
IL-32α _ ✔ _ _ _ _ _ _ 
MIF ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
Serpin E1/PAI-1 ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
TNF-α _ ✔ _ _ _ ✔ _ ✔ 


































Figure 3-35: The effect of 2.5 ng/ml of TNF-α on the secretion of cytokines, 
chemokines, growth factors and soluble proteins by secreted dermal fibroblasts 
after 24h. Conditioned media collected from (migration assay 3-5), (A) Healthy female 
DFs, facial skin, P3 and age 56y. (B) Diabetic female DFs, and (C) Diabetic male DFs, 
lower leg, P3 and ages 65y. Displayed data represents the mean of duplicate spots 
























Figure 3-36: The paracrine effect of 2.5 ng/ml of TNF-α on the production of 
cytokines, chemokines, growth factors and soluble proteins in dermal fibroblasts 
conditioned media after 24h. Double conditioned media (conditioned media from 
healthy females DFs (n=2), facial skin, P7-8, age range (52-60y), was added to 
scratched DFs of the recipient). Double conditioned media was collected from (3-6 
migration assay), female healthy recipient DFs, facial skin, P3 and age 56y and pooled. 
DFs were incubated in the presence and absence of TNF-α of 2.5 ng/ml CM for 24h. 
Displayed data represented the mean of duplicate spots pixel density. Grey columns: 

















4-1: Comparison of the rate proliferation of dermal fibroblasts 
in media supplemented with 2% or 10% FBS 
 
In vivo, human dermal fibroblasts are not rapidly dividing cells; their primary 
function is to maintain the homeostasis of the dermis by collagen synthesis and 
modelling of the ECM (Ejiri et al., 2014). However, during wound healing 
proliferation of dermal fibroblasts is increased and it is also well established that 
dermal fibroblasts can be stimulated to proliferate in vitro (Darby et al., 2014; 
Chen et al., 2014; Shi et al., 2015). Fig 3-1, illustrates the proliferative response 
of dermal fibroblasts to serum, even in fibroblasts cultured from an older donor 
(age 77yrs). A concentration of 10% FBS stimulated proliferation significantly 
faster compared to 2% FBS after 6 days culture and continued to do so over a 
12-day period.  
The difference in cell proliferation in presence of 2% or 10% serum reflects the 
differences in the relative amounts of growth factors, carriers of water-insoluble 
nutrients, hormones and protease inhibitors, as well as the binding and 
neutralization of toxic moieties in the different concentrations of FBS. 
Human dermal fibroblasts are not a homogenous population and they display 
significant variations when isolated from different anatomical regions, even 
within the dermis (reviewed Sriram et al., 2015). It is clear that dermal fibroblast 
sub-populations display differences in morphology, proliferation rates, and 
biochemical activity. The upper papillary layer of dermis contains the papillary 




dermal fibroblasts (Ohyama et al., 2010; Honardoust et al., 2012). A number of 
differences have been characterised that allow these two lineages of dermal 
fibroblasts to be distinguished from one another including differences in ECM 
composition and organisation, which has an effect on controlling the fibroblast 
behaviour and their response in wound healing.  
In vitro, papillary dermal fibroblasts differ from reticular dermal fibroblasts, with a 
higher growth potential and lower contractile property, and when they become 
senescent their expression of collagen XVI and integrin-α5 decline, which leads 
to an impairment of their adhesion properties (Mancini et al., 2012). Moreover, 
senescent papillary dermal fibroblasts (in vitro and even in organotypic cultures) 
release high levels of KGF, VEGF, and MMP-1, 2 and 3, TIMP-1 and 2 (Mine et 
al., 2008; Pageon et al., 2012). Papillary dermal fibroblast exhibit more 
heterogeneity in size, with less potential growth in culture, and they are more 
susceptible to changes caused by aging, which drives them to differentiate into 
fibroblasts with a reticular phenotype (Janson et al., 2013; reviewed by Sriram 
et al., 2015). 
 A study has reported that human dermal fibroblasts from terminal hair-bearing 
skin e.g. scalp and donor-matched vellus skin e.g. female face, display 
differences in vitro (Kamala, 2014). Fluorescence-activated cell sorting (FACs) 
analysis demonstrated that papillary fibroblasts from female facial skin were 
smaller and more granular than donor-matched fibroblasts from scalp skin, and 
at early passages (P3) proliferated faster in medium containing 5% stripped 
serum (Kamala, 2014). In addition, the expression of inhibitors of apoptosis 




corresponding donor-matched scalp fibroblasts (Kamala, 2014). Another study 
by Chipev and Simon (2002), also supports these findings; they reported that 
dermal fibroblasts from glabrous skin are smaller, more proliferative, their 
production of TGF-β1 and expression of TGF-β1-receptors II, α-SMA and 
fibronectin are less than the dermal fibroblasts from non-glabrous skin 
(reviewed by Sriram et al., 2015).  
A comparison of the proliferation rates between donor-matched papillary dermal 
fibroblasts from these two sites (facial and scalp) for up to 14 days, in 10% FBS  
showed no significant difference (Fig 3-2). This is a comparison whether the 
growth rates of papillary dermal fibroblasts from different sites differ, and the 
results of the present study are comparable to previous reports for papillary 
dermal fibroblasts Kamala (2014). The proliferation rate of scalp papillary 
fibroblasts in the Kamala (2014) study was significantly lower than the 
proliferation rate of facial donor-matched fibroblast. However, in the present 
study, the fibroblasts were grown in 10% FBS which provides optimal growth, 
while in the Kamala study, fibroblasts were grown in 5% stripped serum which 
slows the growth in a similar manner to 2% FBS. 
One important factor in the comparison of dermal fibroblasts is passage 
number. It has been reported that high numbers of passaging in culture result in 
a lower replicative rate and may lead to aging of the papillary dermal fibroblasts 
(Gunin et al., 2011).  In addition, a study by Janson et al., (2013) reported that 
the papillary dermal fibroblasts take on a reticular dermal fibroblast phenotype 
after long term passaging in vitro, so they may become more like reticular 




4-2: TNF-α inhibits both donor-matched facial and scalp dermal 
fibroblast proliferation  
 
TNF-α is a pro-inflammatory cytokine, with normal circulating levels of (11.2 ± 
7.31 pg/ml) (Arican et al., 2005). In human skin, TNF-α reduces collagens by 
increasing MMPs production by human dermal fibroblasts (Brembilla et al., 
2015). However, TNF-α in human diabetic foot ulcers increases dermal 
fibroblast apoptosis, collagen degradation and decreases angiogenesis.                                                                          
(Kasiewicz and Whitehead, 2016). Since in vitro effects of TNF-α are time and 
dose-dependent (Barrientos et al., 2008), in this study, three concentrations, 
supra-physiological (2.5, 25 ng/ml) and supra-pathophysiological (250 ng/ml) of 
TNF-α were chosen to simulate the inflammatory environment and to 
investigate changes in the cultured dermal fibroblast phenotype. When 
fibroblasts were pre-incubated with TNF-α at all 3 concentrations for 3 days, cell 
proliferation was inhibited by day 14, even though the medium was replenished 
with 10% normal growth media (Fig 3-3 A and B) for the following 11 days. 
TNF-α had the same inhibitory effect on papillary dermal fibroblast proliferation 
regardless of whether they were derived from scalp or facial skin of the same 
donors. This inhibition may be due to a cytotoxic effect of TNF-α in a rat 
hepatocytes cell line at high concentration (10 ng/ml) (Jones et al., 2000).          
A study by Wang et al., (2014) reported that the proliferation of human 
fibroblasts was inhibited due to overexpression of TNF-α, but this was in 
diabetic wounds. Another explanation is that the cells may have been 
stimulated to secrete their own TNF-α, or other pro-inflammatory cytokines, and 
did not recover (permanent effect), even when the endogenous TNF-α was 




number, maybe due to their differentiation into myofibroblasts induced by 
exposure to TNF-α (reviewed by Distler et al., 2008). To confirm this the 
expression of α-SMA (protein) in dermal fibroblasts exposed to TNF-α could be 
quantitated. 
TNF-α can also be a potent pro-apoptotic stimulus, a recent study displayed 
that (20 ng/ml) TNF-α induces fibroblast (dermal fibroblast and vascular 
adventitial fibroblast) apoptosis by increasing the expression of cleaved 
caspase -8/3, which downregulates Bcl-2/Bax and upregulates FOXO1, an 
apoptosis transcription factor (Wang et al., 2014). Pre-incubation with TNF-α for 
3 days may induce irreversible changes, one of which may be due to increased 
numbers of senescent cells. However, manual cell counts using a 
haemocytometer-slide and trypan blue exclusion dye is not the most sensitive 
method to qualify cell viability. Cells may have detached and floated off into the 
media prior to counting. Since this was not collected, this may not be a true 
representation of the percentage viability. 
Therefore these results were also confirmed using a more sensitive and reliable 
direct cell proliferation assay; CyQUANT direct cell, to confirm this observed 
effect of TNF-α on dermal fibroblast proliferation (Fig 3-4). The experimental 
design was identical to that used for manual cell counting, with the trypan blue 
exclusion dye. The CyQUANT direct cell proliferation assay also confirmed a 
significant reduction in the rate of dermal fibroblast proliferation after a 3 day 
incubation with TNF-α at the lowest concentrations 2.5 and 25 ng/ml at day 14. 
The inhibitory effect of TNF-α at day 14 was similar to that seen using the 




highest concentration of 250 ng/ml did not reach statistical significance, it was 
close (Fig 3-4 C). Another observation using the CyQUANT assay was that the 
inhibitory effect was seen earlier at day 7 (Fig 3-4 B), although it was seen at 
day 12 in the facial using the manual method, at the lower concentrations of 2.5 
and 25 ng/ml respectively. These similarities using two different methods 
confirm that dermal fibroblasts proliferation inhibited by TNF-α. 
 
 
4-3: pre-incubation with TNF-α leads to an increase in the 
metabolic activity of dermal fibroblasts at day 14 
 
Human dermal fibroblasts that are repeatedly treated with (10 ng/ml) of TNF-α 
every 2 days for at least 20 treatments become senescent. Thus, long-term 
exposure to TNF-α induces senescence of human dermal fibroblasts, 
decreases the proliferation rate and increases β-galactosidase expression 
(Mavrogonatou et al., 2018).   
Pre-incubation of dermal fibroblasts with TNF-α at doses between (2.5- 250) 
ng/ml for 3 days, followed by incubation with normal growth media (10% FBS) 
for up to 14 days, demonstrated a significant increase in their metabolism at the 
lowest concentration of 2.5 ng/ml by day 14 (Fig 3-5).  
One possible explanation for the decrease in dermal fibroblast proliferation in 
response to TNF-α may be a result of increased differentiation into a 
myofibroblast phenotype, which is highly metabolically active fibroblasts, and 
the TNF-α ability to induce dermal fibroblasts differentiation into myofibroblasts 




4-4: Induction of senescence in cultured dermal fibroblasts by 
TNF-α 
 
One possible explanation for the inhibition of dermal fibroblast proliferation (Fig 
3-3 A and B) and upregulation metabolic activity is cell senescence. Senescent 
cells are also characterized by altered and enhanced MMP activity (reviewed by 
Borg et al., 2013). An increase in MMP expression leads to degradation of 
growth factor receptors, and dermal fibroblasts are unable to recognise their 
growth factors, resulting in a low proliferative ability, with a high proportion of 
senescent dermal fibroblasts (Chen et al., 2013). Telomere shortening can be 
induced through repeated replications (long term passaging) and can result in 
cellular senescence induced by cell stress via inflammatory factors and 
inflammatory diseases, resulting in increased ROS (Lopez-Otin et al., 2013; 
Lagouge and Larrson, 2013). Therefore the ability of TNF-α to induce 
senescence in this study was analysed using β-galactosidase as a marker. 
TNF-α is believed to have two different roles in preventing tumorigenesis and 
stimulating tumorigenesis, so the excessive proliferation of cells can be limited 
by arresting the cell cycle, resulting in cellular senescence (Wang and Lin, 
2008). Senescence as a cellular stress response, leads to the blockade of cell 
proliferation that is characterized by morphological changes and the expression 
of the senescence marker β-galactosidase (Campisi and d'Adda di, 2007; 
Hirano et al., 2015).  
A recent study in mice, reported that TNF-α at low concentrations (0.5 ng/ml) 
induces p21 (a trigger for cellular senescence) expression in mesangial cells 




expression, yet expression was blocked at a concentration of 50 ng/ml of TNF-
α, demonstrating a dose-dependent effect (Hirano et al., 2015).  
TNF-α induces permanent senescence by increasing β-galactosidase 
expression with persistent ROS production and oxidative stress. In senescent 
human dermal fibroblasts, TNF-α leads to an elevation of ROS levels and 
continual, rapid, transient, p38 MAPK activation, even after long term exposure 
to TNF-α (Kandhaya-Pillai et al., 2017).  
In the present study, incubation with TNF-α induced cell senescence at (250 
ng/ml), the highest level of senescence was seen in cells exposed to a 
concentration of 250 ng/ml TNF-α (Fig 3-6 and 7). The passage number is an 
important factor that contributes to induce β-galactosidase expression. In the 
present study, β-galactosidase was only expressed in cultured dermal 
fibroblasts when they reached passage number 17 (Fig 3-6). However, the 
same cells at earlier passage numbers did not express a significant increase in 
β-galactosidase in response to TNF-α, demonstrating that TNF-α induced 
senescence depends on aging in vitro. It has also been reported that β-
galactosidase induction differs among different cell types. An in vitro study by 
Mϋller et al 2008, found lung fibroblast cultures from emphysema patients 
exhibited a high expression of β-galactosidase when exposed to smoke extract 
as a stress, while dermal fibroblasts from the skin of the same patients did not 
express β-galactosidase, which demonstrate the importance of exposure to 






4-5: Effect of TNF-α on dermal fibroblast migration  
 
Although the release of pro-inflammatory cytokines is important for wound 
healing, but an excessive and prolonged production may result in a chronic non-
healing wound.  
In order to measure the impact of TNF-α on the migration of dermal fibroblasts, 
cells were incubated with TNF-α at two concentrations 2.5 or 25 ng/ml. 
Migration was assessed in both healthy and diabetic dermal fibroblasts. In 
healthy female facial dermal fibroblasts 25 ng/ml of TNF-α significantly inhibited 
cell migration (P<0.01) after 24h (Fig 3-8 and 3-10 A).  
In diabetic dermal fibroblasts, both concentrations of TNF-α 2.5 and 25 ng/ml 
inhibited cell migration significantly (P< 0.05) after 24h (Fig 3-9 and 3-10 B), 
However, the percentage inhibition compared to the control was similar in both 
concentrations 2.5 and 25 ng/ml (28% and 28.2%, respectively).  
A previous study by AL-Mulla et al., (2011) reported that 1ng/ml of TNF-α 
impaired the migration of human dermal fibroblasts by blocking Smad2/3 and 
inducing Smad7 (Smad7- is required for differentiation into myofibroblasts and 
migration of dermal fibroblasts).  
Interestingly, the TNF-α impacts on cellular migration appear to depend on the 
cell type/tissue specific. For example, a concentration of 1ng/ml TNF-α induced 
endothelial migration, while 100 ng/ml TNF-α inhibited endothelial cell migration. 
Conversely, low concentration of 1ng/ml TNF-α inhibited the migration of 
epidermal dendritic cells and human dermal fibroblasts (Takemura et al., 2006). 




migration of healthy dermal fibroblasts, while dermal fibroblasts derived from 
diabetic skin were also inhibited by the low concentration 2.5 ng/ml of TNF-α 
(Fig 3-10). 
Since MMPs are strongly upregulated in inflammatory diseases, excessive 
expression of MMPs induced via pro-inflammatory cytokines such as TNF-α 
leads to excessive degradation of cell-cell and cell-ECM receptors (Ligi et al., 
2016a). This can result in the inhibition of cell migration, while under normal 
conditions the release of MMPs facilitates cell migration to the wound site by 
ECM degradation (Löffek et al., 2011; Chen et al., 2013; Brembilla et al., 2015).  
TNF-α also stimulates the release of MMPs, including the collagenases (MMP-
1,-3 and -13), and the gelatinases (MMP-2 and -9), but not the TIMPs. 
Increased activity of all these MMPs has been shown to impair dermal fibroblast 
migration in an inflamed environment, in human (Barrientos et al., 2008; 
reviewed by Xu et al., 2013; Agren et al., 2015).  
There is increasing evidence that diabetes has an effect on essential aspects of 
fibroblast biology such as migration. Diabetic mice/human dermal fibroblasts 
have displayed a reduction in proliferation and migration, but an elevation in 
apoptosis compared to non-diabetic fibroblasts (Desta et al., 2010; reviewed by 
Baltzis et al., 2014; Shi et al., 2015).  
Diabetic, murine dermal fibroblasts exhibited an impaired migratory ability, they 
migrate 75% less than the normal dermal fibroblasts (Lamers et al., 2011). 
However, the present study showed that human diabetic dermal fibroblasts 
migrate faster than the non-diabetic dermal fibroblasts by 25%, but under TNF-α 




TNF-α, and these diabetic cells migrated faster (17%) than non-diabetic cells 
only at the concentration of 25 ng/ml of TNF-α (Fig 3-10), which shows the 
different impact of different concentrations of TNF-α (concentration-dependent).  
Lamers and colleagues also have shown that high glucose levels 
(hyperglycemia) mediate oxidative stress, which causes the loss of cell polarity 
and impaired cell migration. Moreover, wound healing can be blocked by 
impairing fibroblast functions; migration and proliferation via AGEs (proteins or 
lipids become glycated by high glucose) accumulation products, which mediates 
the activation of ROS (Loughlin and Artlett, 2010). 
Several studies have demonstrated the imbalance between MMPs and TIMPs 
in the chronic diabetic wound environment, with an increase in MMP-1, -2, -8 
and -9, and a decrease in TIMP-2, which may explained the impaired cell 
migration (reviewed by Xu et al., 2013; Ligi et al., 2016b).  
In human skin, Shi (2015), has reported that diabetic wounds are recovery 
poorly due to chronic hyperglycemia (high glucose levels), and the migration of 
human diabetic dermal fibroblasts is impaired under these conditions.  
 
4-6: Does TNF-α stimulate secretion of paracrine factors that 
can modulate neighbouring dermal fibroblast migration? 
 
Paracrine soluble factors including cytokines, chemokines, growth factors and 
proteases (MMPs) (Davalos et al., 2010) can affect neighbouring cells by 
changing the microenvironment through activating various cell surface receptors 




induces a change in the secretory phenotype of dermal fibroblasts, the 
conditioned media in the presence and absence of TNF-α was collected and 
other dermal fibroblasts were assessed for their ability to migrate in its 
presence. 
Dermal fibroblasts from healthy donors were incubated with, or without, TNF-α 
in concentrations of 2.5 and 25 ng/ml in normal growth media for 3 days to 
produce conditioned media. Other dermal fibroblasts from different healthy 
donors were incubated with this conditioned media (Fig 3-11). The conditioned 
media, in the presence of TNF-α showed a lower migration of healthy dermal 
fibroblasts by 48.6% and 35.8%, similar to what was seen by adding TNF-α 
directly (Fig 3-10), although this did not achieve statistical significance (Fig 3-
13). A similar effect was observed when control conditioned media had TNF-α 
added after conditioning) (Fig 3-12) and (Fig 3-13). These results need 
confirming but may imply that TNF-α has a direct effect on dermal fibroblasts by 
inhibiting their migration, but it does not stimulate paracrine factors that have 
any significant effect on modulating fibroblast migration. 
  
4-7: Secretion of active MMP-2 and -9 by dermal fibroblasts in 
response to TNF-α  
 
In order to determine whether the TNF-α conditioned media of cultured dermal 
fibroblasts represents an inflammatory in vitro environment, the activity of the 
MMP-2 and -9 profile as a potential marker for chronic inflammation and their 




optimisation of this study. The diluted conditioned media at all dilutions (1:1, 
1:20, 1:40 and 1:80), exhibited MMP-2 and MMP-9 activity after incubation for 
48h with TNF-α (Fig 3-14 A, B, C, and D). The bands were the clearest, with a 
dilution of 1:40 which was identified as the optimum dilution, where the bands 
were not saturated and clearly showed the gelatin lysis activity that supports the 
activity of high levels of MMPs seen in chronic inflammatory states. The results 
here can be explained that increased activity of these MMP-2 and -9 are 
inflammatory markers, and can be induced by inflammatory cytokines such as 
TNF-α.  
Both MMPs are active as they can carry out their degradational function for 
gelatin as identified by specific bands (Parks et al., 2004). In vivo, both 
gelatinases can degrade the basement membrane which contains collagen type 
IV and laminin as substrates for them (Löffek et al., 2011). A functional 
basement membrane is essential for keratinocyte migration, proliferation and   
re-epithelialization to restore the barrier membrane (Barrientos et al., 2008).  
A recent study examined increased gelatinase activity as a possible cause for 
impairing dermal fibroblast migration during wound healing. A study in mice      
by Gao et al., (2015), showed that increased MMP-9 is involved in 
delayed/impaired diabetic wound healing, while MMP-9 deficiency leads to 
impaired wound healing. This is probably due to the fact that MMP-9 also 
contributes to keratinocyte migration during the re-epithelialization phase (Caley 
et al., 2015). The expression of MMP-2 in acute wounds is associated with 




The present findings indicate that MMP-2 and MMP-9 secretion was higher than 
the controls under TNF-α stimulation in both healthy and diabetic dermal 
fibroblasts under both scratched and non-scratched conditions but there were 
no statistically significantly differences (Fig 3-15, 16, 17 and 18).  
There was no difference in MMP-2 secretion in scratched or non-scratched 
healthy dermal fibroblasts incubated with either concentration of TNF-α (2.5 or 
25 ng/ml) (Fig 3-15 A and17 A). Furthermore, due to donor variability, diabetic 
dermal fibroblasts demonstrated no significant differences in MMP-2 secretion 
at either concentration of TNF-α (Fig 3-15 B and 17 B).  
Similarly there was higher MMP-9 secretion under scratched and non-scratched 
conditions in both healthy dermal fibroblasts and diabetic dermal fibroblasts, but 
due to donor variability, a significant difference at either concentration of TNF-α 
(2.5 or 25 ng/ml) was not demonstrated (Fig 3-16 and 18).  
The study by Han et al., (2001a), reported that concentrations of (5, 10 and 50 
ng/ml) of TNF-α all induced MMP-2 secretion by human dermal fibroblasts in 
monolayer cultures. They confirmed that exposing dermal fibroblasts to TNF-α 
leads to activation of the NF-kB pathway, which stimulates the degradation of    
I-kB by a cascade of events that lead to the translocation of NF-kB to the 
nucleus and thereby the transcription of target genes. Thus, NF-kB induces 
MT1-MMP activation, and the MT1-MMP, in turn, activates MMP-2.  
In humans, MMP-9 is upregulated by inflammatory signals such as TNF-α, and 




α will increase the binding of these two transcription factors to the MMP-9 DNA 
sequence, which leads to upregulation of MMP-9.  
The present study showed a much higher secretion of MMP-9 in diabetic both 
scratched (1983% vs 55%) and (18,432% vs 40%) and non-scratched (456% vs 
13%) and (617% vs 30%) dermal fibroblasts compared to healthy scratched and 
non-scratched cells (MMP-9 was below the level of detection in dermal 
fibroblasts cultured from most of the healthy donors) (Fig 3-16 B) and (Fig 3-18 
B). Furthermore, the secretion of MMP-9 was increased following scratching in 
the presence of TNF-α in a dose-dependent fashion, particularly in the diabetic 
fibroblasts. A recent study has shown that MMP-9 is upregulated only in 
diabetic wounds (Gao et al., 2015) suggesting a possible detrimental role.  
Most published studies indicate that normal human dermal fibroblasts do not 
express MMP-9, but Gawronska-kozak et al., (2011), reported that both 
(1ng/ml) of TGF-β1 and (10 ng/ml) of TNF-α stimulate and regulate MMP-9 
expression in human dermal fibroblasts from explants of skin (reconstructive 
surgery), by zymography and western blot.  
Pathologically elevated levels of MMP-2 and -9 are indicated in impaired wound 
healing. A study in mice by Lerman et al., (2003), suggests that MMP-9 is 
elevated in chronic wounds, due to high glucose levels depending on the cell 
type. Previous studies have reported elevated MMP-9 levels are the cause of 
prolonged inflammation in mice, or maybe due to microbial infection in vivo 
(Lerman et al., 2003).  
Furthermore, diabetic chronic wounds display an imbalance between MMPs 




TIMP-1 and TIMP-2 expression (Menghini et al., 2013; reviewed by Baltzis et 
al., 2014). Also, the prolonged inflammation in diabetic chronic wounds directs 
the inflammatory cells to produce TNF-α, which then acts synergistically with   
IL-1β to increase the MMPs levels and decrease the TIMPs (McCarty and 
Percival, 2013). 
From recent results, it seems that incubation cell monolayers with TNF-α does 
not modulate the secretion of MMP-2 and -9, in either healthy or diabetic dermal 
fibroblasts under either scratched and non-scratched conditions. A recent study 
by Argyropoulos et al., (2016), reported that MMP-1 and MMP-2 mRNA 
expression increased significantly in diabetic skin compared with normal skin. 
Patel et al., (2016), suggested in terms of MMPs to TIMPs ratio, the mean 
MMP-9/TIMP-1 ratio in fluids decreased significantly with increased ulcer 
healing chances. Thus, the lower the mean MMP-9/TIMP-1 ratio collected from 
wound fluids, the higher ultimately healed wounds compared with non-healed 
wounds, which showed the harmful effect of MMP-9 in chronic wounds. This 
supports our findings especially MMP-9 was overexpressed in diabetic wounds 
and led to inhibit wound healing in migration assay, although of the inhibitory 
effect of TNF-α.    
 
 
4-8: TNF-α paracrine effect on the secretion of active MMP-2 
and -9 by healthy dermal fibroblasts  
 
To assess whether TNF-α has a paracrine effect on MMP-2 and -9 secretion, 




scratched and non-scratched conditions, (Fig 3-19 and 20). In scratched dermal 
fibroblasts, doubled conditioned media at both concentrations (2.5 and 25 
ng/ml) of TNF-α induced MMP-2 secretion significantly, while in non-scratched 
cells, due to donor variability, there was no significant difference in MMP-2 
secretion at either concentration of TNF-α (Fig 3-19). This was not due to the 
presence of TNF-α since when TNF-α was added to the control media this 
stimulation in MMP-2 secretion was not seen.  
With MMP-9 secretion, there was no significant difference at either 
concentration of TNF-α, by scratched or non-scratched dermal fibroblasts (Fig 
3-20), suggesting TNF-α does not stimulate the secretion of paracrine factors 
that modulate the secretion of MMP-9. 
Many possible explanations arise here, MMP-2 secretion by scratched cells (Fig 
3-19 A), is stimulated directly by low levels of TNF-α which are still present in 
the double conditioned media and not by soluble factors, or there could be an 
alternate explanation. As TNF-α conditioned media was pooled from two 
donors, TNF-α can induce the secretion of other cytokines, which modulate the 
production of MMPs, and then interfere with ECM protein secretion by 
fibroblasts via autocrine and paracrine pathways (Wong et al., 2001). 
Furthermore, soluble factors may involve pro-inflammatory cytokines such as 
IL-1 and IL-6, which can normally induce MMP-2 secretion directly, or these 
pro-inflammatory cytokines induced by TNF-α and they, in turn, stimulate the 





4-9: Changes in gene expression in response to TNF-α 
 
4-9-1: Effect of TNF-α on MMP-1 mRNA expression in healthy 
and diabetic dermal fibroblasts 
 
Dermal fibroblasts secrete MMP-1 a protease, which degrades collagen 
particularly type I and III in connective tissue and ECM in response to pro-
inflammatory cytokines such as TNF-α during the wound healing process 
(Brown Lobbins et al., 2017).  
The results of this study of the effect of TNF-α on MMP-1 mRNA expression in 
healthy dermal fibroblasts have shown that, in healthy non-scratched dermal 
fibroblasts TNF-α induces a significant increase in the MMP-1 expression at 
both concentrations of TNF-α (2.5 and 25 ng/ml).  
In scratched fibroblasts, there were no significant differences, due to donor 
variability (Fig 3-21 A). A study by Lindner et al., (2012), where the human 
dermal fibroblasts were incubated with (10 ng/ml) TNF-α for 24h, reported that 
MMP-1 mRNA expression was also significantly increased, while for wounded 
dermal fibroblasts, an older study by Dayer (1985) had reported that TNF-α 
induces the MMP-1 mRNA and protein expression in dermal fibroblasts, 
concluding that the MMPs are upregulated in response to exogenous cytokine 
signals temporarily in skin which resulting in alterations in cell-to-cell contacts.  
The results of diabetic dermal fibroblasts, showed TNF-α produced a significant 
increase in the expression of MMP-1 only at the highest concentration of TNF-α 
at 25 ng/ml in scratched cells (Fig 3-21 B). It is well known that TNF-α can also 




conditions, which together can induce MMP-1 mRNA expression (Bauer et al., 
2009). 
Interestingly, basal levels of MMP-1 mRNA were higher in diabetic dermal 
fibroblasts (1637% vs 235%) compared to healthy control fibroblasts (1669% vs 
478%) under control conditions (Fig 3-21 A and B). Hence, since the levels of 
MMP-1 expression in response to TNF-α were similar in both while the level of 
expression in the presence of TNF-α in diabetic fibroblasts was approximately 
double that seen in normal fibroblasts. However, these suggestions require 
confirmation with larger sample sizes as they did not reach statistical 
significance. Other recent studies have reported similar findings, for example, a 
study by Argyropoulos (2016), reported that MMP-1 and MMP-2 expression was 
significantly (3.2 fold) and (4.4 fold) higher in diabetic skin compared with non-
diabetic skin. Further quantification of the protein levels by western blot 
confirmed that MMP-1 was elevated in diabetic skin. For diabetic wounds, a 
study by Lobmann (2002), demonstrated that MMP-1 expression was elevated 
by 65 fold in biopsies taken from diabetic foot ulcers (DFU) compared to those 
from acute wounds. This study was further confirmed by the Lopez- Lopez 
(2014) study, when they found the same upregulation in MMP-1 expression in 
DFU compared to the control. 
The effect of TNF-α on MMP-1 mRNA expression in both gender cells (two 
females) and (two males) was also compared (Fig 3-21 C and D). No significant 
observations have seen due to sample small size.  MMP-1 expression was 
higher at the highest concentration of TNF-α in both scratched and non-




was more variable. These results may due to how long they have had diabetes 
or how long they had a chronic wound before amputation. 
 
 
4-9-2: Effect of TNF-α on MMP-2 mRNA expression in healthy 
and diabetic dermal fibroblasts 
 
MMP-2, or (gelatinase A) is a major protease which degrades denatured 
collagens and gelatins. The results of healthy dermal fibroblasts showed, a non-
significant increase in MMP-2 mRNA expression TNF-α in non-scratched cells, 
while the results from the scratched cells showed no effect of TNF-α on MMP-2 
mRNA expression at either concentration (Fig 3-22 A). However, scratching the 
cells induced expression of MMP-2 by 3-fold, even in the absence of TNF-α 
(2104% vs 650%). Interestingly, zymography results in healthy dermal 
fibroblasts are mirrored to MMP-2 mRNA expression results, TNF-α had no 
effect on MMP-2 secretion in scratched cells (Fig 3-15 A), and a dose-
dependent effect on   MMP-2 secretion in non-scratched cells (Fig 3-17 A). Also 
scratching increased secretion of MMP-2 (about 1000 in non-scratched – just 
under 2000 in scratched) (1230% vs 1450%) and (1130% vs 1587%, 
respectively) (Fig 3-15 and 17 A). In contrast to the present results, Lindner et 
al., (2012), found that 10 ng/ml of TNF-α increased the MMP-2 mRNA 
expression significantly in dermal fibroblasts after 24h incubation.  
In non-scratched diabetic dermal fibroblasts, MMP-2 mRNA gene expression 
was more than 2 fold higher than in healthy fibroblasts at basal levels (Fig 3-22 




scratched diabetic dermal fibroblasts at basal levels in zymography (Fig 3-17 A 
and B). In contrast to healthy fibroblasts, scratching diabetic fibroblast 
monolayers did not alter MMP-2 expression (Fig 3-22 B). Conversely, scratched 
diabetic dermal fibroblasts did alter MMP-2 secretion in zymography (Fig 3-15 
B). 
In contrast, to healthy scratched fibroblasts, MMP-2 mRNA expression following 
incubation with TNF-α was double that of the controls although due to donor 
variability this did not achieve statistical significance (Fig 3-22 B). This result 
mirrors the results obtained for TNF-α on MMP-2 secretion in scratched diabetic 
dermal fibroblasts and was non-significant (Fig 3-15 B). A report by Lauhio et 
al., (2008) displayed that MMP-2 levels increased in the serum of diabetic 
patients, while another study reported a high decrease in MMP-2 mRNA 
expression in type 2 diabetic patients (Xu et al., 2014).  
When the diabetic fibroblasts were split by gender, TNF-α had no significant 
effect on MMP-2 expression in both genders under both conditions due to the 
small sample size (Fig 3-22 C and D). The variant in data of genders may also 
be due to differences in diabetes duration, sex hormones and in response to 
diabetes. 
This increased expression of MMP-1 and MMP-2 in the phenotypic profile of 
diabetic dermal fibroblasts indicates a combined action of elevated levels of 
these MMPs in the dermis of diabetic skin may be a significant factor that leads 






4-9-3: Effect of TNF-α on MMP-9 mRNA expression in healthy 
and diabetic dermal fibroblasts 
 
MMP-9 or gelatinase B is a protease which degrades denatured collagens and 
gelatins. The results of this study showed that MMP-9 was only expressed 
when non-scratched healthy dermal fibroblasts were incubated in the presence 
of TNF-α (Fig 3-23 A). MMP-9 secretion in zymography is similar to MMP-9 
mRNA expression in non-scratched cells with too low MMP-9 secretion at the 
control (Fig 3-18 A). There was no statistically significant effect of MMP-9 
mRNA expression in response to TNF-α in non-scratched cells. This is similar to 
MMP-9 secretion in zymography in non-scratched cells (Fig 3-18 A). 
In scratched cells MMP-9 mRNA expression was highly variable (Fig 3-23 A), 
and similar to MMP-9 secretion in zymography in scratched cells. There was no 
differences in basal MMP-9 mRNA expression between healthy and diabetic 
controls under scratched and non-scratched conditions (Fig 3-23 A and B).     
In diabetic dermal fibroblasts the presence of TNF-α also had no statistically 
significant effect on MMP-9 mRNA but was several-fold higher than the controls 
in a concentration-dependent manner under both scratched and non-scratched 
conditions (Fig 3-23 B) and was approximately twice that seen in the healthy 
fibroblasts (16% vs 7%) in non-scratched cells and (20% vs 3%) in scratched 
cells. This suggests they may be more sensitive to TNF-α but requires 
confirming with larger sample sizes. This is similar to that seen in MMP-9 
secretion (zymography), (Fig 3-16 and 18). 
Lobmann et al., (2002), have found MMP-9 expression in diabetic wounds was 
14 fold compared to acute wounds. Also, a study by Zhou et al., 2000 in human 




wounds, and very low levels in acute, healed-wounds. In addition, these authors 
reported that in dermal fibroblasts isolated from healed and non-healed wounds 
incubated with 10 ng/ml of TNF-α for 16h, that TNF-α induced MMP-9 mRNA 
expression via activation of the PAK1 pathway, which in turn activates the JNK 
pathway resulting in transcription of MMP-9. 
This concurs with a study showing MMP-9 expression levels are higher in DFU 
biopsies and patient serum, and associated with poor healing especially when 
compared with healed DFU (Liu et al., 2009).  
When the diabetic fibroblasts were split by gender, the responses to TNF-α 
were similar, particularly in the scratched cells (Fig 3-23 C and D). The actual 
increase in MMP-9 mRNA expression in male fibroblasts in response to TNF-α 
was approximately 3 times that seen in female fibroblast (7% vs 2% ) and (29% 
vs 3%) in non-scratched cells, while it was higher (9% vs 1%) and (31% vs 9%) 
in scratched cells. Gender is more likely to explain these differences, or gender 
differences inflammatory responses but the group sizes were extremely small 
so any repeat should be with larger groups sizes.    
 
4-9-4: Effect of TNF-α on TIMP-1 mRNA expression in healthy 
and diabetic dermal fibroblasts 
 
Dermal fibroblasts also secrete the MMP inhibitors such as TIMP-1, which is a 
specific inhibitor of MMP-9 (gelatinase B), but also has overlapping inhibitory 




The data of healthy dermal fibroblasts showed that, TNF-α significantly 
increased TIMP-1 mRNA expression at the highest concentration in non-
scratched cells, while the TNF-α effect was not significant in scratched cells (Fig 
3-24 A). A previous study using neonatal dermal fibroblasts from foreskin 
reported that different concentrations of TNF-α (0.1, 10 or 100 ng/ml) did not 
modulate TIMP-1 expression (Wong et al., 2001), while another study by Dasu 
et al., (2003) agree with the current data, since when they incubated human 
dermal fibroblasts with 10 ng/ml of TNF-α for 6 h, the TIMP-1 protein levels and 
mRNA expression levels were increased significantly.   
In diabetic dermal fibroblasts, TNF-α had no effect on TIMP-1 mRNA 
expression in non-scratched and scratched cells (Fig 3-24 B). Previous studies 
(Rysz et al., 2007; Xu et al., 2014) have found circulating TIMP-1 levels in 
patient with diabetic nephropathy to be decreased, while others have reported 
an increase in TIMP-1 in diabetic patients sera (Lauhio et al., 2008; Xu et al., 
2014). Furthermore, TIMP-1 mRNA expression was found to be significantly 
higher in DFU compared to control biopsies (Lopez- Lopez et al., 2014).             
It is suggested that the high ratio of MMP-1/TIMP-1 is associated with impaired 
wound healing in DFUs, due to possibility that high levels of TIMP-1 may delay 
wound healing in DFU biopsies (Muller et al., 2008).  
The basal expression of TIMP-1 mRNA was higher in diabetic cells than in 
healthy cells under non-scratched conditions. There was no significant effect of 
scratching increased TIMP-1 expression in healthy or diabetic cells (Fig 3-24 A 
and B). According to the prediction of Muller et al., basal diabetic MMP-1 and 
TIMP-1 mRNA expression was higher than healthy non-scratched cells (Fig 3-




condition.  However, the sample sizes in the present studies were very small so 
the results need confirmation. Similarly, gender results showed no effect on 
TIMP-1 expression, again due to the small size of the sample (Fig 3-24 C and 
D).  
 
4-9-5: Effect of TNF-α on TIMP-2 mRNA expression in healthy 
and diabetic dermal fibroblasts 
 
TIMP-2 is a specific inhibitor of MMP-2 (gelatinase A) (reviewed by Ayuk et al., 
2016). The results of healthy dermal fibroblasts showed that, TNF-α had no 
effect on TIMP-2 expression under both cell conditions (Fig 3-25 A). A study by 
Wong et al., (2001) reported that TIMP-2 expression remained unchanged 
when neonatal dermal fibroblasts were incubated with TNF-α for 24h.   
Basal levels of TIMP-2 mRNA expression in diabetic fibroblasts was higher than 
healthy controls under both conditions (Fig 3-25 A and B). This is in contrast to 
an in vivo study by Argyropoulos (2016), which reported there was no difference 
between diabetic skin and healthy skin in relation to the mRNA levels of TIMP-1 
and TIMP-2 and a study by Lobmann, et al., (2002), who reported that in 
diabetic wounds TIMP-2 expression was 2-fold lower than that seen in non-
diabetic wounds. Furthermore, a study by Lopez- Lopez (2014) found no 
difference in TIMP-2 mRNA expression between healthy skin (control) and DFU 
biopsies.         
In diabetic dermal fibroblasts, under both cell conditions, TNF-α had no 




significant effect on TIMP-2 expression because of n=2 for each males and 
females (Fig 3-25 C and D).  
 
4-9-6: Effect of TNF-α on Sirt1 mRNA expression in healthy and 
diabetic dermal fibroblasts 
 
Sirt1 is a member of the family of mammalian sirtuins, which can stimulate 
dermal fibroblast migration, keratinocyte proliferation and differentiation, and 
has an important role in aging and inflammation (Kown et al., 2016; Qiang et al.,  
2017). The results of RT-qPCR showed there was no effect of TNF-α on Sirt1 
mRNA expression in either non-scratched or scratched in healthy dermal 
fibroblasts (Fig 3-26 A). Present results in contrast with Saini et al., (2012)      
who reported that Sirt1 mRNA expression was elevated in mouse skeletal 
myoblasts when incubated with (10 ng/ml) TNF-α for 48h, which means that 
Sirt1 down-regulates the TNF-α effect, via its elevation trying to keep the 
balance against the pro-inflammatory cytokine, other explanations, this 
elevation in Sirt1 expression is due to TNF-α dose-dependent, or Sirt1 effects 
are tissue dependent.  
In addition, Sirt1 functions in wound healing are modulated depending on cell-
type or wound healing stage-specific. In mice, overexpression of Sirt1 impaired 
the corneal epithelial wound healing (diabetic keratopathy) in vitro (Wang et al., 
2013). 
In diabetic dermal fibroblasts, TNF-α also had no effect on the expression of 
Sirt1 in non-scratched and scratched cells (Fig 3-26 B). High glucose levels in 




Sirt1 expression in human myocardium tissue (Sulaiman et al., 2010; Frati et 
al., 2017).  Basal levels of Sirt1 mRNA were higher in diabetic fibroblasts 
compared to healthy fibroblasts under both conditions (Fig 3-26 A and B).     
Aioi, (2017) reviewed that Sirt1 and Sirt6 inhibit MMP-9 expression, and this 
may explain the upregulation in Sirt1 mRNA expression by diabetic basal cells 
led to inhibit the MMP-9 mRNA expression levels in diabetic basal cells (Fig 3-
23 B), although the same effect was seen in healthy basal cells (Fig 3-23 A). 
Both gender cells showed no significant observations on Sirt1 expression but 
the sample size was 2 (Fig 3-26 C and D).    
 
 
4-9-7: Effect of TNF-α on Sirt6 mRNA expression in healthy and 
diabetic dermal fibroblasts 
 
Sirt6 is also a member of the family of mammalian sirtuins, which is involved in 
cell metabolism, metabolic diseases such as diabetes, aging, and inflammation          
(reviewed by Bae, 2017). Similar to Sirt1, healthy dermal fibroblasts showed 
that, TNF-α had no effect on Sirt6 mRNA expression in non-scratched and 
scratched cells (Fig 3-27 A). Present results in contrast to He et al., (2017) 
study in rodent vascular adventitial fibroblasts treated with TNF-α in 
concentrations (5, 10, 20 and 40 ng/ml) for 8h, showed a decrease in Sirt1 and 
Sirt6 expression concentration-dependently.  
In diabetic dermal fibroblasts, TNF-α had no effect on Sirt6 expression under 
both cell conditions (Fig 3-27 B). Present results also not agree with a study in 
mice, where found high levels of Sirt6 expression in diabetic and an old mice 




wounds of mice that treated with Sirt6 siRNA showed a significant delay in 
healing in full-thickness skin wounds compared to control wounds (non-siRNA 
treated wounds), which means Sirt6-knockdown delays wound healing in 
diabetic mice (Thandavarayan et al., 2015).  
Basal levels of Sirt6 mRNA were higher in diabetic fibroblasts compared to 
healthy fibroblasts under both conditions (Fig 3-27 A and B). It has been 
reported that Sirt6 expression is significantly higher in human psoriatic skin 
biopsy than in control skin biopsy, this can be explained that Sirt6 upregulates 
TNF-α synthesis, which induces chronic inflammation, and detrimental effect on 
psoriasis (Rasheed et al., 2016). Both diabetic genders did not show significant 
observations on Sirt6 expression because n=2 (Fig 3-27 C and D).  
 
 
4-10: Paracrine effect of TNF-α on MMP-1, MMP-2 and MMP-9 
mRNA expression by healthy dermal fibroblasts 
 
Since it is possible that as well as having a direct effect on MMP secretion, 
TNF-α may also stimulate the secretion of other pro-inflammatory factors that 
may modulate MMPs (McCarty and Percival, 2013). The results of incubating 
normal dermal fibroblasts with conditioned medium taken from other dermal 
fibroblasts that had been incubated in the presence or absence of TNF-α are 
shown in (Fig 3-28 A). These data showed that the expression of MMP-1 mRNA 
with 25ng/ml TNF-α conditioned medium was several-fold higher than the 
controls, similar to what had been previously seen when fibroblasts were 




statistically significant, adding TNF-α to the control conditioned media induced 
the same response so if confirmed, this possible increase in MMP-1 mRNA 
expression would be likely to be directly stimulated by TNF-α. 
In scratched cells, the pattern was the same as seen with the direct application 
of TNF-α with the TNF-α conditioned media significantly increasing MMP-1 
mRNA at the highest concentration of TNF-α (Fig 3-28 B), again suggesting that 
is due directly to the presence of TNF-α rather than any additional induced 
soluble factors.  
In contrast, TNF-α conditioned medium had no effect on MMP-2 expression in 
either non-scratched or scratched fibroblasts (Fig 3-29 A and B), which concurs 
with the results seen when fibroblasts were incubated directly with TNF-α (Fig 
3-22 A). The results with TNF-α conditioned medium were similar for  MMP-9 
mRNA expression in both non-scratched and scratched cells (Fig 3-30 A and B) 
as seen with the direct effect; when TNF-α was added to the control conditioned 
medium, the result was even higher, although this also did not reach statistical 
significance and was very variable in the scratched cells. However, this may 
indicate an additive effect of TNF-α with a soluble paracrine factor in the 
conditioned medium, which warrants further investigation. Data of MMP-1,-2 








4-11: Paracrine effect of TNF-α on TIMP-1 and TIMP-2 mRNA 
expression by healthy dermal fibroblasts 
 
TNF-α conditioned media yielded a similar result to the direct application of 
TNF-α on the expression of TIMP-1 mRNA in non-scratched cells, which did not 
reach statistical significance (Fig 3-31 A). In scratched cells the results were 
also non-significant (Fig 3-31 B). A previous study by Wong et al., (2001) found 
that TNF-α had no modulating effect on TIMP-1 and TIMP-2 expression in the 
supernatant of dermal fibroblasts using enzyme-linked immunosorbent assays 
ELISA. TNF-α conditioned media decreased TIMP-2 mRNA expression at both 
concentrations in non-scratched cells (Fig 3-32 A), in a similar way to what was 
seen in with the direct application of TNF-α. It had no effect on the expression of 
TIMP-2 mRNA in scratched cells (Fig 3-32 B), again concurring with what was 
observed with the direct effect of TNF-α. TIMP-1 and TIMP-2 expression results 
show that there is no paracrine effect.   
 
 
4-12: Paracrine effect of TNF-α on Sirt1 and Sirt6 mRNA 
expression by healthy dermal fibroblasts 
 
TNF-α conditioned media had no effect on Sirt1 mRNA in either non-scratched 
cells (Fig 3-33 A), or scratched cells (Fig 3-33 B), which mirrored the results 
when TNF-α was added directly to the culture medium (Fig 3-26 A). 
Similarly, there was no effect of TNF-α conditioned media on the expression of 




again was similar to the results obtained with the direct addition of TNF-α to the 
culture medium (Fig 3-27 A). The results indicate that TNF-α has no effect on 
Sirt1 or Sirt6 expression either directly or via induction of soluble paracrine 
factors. 
 
4-13: TNF-α induces the secretion of different cytokines 
secretion in dermal fibroblast from normal and diabetic skin  
 
The human dermal fibroblast secreted protein profile can be determined by 
antibody arrays. This study sought to clarify which cytokines associated with 
inflammation are modulated by TNF-α and secreted into the media by dermal 
fibroblasts as potential candidates responsible for influencing proliferation, cell 
migration and/or the release of wound healing mediators (Appendix 8-4). 
The findings from the human cytokine array analysis have shown that under 
basal conditions, healthy female dermal fibroblasts, secrete of 7/36            
factors associated with inflammation. There are (Chemokine C-C motif ligand 2/ 
monocyte chemoattractant protein-1 CCL2/MCP-1, Chemokine C-X-C motif 
ligand 1/Growth-Regulated Protein alpha CXCL1/GROα, Chemokine C-X-C 
motif ligand 12/ stromal cell-derived factor 1 CXCL12/SDF-1, Interleukin-6 IL-6, 
Interleukin-8 IL-8, Macrophage migration inhibitory factor MIF and Serpin 
E1/Plasminogen activator inhibitor-1 SerpinE1/PAI-1). CCL2/MCP-1 has a role 
in recruiting monocytes, neutrophils and lymphocytes, thus it facilitates their 
migration and infiltration, and also recruits the leukocytes to the site of 




CCL2/MCP-1 to accelerate leukocytes homing and promote endothelial 
activation in inflammation (Nash et al., 2004). CXCL1/GROα is a pro-
inflammatory cytokine, which promotes neutrophil infiltration. Full-skin 
substitutes and autograft studies have shown high levels of IL-6, CCL2/MCP-1, 
CXCL1/GROα, and CXCL8/IL-8 were secreted by keratinocytes and dermal 
fibroblasts, and these mediators are important for wound healing (Spiekstra et 
al., 2007).  
In normal and psoriatic human skin, CXCL12/SDF-1 is the chemokine that is 
produced by human dermal fibroblasts (particularly by papillary dermal 
fibroblasts), and stimulates keratinocyte proliferation (Quan et al., 2015).     
Kim et al., 2008, suggested that MIF is a pro-inflammatory cytokine that inhibits 
random migration of macrophages, and induces other cytokines such as;     
TNF-α, INF-γ, IL-1, IL-2, IL-6, and IL-8. In the wound healing process, MIF 
secreted by endothelial cells, so it is enhanced after wounding, and in dermal 
fibroblasts from wound sites compared to non-wounded sites (reviewed by 
Shimizu et al., 2005; Simons et al., 2011). In mice, inhibition of SerpinE1/PAI-1 
in wounds, prevents wound closure, impairs keratinocyte re-epithelialisation and 
dermal fibroblast proliferation, recruitment and differentiation into myofibroblasts 
via antagonist PAI-1, in vitro (Simone et al., 2015).  
The same seven cytokines were also secreted by male diabetic dermal 
fibroblasts under basal conditions, however, in diabetic female dermal 
fibroblasts under basal conditions, secretion of the cytokines CCL2/MCP-1 and 
IL-6 were not observed, Table 3-1 and (Fig 3-35 B and C). In diabetic wounds, 




poorly due to insufficient CCL2/MCP-1 (Satish, 2015). These results concur with 
these studies, since CCL2/MCP-1 was not detected at basal levels in diabetic 
female fibroblasts, and although it was secreted by diabetic male fibroblasts, 
levels were very low and almost below the level of detection. 
Differences between the male and female secretion of IL-6 may be explained by 
the fact that IL-6 is increased significantly in chronic wounds due to wound 
bacterial infection (Satish, 2015). While we do not have this data on the donors, 
future studies may need to take this into account. 
The much higher level of CCL2/MCP-1 secretion by healthy dermal fibroblasts 
compared to male diabetic dermal fibroblasts, under basal conditions (Fig 3-35), 
agree with an in vivo study in mice that showed the lack in this chemokine  
delayed wound healing by impairing re-epithelialisation, angiogenesis and 
tissue remodelling (reviewed by Ridiandries et al., 2018). In contrast, the 
elevated secretion of IL-6 by diabetic male fibroblasts which is important (during 
the inflammatory phase) of wound healing, is highly expressed in chronic 
wounds in diabetic mice, which results in impaired wound healing caused by an 
infiltration of leukocytes (reviewed by Behm et al., 2011; Buskermolen et al., 
2017).  
When healthy dermal fibroblasts were incubated in the presence of 2.5 ng/ml 
TNF-α (Fig 3-35 A), the secretion of 5 additional cytokines was induced 
(Macrophage Inflammatory Proteins α and β MIP-1α/β, Granulocyte-colony 
stimulating factor G-CSF, Granulocyte-macrophage colony-stimulating factor 
GM-CSF, Interleukin-32α IL-32α and Tumour necrosis factor-alpha TNF-α), 




important in attracting and recruiting the monocytes and T cells to inflammatory 
sites. In humans, MIP-1 secretion is restricted to hematopoietic cells and 
fibroblasts and is induced by inflammatory cytokines such as IL-1 and TNF-α 
(Coondoo, 2012). 
G-CSF and GM-CSF can be induced by TNF-α, which leads to an increase in 
white blood cell number (haematopoiesis) (Gulati et al., 2016). The G-CSF 
cytokine has an important role in wound healing, via inducing the neutrophil 
differentiation, maturation and mobilization into the bloodstream (Shiomi and 
Usui, 2015). GM-CSF stimulates the mobilization of hematopoietic and non-
hematopoietic cells, and thus it increases the number of neutrophils at the 
wound site and induces keratinocyte proliferation (Wong and Crawford, 2013). 
Moreover, IL-32α is a pro-inflammatory cytokine that is expressed in response 
to TNF-α (Alsaleh et al., 2010; Kandhaya-Pillai et al., 2017) and also it secreted 
by fibroblast-like synoviocytes of rheumatoid arthritis patients.  
For TNF-α observation, the most likely explanation is that TNF-α is still in the 
conditioned media (TNF-α direct addition to dermal fibroblasts). 
The production of IL-6 can be induced by TNF- α in human dermal fibroblasts 
(Khan, 2009). Finally, the increase in CXCL1/ GRO-α chemokine that is 
important in promoting angiogenesis may be explained by the fact that dermal 
fibroblasts secrete CXCL1 in response to TNF-α (Kolar et al., 2012), since in 
vitro human endothelial cells also secrete CXCL1 when induced by TNF-α (LO 
et al., 2014). 
Female diabetic dermal fibroblasts, the presence of TNF-α induced the 




CCL5/RANTES, Intercellular Adhesion Molecule/CD54 ICAM-1/CD54,           
GM-CSF, IL-6 and TNF-α), Table 3-1 and (Fig 3-35 B). A study by Galindo et 
al., (2001) reported that incubation of dermal fibroblasts with TNF-α at 10, 25 
and 50 U/ml (Units per millilitre, 1U/ml=1.66054e-15 ng/ml), stimulated a dose-
dependent increase of CCL5/RANTS, CCL2/MCP-1, CXCL10/IP-10, and IL-8.  
A study has shown elevated levels of CCL5/RANTES in diabetic type 2 patients 
(Pais et al., 2014), Nakajima and colleagues (2003), suggest that an increase in 
the secretion of pro-inflammatory cytokines such as TNF-α or IL-1 β in diabetic 
type 2 (nephropathy) resulting from high glucose levels, which in turn induce the 
CCL5/RANTES secretion in mesangial cells in the kidney.  
For ICAM/CD54, TNF-α upregulates high expression of the ICAM adhesion 
molecule on dermal fibroblasts indirectly in presence of INF-γ, which leads to 
the recruitment of a high number of inflammatory cells during chronic 
inflammation (Coondoo, 2012). Also, ICAM has been reported to be a 
biomarker of diabetes/diabetic neuropathy due to its high levels in patients, 
while high gene expression in the kidney of a diabetic animal model has also 
been reported (Gu et al., 2013). Fang and others (2010), showed that GM-CSF 
decreased significantly by 50% in murine diabetic wounds compared to control, 
and it can enhance wound healing via stimulating pro-inflammatory cytokines 
such as IL-6 and MCP-1. In patients with diabetic foot ulcers, there is a 
significant elevation of IL-6 level compared to control (Weigelt et al., 2009). 
Again TNF-α was detected in the supernatants which may be the residual TNF-
α, although, in diabetic wounds there is also an increase in the level of           




Shornick (2015), have reported that the pro-inflammatory cytokines IL-1, IL-6, 
and TNF-α are significantly elevated in diabetic wounds, while TGF-β and IL-10 
are not. 
In the male diabetic dermal fibroblasts, the presence of TNF-α also induced 
ICAM-1/CD54 and TNF-α similar to what was seen in diabetic female dermal 
fibroblasts, although in contrast there was no secretion of GM-CSF                    
or CCL5/RANTS in response to TNF-α Table 3-1 and (Fig 3-35 C). The 
absence of both GM-CSF and CCL5/RANTS may due to how long the male had 
diabetes before amputation. 
The diabetic fibroblasts show similarities in cytokine secretion in both genders 
induced by TNF-α, e. g.  an increase in CXCL1/GROα, with a decrease in MIF 
and Serpin E1/PAI-1, Table 3-1 and (Fig 3-35 B and C). Interestingly, MIF has 
shown to have an immunological role induced by pro-inflammatory cytokines 
such as TNF-α in autoimmune diseases (Bautista-Herrera et al., 2017).             
In contrast, Abe and colleagues (2000) have shown an increase in MIF levels 
would improve wound healing in rats. However, in human chronic venous 
ulcers, MIF levels are significantly increased (reviewed by Shimizu, 2005). 
High levels of Serpin E1/PAI-1 are considered to be biomarkers for diabetes 
type2 (Yasar Yildiz et al., 2014). Miyashita et al., 2012, also reported that Serpin 
E1/PAI-1 is associated with obesity, diabetes type2 obesity, and insulin 
resistance, but an older study by Chandler, (1991) displayed that Serpin 
E1/PAI-1 levels showed variations even in normal populations which may 
explain these results.  
To explain these variations, it is well known that diabetic patients differ in their 




addition to any differences between genders including biological, psychosocial 
factors, sex hormones, obesity, and inflammatory response.    
 
  
 4-14: There was no TNF-α induced a paracrine effect on 
cytokine secretion by healthy dermal fibroblast  
                                                                                                                            
To determine whether dermal fibroblasts secrete soluble factors that may alter 
the secretory profile of neighbouring dermal fibroblasts in a paracrine manner, 
medium was also collected from fibroblasts that had been treated with 
conditioned medium from other cells that had been conditioned both in the 
presence and absence of 2.5 ng/ml TNF-α. This secretory profile was identical, 
showing similar amounts of the same 7 cytokines were secreted, table 3-1 and 
(Fig 3-36). This suggests that secreted cytokines derived from aged dermal 
fibroblasts (passage 7-8), are similar to soluble factors seen in healthy dermal 

















5 Conclusion  
 
Data from this study has shown a significant difference in the proliferation rate 
between dermal fibroblasts cultured in different percentages of FBS (2% and 
10%) from the same donor, with cells proliferating faster in 10% than 
corresponding cells in 2% FBS. However, no differences between the rates of 
proliferation of dermal fibroblasts cultured from facial and scalp (haired) skin 
from the same donor in normal growth media (10% FBS) was observed, 
suggesting that there are no significant anatomical differences in the response 
to TNF-α in terms of proliferation. 
Interestingly, pre-treatment (3 days) of both scalp and facial dermal fibroblasts 
with TNF-α significantly decreased proliferation by day 14. The inhibitory effect 
of TNF-α was only seen after this protracted time period, and this may suggest 
that in vitro studies should be carried out over longer periods.  
Additional studies using the same experimental conditions, demonstrated that 
dermal fibroblasts pre-incubated with TNF-α for 3 days also increased their 
metabolic activity significantly by day 14.  
One explanation for decreased proliferation and increased metabolic activity is 
that TNF-α is inducing cellular senescence. However, since β-galactosidase 
was not detected in cultured dermal fibroblasts until they reached passage 17, 
and was not observed at the earlier passage numbers of P4-8 when the 
proliferation and metabolic assays were performed, this does not seem to be 
the obvious explanation. Notwithstanding, TNF-α induced senescence in high 
passage dermal fibroblasts, which confirms that they become more susceptible 




In a scratch wound assay, TNF-α inhibited migration of both healthy and 
diabetic dermal fibroblasts. However, the higher concentration of TNF-α (25 
ng/ml) was required to inhibit the migration of healthy dermal fibroblasts, while 
in diabetic dermal fibroblasts the lower concentration of TNF-α (2.5 ng/ml) was 
also able to inhibit cell migration after 24h, suggesting that fibroblasts derived 
from diabetic donors are more susceptible to inhibition by inflammatory 
cytokines during wound healing.  
To determine whether TNF-α induced dermal fibroblasts to secrete paracrine 
factors that may influence neighbouring cells, conditioned media was collected 
from pre-treated dermal fibroblasts with TNF-α (soluble factors), but this had no 
effect on migration of other dermal fibroblasts after 24h. However, whether a 
longer exposure is required warrants further investigation, as does effects on 
other parameters of fibroblast biology during wound healing such as ECM 
synthesis.  
To investigate the proteolytic activity, zymography of media collected from both 
healthy and diabetic dermal fibroblasts demonstrated that TNF-α induced an 
inflammatory environment which upregulates gelatinases (MMP-2 and -9) 
activity, which are potential candidates for the inhibitory factors that impair the 
migration of dermal fibroblasts. 
Interestingly, there was an independent paracrine effect on MMP-2 secretion by 
healthy scratched dermal fibroblasts, suggesting TNF-α induced soluble factors 
on MMP-2 activity, which was not due to the direct effect of TNF-α. 
Exposure of healthy and diabetic dermal fibroblasts to TNF-α at concentrations 
of 2.5 and 25 ng/ml under both scratched and non-scratched conditions allowed 




1, and -2) and senescence (Sirt1 and 6) to be quantitated by RT-qPCR. TNF-α 
at both concentrations upregulated mRNA expression of MMP-1 significantly in 
healthy non-scratched cells, providing further support that TNF-α increases 
MMP expression in dermal fibroblasts which may significantly impact on ECM 
turnover. In scratched diabetic dermal fibroblasts the highest concentration of 
TNF-α was required to increase MMP-1 expression. While a significant increase 
in TIMP-1 mRNA expression in the presence of 25 ng/ml TNF-α was observed 
in healthy non-scratched cells, this was not mirrored in diabetic fibroblasts, 
suggesting the regulation of MMPs by TIMPs may be impaired. While TNF-α 
also modulated MMP-2, MMP-9 and TIMP-2 mRNA expression in some donors, 
there was also significant donor variability. TNF-α plays an important role in 
tissue inflammatory, repair and remodelling processes or modulating the 
synthesis of ECM proteins. No changes were seen in Sirt1 and Sirt6 mRNA 
expression in the presence of TNF-α and there was no evidence of any 
paracrine effect on any of the genes studied, at least in the healthy cells. 
The cytokine arrays provide the profile of the changes in the inflammatory 
secretome of the healthy and diabetic dermal fibroblasts under scratched 
conditions in the presence of TNF-α.  
In healthy female and diabetic male dermal fibroblasts, under basal conditions, 
the same seven cytokines were secreted (CCL2/MCP-1, CXCL1/GROα, 
CXCL12/SDF-1, IL-6, IL-8, MIF and Serpin E1/PAI-1). These cytokines are 
involved in the biological phases/events of wound healing process such as 





In healthy cells, TNF-α stimulated the secretion of a further five cytokines (MIP-
1α/ MIP-1β, G-CSF, GM-CSF, IL-32α and TNF-α). Therefore, TNF-α can induce 
other pro-inflammatory cytokines that attract, stimulate and recruit the 
neutrophils to the wound site mimic to in vivo inflammatory stage.   
In female diabetic cells, TNF-α stimulated the secretion of a further six 
cytokines, which were not secreted under basal conditions (CCL2/MCP-1, 
CCL5/RANTES, ICAM-1/CD54, GM-CSF, IL-6, and TNF-α). Therefore, 
adhesion molecules involved in the inflammation process can be induced by 
TNF-α, as well as chemotactic cytokine for leukocytes for prolonged 
inflammatory process at the wound site.  
In male diabetic cells, TNF-α induced the secretion of the same cytokines as 
seen in female diabetic cells, with the exception of GM-CSF and 
CCL5/RANTES. This variation in secreted cytokines may be due to gender 
and/or how long the donor has had type 2 diabetes. 
To investigate the paracrine effect of TNF-α in healthy dermal fibroblasts the 
conditioned media was collected from dermal fibroblasts that had been treated 
with conditioned medium with or without TNF-α (soluble factors), but there was 
no differences in cytokine secretion between the control conditioned medium or 
TNF-α conditioned media.  
In summary, TNF-α impairs dermal fibroblast proliferation, without reducing cell 
metabolic activity, but can increase senescence. It also inhibits the migration of 
healthy and diabetic dermal fibroblasts. TNF-α had no significant effect on 
MMP-2 and MMP-9 secretion by healthy and diabetic fibroblasts under 
scratched and non-scratched conditions. However, TNF-α upregulates the 




fibroblasts. TNF-α increased the expression of MMP-1 mRNA expression in 
healthy and diabetic cells, and also increased TIMP-1 mRNA expression in 
healthy cells, but had no effect on Sirt1 and Sirt6 mRNA expression.    
TNF-α induces secretion of wound healing cytokines in both healthy and 
diabetic fibroblasts. While there may be possible gender differences in response 
to TNF-α in diabetic fibroblasts, this was not confirmed in healthy donors, since 
they were all derived from female donors TNF-α did not induce any paracrine 
effects on cytokine secretion by healthy dermal fibroblasts, at least in the time 



















6 Future studies 
 
One possible explanation for a decrease in dermal fibroblast proliferation may 
be the result of an increase in the differentiation of dermal fibroblasts to 
myofibroblasts. In future studies, the ability of TNF-α to directly or indirectly 
induce dermal fibroblast differentiation can be investigated by quantifying 
changes in α-SMA expression using qRT-PCR and immunocytochemistry. 
TNF-α induced senescence in high-passage dermal fibroblasts, which confirms 
that they become more susceptible to senescence induced by inflammation with 
aging. In future studies, it is possible to compare the senescence expression of 
dermal fibroblasts derived from older donors e.g. 60 years and more, and from 
diabetic patients, to find out whether diabetic cells show a more aged 
phenotype and become more susceptible, which could help explain why these 
patients experience more chronic wounds. 
In future studies, to determine whether TNF-α induced dermal fibroblasts to 
secrete paracrine factors that may influence neighbouring cells, the scratch 
wound assay can be used to assay the paracrine effect of TNF-α on other cells 
such as keratinocytes (affect re-epithelialization), endothelial cells (affect 
angiogenesis), and immune cells whether they attract inflammatory cells e.g. 
neutrophils, monocytes, macrophages, mast cells etc to wound site and cause a 
chronic wound. 
Since changes in ECM proteins are also significantly altered in chronic 
inflammation that can lead to impaired wound healing, changes in the synthesis 
of specific ECM proteins such as laminin, fibronectin, collagen in wound healing 





The cytokine arrays provide the profile of the changes in the inflammatory 
secretome of the healthy and diabetic dermal fibroblasts under scratched 
conditions in the presence of TNF-α. In future studies, the cytokines profile 
measurement can be done using ELISA and Western blot. In addition, the most 
important secreted cytokines that induced by TNF-α by scratched healthy and 
diabetic dermal fibroblasts can be validated by qPCR, such as (CCL2/MCP-1, 
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8-1: Solutions Preparation 
8-1-1: Gelatine zymography Reagents and solutions 
 
8-1-2: Separating Gel Buffer (1.5M Tris base) 
1. 90.86g Tris-base, final concentration 1.5M 
2. 275 ml D.W 
The Tris -base was dissolved in 275 ml D.W and made up to 500ml D.W, the 
pH was adjusted to 8.8, and stored at 4˚C. 
 
8-1-3: Stacking Gel Buffer (0.5M Tris base) 
1. 6g Tris base, final concentration 0.5M     
2. 60ml D.W 
The Tris -base was dissolved in 60 ml D.W and made up to 100ml, the pH was 
adjusted to 6.8 and stored at 4˚C. 
 
8-1-4: Running Buffer 
1. 15g Tris base, final concentration 25 mM 
2. 72g Glycine, final concentration 200 mM 
3. 5g SDS, final concentration 0.5 % w/v  
The Trise-base, glycine and SDS were dissolved in 1L using D.W and was 
stored at 4˚C .The prepared solution was diluted as (280ml D.W plus 70ml 
Running Buffer) when was used. 
 
8-1-5:  2× Non-reducing Sample Buffer 
1. 3.125ml (0.5 M Tris base, pH 6.8) Stacking gel buffer, final concentration 
62.5 mM 
2. 10ml 10% SDS, final concentration 40 % v/v 
3. 10ml glycerol, final concentration 40 % v/v 
4. 1.87 ml D.W 
5. 125µl Bromophenol Blue  





8-1-6: 5x Washing Buffer 
1. 125 ml Triton X-100. 
2. 875 ml D.W 
The125 ml Triton X-100 was added as 5 parts until full dissolved and stored at 
RT. The solution was diluted as (200ml D.W plus 50ml washing buffer) when 
was used.  
 
8-1-7: 10x Incubation Buffer 
1. 78.8g Tris base, final concentration 50 mM 
2. 14.7g CaCl2. 2H2O, final concentration 100 mM 
3. 29.2g NaCl, final concentration 50 mM 
4. 5 ml Brij-35, final concentration 0.5 % v/v 
All components were dissolved in 1L D.W, the pH was adjusted at 7.6, and 
stored at 4˚C. The solution was diluted as (180ml D.W plus 20ml Incubation 
Buffer) when was used. 
 
8-1-8: Coomassie Blue Staining Solution 
1. 0.2g Coomassie brilliant blue R-250, final concentration 0.02 % v/v 
2. 100 ml glacial acetic acid, final concentration 10% v/v 
3. 250 ml Methanol, final concentration 25 % v/v 
 All components were dissolved in 1L D.W with magnetic stirring overnight, and 
the solution was stored at RT.  
 
8-1-9:  Destain Solution 
1. 50 ml Methanol, final concentration 5% v/v 
2. 50 ml Glacial acetic acid, final concentration 5% v/v 
The Methanol and Glacial acetic acid were dissolved in 1L D.W, and was stored 
at RT. 
 
8-1-10: 10% SDS Solution  
1. 10g SDS. 
2. 80 ml D.W 
The SDS was dissolved in 80ml DW and made up to 100ml D.W, and when fully 






8-1-11: 10% APS Solution  
1. 0.12g ammonium persulfate (APS). 
2. 1.2 ml D.W 



















































Representative standard curve for the CyQUANT- (direct cell proliferation). The 
fluorescence intensity measured at peak excitation wavelength of 508nm and at peak 


















































8-3: ORAL AND POSTER PRESENTATIONS 
 
1. ORAL PRESENTATIONS 
a) A Al-Rikabi, K Riches, DJ Tobin, MJ Thornton. Changes in the secretory 
phenotype of human dermal fibroblasts by a pro-inflammatory 
environment: implications for wound healing. British Inflammation 
Research Association Meeting 2018, Manchester, Alderley Edge, UK 
b) A Al-Rikabi, K Riches, DJ Tobin, MJ Thornton. A pro-inflammatory 
environment modulates the human dermal fibroblast phenotype: 
implications for chronic wounds. 13th World Congress on Inflammation 
Conference 2017, London, UK (published in the conference proceeding) 
 
2. POSTER PRESENTATIONS 
a) A Al-Rikabi, K Riches, DJ Tobin, MJ Thornton. A pro-inflammatory 
environment induces changes in the phenotype of human dermal 
fibroblasts derived from diabetic and non-diabetic donors: implications for 
wound healing. British Society of Investigative Dermatology Annual 
Meeting 2019, Bradford, UK 
b) A Al-Rikabi, K Riches, DJ Tobin, MJ Thornton. A pro-inflammatory 
environment modulates the human dermal fibroblast secretory 
phenotype: implications for chronic wounds.  International Investigative 
Dermatology Conference 2018, Orlando, Florida, USA (published as a 
late breaking abstract in the JID) 
c) A Al-Rikabi, K Riches, DJ Tobin, MJ Thornton. A pro-inflammatory 
environment modulates the human dermal fibroblast secretory 
phenotype: implications for chronic wounds. British J. Dermatol. Mar 
(2018),178: P48 
d) A Al-Rikabi, K Riches, DJ Tobin, MJ Thornton. Tumour necrosis factor-α 
modulates the human dermal fibroblast phenotype: implications for 
inflammation, impaired wound healing and ageing. British J. Dermatol. 
Apr 2017; 176:e58 
e) A Al-Rikabi, K Riches, DJ Tobin, MJ Thornton. TNF-α and dermal 
fibroblasts: Implications for inflammation, impaired wound healing and 




8-4: Human cytokine array 
 
8-4-1: List of the human cytokines array coordinator-key table 
(2015, R&D Systems, ARY005B) 
 
Coordinate Target/Control Gene/ function and location 
A1, A2 Reference spots Nil 
A3,A4 CCL1/I-309 Chemokine, (C-C motif) ligand1/ Human Cytokine 
I-309, produced by activated Tells, monocytes 
chemoattractant and other immune cells, 
inflammatory cytokine 
A5,A6 CCL2/MCP-1 Chemokine, (C-C motif) ligand 2/ monocyte 
chemoattractant protein 1, produced by 
macrophage, monocytes and dendritic cells, 
chemotactic for immune cells 
A7,A8 MIP-1α/MIP-1β Chemokine, Macrophage Inflammatory Proteins (α 
and β/ CCL3 and CCL4), produced by 
macrophages, dendritic cells and lymphocytes, 
chemotactic, activates granulocytes and caused 
(neutrophilic inflammation), stimulates pro-
inflammatory cytokines from fibroblasts 
A9,A10 CCL5/RANTES Chemokine, C-C motif ligand 5/ RANTES, 
produced by activated T cells, chemotactic for 
immune cells especially for recruiting leukocytes 
into inflammatory sites 
A11,A12 CD40Ligand/TNFSF5 Protein, (member of TNF-α superfamily)/ CD154 
expressed on T cells, produced by CD4 cells, and 
other immune cells, it binds to (APCs) 
A13,A14 Complement 
component C5/C5a 
Protein ,Complement component 5 (complement 
system) can be cleaved into C5a and C5b, coded 
by C5 gene, a role in chemotaxis and attacks 
immune complexes 
A15,A16 CXCL1/GROα Chemokine, C-X-C motif ligand 1/GROα, produced 
by macrophages, neutrophils and epithelial cells, 
a chemoattractant to neutrophils, a role in 
inflammation, wound healing and angiogenesis  
A17, A18 CXCL10/IP-10 Chemokine, C-X-C motif ligand 10/ Interferon 
gamma-induced protein 10 (IP-10), produced by 
monocytes, endothelial cells and fibroblasts in 
response to IFN-γ, a chemoattractant to immune 
cells 




B3,B4 CXCL11/I-TAC Chemokine, C-X-C motif ligand 11/ Interferon-
inducible T-cell alpha chemoattractant, produced 
by blood cells/leukocytes pancreas and liver, a 
chemotactic 
B5,B6 CXCL12/SDF-1 Chemokine, C-X-C motif ligand 12/ stromal cell-
derived factor 1 (SDF1), produced by many 
tissues e.g. brain, thymus...etc., lymphocytes 
chemotactic, induced by TNF-α 
B7,B8 G-CSF Granulocyte-colony stimulating factor, 
Glycoprotein, as cytokine, produced by tissues, 
an inducer for granulocytes and stem cells in 
bone morrow to release into blood stream, a 
neutrophils stimulator 
B9,B10 GM-CSF Granulocyte-macrophage colony-stimulating 
factor, Glycoprotein, produced by macrophages, 
immune cells fibroblasts and endothelial cells as 
stimulator cytokine 
B11,B12 ICAM-1/CD54 Intercellular Adhesion Molecule/CD54, expressed 
by endothelial and immune cells, induced by TNF-
α, a molecule for stabilizing cell-cell signalling 
and facilitating leukocyte endothelial 
transmigration 
B13,B14 IFN-γ Cytokine, Interferon gamma, produced by 
activated T cells and macrophages, defends 
against virus   
B15,B16 IL-1α/IL-1F1 Interleukin-1 alpha/ IL-1F1 Protein, produced by 
activated macrophages, neutrophils, endothelial 
and epithelial cells, promotes release of multiple 
inflammation mediators 
B17,B18 IL-1β/IL-1F2 Interleukin-1 beta/ IL-1F2 Protein, produced by 
activated macrophages, monocytes and other 
immune cells, promotes inflammation response, 
fever and sepsis  
C3,C4 IL-1ra/IL1-F3 Interleukin-1 receptor antagonist (IL-1RA), 
produced by immune cells, epithelial cells and 
adipocytes, binds to IL-1 receptor, a natural 
inhibitor of IL-1 α and β  
C5,C6 IL-2 Interleukin-2, produced by activated CD4+ T cells, 
immunity-immune tolerance, influences all 
lymphocytes differentiation and regulation, can 
recognize self and non-self antigens  
C7,C8 IL-4 Interleukin-4, produced by T helper type 2 CD4 T 
cells, basophils, and mast cells.  stimulates the 
differentiation of Th0cells into Th2 cells and B-
cells into plasma cells  
C9,C10 IL-5 Interleukin-5, produced by T helper type 2 and 
mast cells, stimulates B cells growth, increases 
IgG and IgA secretion as mediator 




C11,C12 IL-6 Interleukin-6, produced by osteoblasts, smooth 
muscle cells of blood vessels, its role a pro-
inflammatory and an anti-inflammatory cytokine 
(inhibitor effect to TNF-α), mediates fever and 
acute phase response    
C13,C14 IL-8 Interleukin-8, produced by macrophages, 
epithelial cells, airway smooth muscle cells and 
endothelial cells, it’s a neutrophil chemotactic 
factor, stimulates phagocytosis and promotes 
angiogenesis 
C15,C16 IL-10 Interleukin-10, produced by Th2 cells, monocytes 
and other immune cells, anti –inflammatory 
cytokine 
C17,C18 IL-12 p70 Interleukin-12/ (active heterodimer is p70), 
produced by APCs, acts as T cells stimulating 
factor, T cell differentiation into Th1 cells, role in 
NK cells activation 
D3,D4 IL-13 Interleukin-13, produced by T helper type 2 CD4 t 
cells, NK cells, mast cell and granulated white 
cells, it mediates allergic, inflammation e.g. 
Asthma 
D5,D6 IL-16 Interleukin-16, produced by lymphocytes, CD4 T 
cells and epithelial cells, a chemoattractant for 
CD4 T cells 
D7,D8 IL-17A Interleukin-17A, produced by activated T cells (T 
helper 17 cells), a pro-inflammatory cytokine 
(allergic responses),    
D9,D10 IL-17E Interleukin-17E or IL-25, produced by mast cells 
and T helper type 2, epithelial cells and 
granulated white cells, induces NF-kB activation, 
stimulates for IL-8 
D11,D12 IL-18/IL-1F4 Interleukin-18 belongs to IL-1 family , produced by 
macrophages and other immune cells, pro-
inflammatory cytokine  
D13,D14 IL-21 Interleukin-21, produced by activated CD4 T cells, 
it reregulates the immune cells functions e.g. NK 
cells, cytotoxic t cells  
D15,D16 IL-27 Interleukin-27, a member of IL-12 family, 
expressed by APCs, stimulates T cells 
differentiation, upregulates IL-10 secretion 
D17,D18 IL-32α Interleukin-32α, produced by NK cells, 
macrophages and other immune cells, fibroblasts, 
epithelial and endothelial cells, pro-inflammatory 
cytokine 
E1,E2 Reference spots Nil 
E3,E4 MIF Macrophage migration inhibitory factor, produced 





E5,E6 Serpin E1/PAI-1 Serpin E1/Plasminogen activator inhibitor-1, an 
enzyme-a specific inhibitor of tissue plasminogen 
activator (tPA), produced by endothelial cells and 
adipose tissue, controls biological processes e.g. 
coagulation, inflammation, its high levels are 
indicator of thrombosis and atherosclerosis 
E7,E8 TNF-α Tumour necrosis factor-α, produced by 
macrophages and other immune cells, a pro-
inflammatory cytokine 
E9, E10 TREM-1 Receptor, Triggering receptor expressed on 
myeloid cells 1, primes myeloid cells to respond 
to other stimuli 
E19, E20 Negative control Nil 
















































1. Representative images of human cytokine Array. Conditioned media’s 
(supernatant’s), antigens binding to capture antibodies on membranes. (A) In 1ml of 
control (B) In 1ml of 2.5ng/ml TNF-α (C) In 1ml of conditioned control, and (D) In 1ml of 





























2. Representative images of human cytokine Array. Conditioned media’s 
(supernatant’s), antigens binding to capture antibodies on membranes. (A) In 1ml of 
control, and (B) In 1ml of 2.5ng/ml TNF-α, both from female diabetic patient. (C) In 1ml 






8-5: Quantitate the TNF-α levels (ELISA) 
 
To quantitate the relative levels of human TNF-α cytokine in the diabetic and 
non-diabetic dermal fibroblasts supernates (conditioned media), 10% FBS 
control conditioned and 2.5 ng/ml of TNF-α conditioned media were assessed to 
measure the TNF-α concentration), which were collected from migration assay 
(section 2-14). The ELISA kit (Abcam TNF-α SimpleStep ELISA, ab18142, UK) 
was used to carry out these measurements with a limitation of (15.6- 2000 
pg/ml). The principle of the assay is, that labelled capture antibodies and 
detector antibodies which immunocaptured the sample analyte (protein) in 
solution, forming complexes of (capture antibody- analyte- detector antibody) 
are fixed in the wells. Reagents were prepared according to manufacturer’s 
instructions, 1X wash buffer PT (was prepared by diluting 5ml of 10X wash 
buffer PT with 45 ml distilled water with a final volume of 50 ml), and also 3 ml 
of antibody cocktail mixture was prepared (by mixing 300µl of capture antibody 
and detector antibody with 2.4 mL of antibody diluent 5BI). All standards, 
samples, and controls wells were performed in duplicate of 50 µl volume of 
each in one plate. The standard curve was generated, by adding 500 µl of 
sample diluent NS to lyophilized TNF-α recombinant protein, mixing, and 
incubating at room temperature (RT) for 10 minutes to get stock standard 
solution with a concentration of 10000 pg/ml. Eight standards tubes were 
prepared (7 standard tubes + 1 blank tube -no protein), after 360 µl of sample 
diluent NS was added to standard micro tube1 and 150 µl were added for the 7 
left standards microtubes. To prepare the standard tube1 (40 µl of stock 




tube1 and added to standard tube 2 (by this way the standard tube 2 is 
prepared), this way was repeated to prepare the other 3-7 standard tubes, while 
standard tube 8 is blank (zero TNF-α protein).   
Fifty microliter from each standards, conditioned media and controls were 
added into appropriate wells of 96 microtiter well plate. Then, 50 µl of antibody 
cocktail mixture was added to each well, the plate was wrapped in foil (kit 
supplier) to avoid the light and incubated for an hour at RT on a shaker at 400 
rpm. After the wells were washed for three times with 350 µl of 1X wash buffer 
PT and the plate was dried carefully by inverting the plate on a paper towel after 
the final wash. TMB development solution was added in the amount of 100 µl to 
each well and the wrapped plate incubated for 10 minutes on a shaker (at 400 
rpm) at RT. Immediately, when the blue colour was developed the absorbance 
readings were taken at 600 nm using Infinite 200 PRO microplate reader 
(Tecan, Switzerland), and the standard curve was performed, the absorbance 
versus treatment concentrations. 
 
8-5-1: Analysing of TNF-α levels (ELISA) 
 
The average of duplicate absorbance readings was calculated for each well and 
the average zero (standard blank) was subtracted from all absorbance 
readings. A standard curve was performed by excel, which used to find out the 
concentration of TNF-α for the unknown samples.  GraphPad prism7 is used to 












Representative standard curve of TNF-α (ELISA). The absorbance measured at 600 







































































Fig1: The TNF-α levels in conditioned media of diabetic and non-diabetic DFs in 
(pg/ml). Dermal fibroblasts were scratched and incubated with or without 2.5 ng/ml of 
TNF-α for 24h, and the conditioned media were collected. (A) Healthy DFs from female 
donors (n=4), facial skin, P3, and age range (45-67y). (B) Diabetic DFs from 
2females/2males (n=4), lower leg, P3, and age range (55-67y). *P<0.05, one-way 








8-5-3: The quantitative determination of TNF-α for diabetic and 
non-diabetic dermal fibroblasts 
 
The conditioned media (biomarkers) were used to assess and compare the 
TNF-α level measurements of scratched diabetic and non-diabetic dermal 
fibroblasts, to find out whether these levels are pathological that lead to 
inflammation or progress diabetes and its complications or as a result of ageing.  
In cutaneous of old people, TNF-α was found as a key responsible of collagen 
degradation via upregulating the expression of MMP9 in dermal fibroblasts (all 
of donors /patients are aged (45-67 years) (Borg et al., 2013), as well as the 
inflammation,  is associated with diabetes and its complications, such as micro- 
and macro- vascular especially in type 2. More, diabetes is characterised by 
chronic hyperglycemia which promotes the increase of pro-inflammatory 
cytokines as TNF-α which in turn leads to apoptosis of pancreatic β-cells 
resulting in diabetes progression (Ping et al., 2017). Results have shown, a 
similarity of both healthy donors and diabetic patient’s plots, but there was a 
significant increase (P< 0.05) in the concentration of TNF-α in healthy cells that 
incubated with (2.5 ng/ml) compare to control (Fig 1). The concentration of TNF-
α in control of diabetic cells was (92-119 pg/ml), while for healthy cells was (77-
107 pg/ml), while the concentration of TNF-α of diabetic cells that incubated in 
(2.5 ng/ml) was (146 – 471 pg/ml), while for healthy cells was (212- 521 pg/ml), 
from present results it seems that TNF-α has induced TNF-α/inflammation in 
healthy cells that incubated in (2.5 ng/ml) more than diabetic. This may be due 
to that diabetic patients may have taken medicine or the stage of diabetes.  
 
